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ABSTRACT
In the first part of the study, I developed a model to study the CSC/TIC 
population of the A431 cell line based on the capability of these cells to 
form spheres in suspension.
Putative A431 CSC/TIC were characterized for ‘sternness’ properties such 
as self-renewal and clone forming capability, presence of a SP and ALDH 
enzymatic activity, putative stem cell marker expression and in vivo 
tumorigenicity. The results indicate that the growth of A431 cells, as 
spheres, was not sufficient by itself to define a stem like population, but it 
was essential for the emergence of a small population of tumour cells with 
CSC properties.
Then, I investigated CSC/TIC in Epithelial Ovarian Cancer (EOC), with a 
focus on CD 133 and CXCR4 molecules.
In a wide range of primary EOC and ascites the expression of CD 133 and 
CXCR4 was found restricted within two separate subpopulations of tumour 
cells.
Enrichment in mRNA levels of OCT4, NANOG and NESTIN  was observed 
with good reproducibility in CXCR4 positive cells, whereas it was more 
variable in CD133 positive cells. Real Time analyses of ABC transporter 
expression showed there was a slight increase in CXCR4 positive cells 
while in CD 133 positive cells this increase was much more evident, 
revealing a clear difference between CXCR4 and CD 133 subpopulations in 
term of chemoresistance potential.
Furthermore positive cells isolated from xenograft-derived ascites and 
sorted for CXCR4 and CD133 were not characterized by higher tumorigenic 
capacity.
In summary, no correlation between CD 133 positivity and the ovarian 
cancer sternness phenotype was found. However detection of CD133 
positive cells may be useful to predict the efficacy of specific cytotoxic 
therapy.
On the contrary, CXCR4 positive cells may identify those tumour cells 
which maintain a partially un-differentiated state (high levels of stem cell 
marker expression) and possibly responsible for tumour invasion and 
metastasis.
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CHAPTER 1
INTRODUCTION
Normal and cancer stem cells
“The simplest view appears to me undoubtedly to be that in an 
early stage o f embryonic development more cells are produced 
than are required for building up the part concerned, so that there 
remains inappropriate a quantity o f cells, it may be very few  in 
number, which, owing to their embryonic character, are endowed 
with a marked capacity for proliferation... the real cause o f the 
subsequent tumour is to be sought in a fault or irregularity o f the 
embryonic rudiment. ”
J u l iu s  C o h n h e im , 1889
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1.1 Stem cells in the life of an organism.
Embryonal, germinal and somatic stem cells
There are three kinds of stem cells- embryonal, germinal, and somatic or 
adult stem cells (6). Embryonal stem cells (ES) derive from the first five or 
six divisions of the fertilized egg. The progeny of embryonal stem cells are 
the precursors for all of the cells in the adult organs. The unicellular zygote 
is recognized to be the first stem cell in a human life and is identified as 
being totipotent, due to its ability to generate an entire organism (7). After 
about four days these totipotent cells begin to specialize, forming a 
“structure of cells” called the morula. The first recognized differentiation 
event in development occurs at the late morula stage, when the outer cell 
layer of the embryo adopts epithelial features and initiates the formation of 
blastocysts that contains two cell types: trophectoderm and inner cell mass 
(ICM) (8) (FIG. 1.1). The trophectoderm gives rise to the trophoblast, while 
the ICM undergoes a second differentiative step to form the epiblast and 
the endoderm, thereby progressing toward the blastocyst stage (9). The 
epiblast or primitive ectoderm further gives rise to the embryo, while the 
primitive endoderm develops into the extraembryonic endoderm, which 
provides nutrient and developmental cues to the embryo and contributes, 
together with the trophectoderm, to the development of the yolk sack and 
placenta.
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Figure 1.1: Differentiation event during embryo development. Figure from (1)
At the blastocyst stage ICM stem cells are no longer totipotent but are 
recognized as being pluripotent (10) (1). This partial commitment in 
combination with the similarities observed between mouse and human ES 
cells suggest that human ES cells are actually equivalent to the early post­
implantation epiblast, rather than its ICM progenitor (11). During further 
embryonic development, a gradient of decreased regenerative potential is 
produced and distributed in specific stem cell compartments in a developing 
embryo. This decrease in regenerative capability leads to a subsequent loss 
of totipotency but a concurrent retention of pluripotency by stem cell in the 
embryo, in a poorly understood process called determination. The next 
recognized landmark during embryonic differentiation is gastrulation, when 
the epiblast is transformed into the three germ layers of the embryo 
(ectoderm, mesoderm, and endoderm) and the basic body plan of the animal 
is established (12). The remaining events of embryogenesis, a major part of
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Figure 1.2* Differentiation of human tissues (Image from www.ncbi.nlm.nih.gov)
The formation of germ cells during embryogenesis is of crucial importance 
for the maintenance of every species. Development of germ cells begins 
with the specification of the primordial germ cells. Primordial germ cell 
(PGC) specification or formation marks the initiation of the life cycle of the 
germ cell lineage in all species. The multipotent germ cells, derived from 
PGC, have been identified in neonatal gonads, tes tes, and ovaries in mouse 
and human (17) (18).
Germ cells in the male en ter into mitotic a rrest  and are reactivated to 
initiate sperm atogenesis after birth (6). Spermatogenesis continues during
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which is organogenesis, rely of the functioning of localized stem cells that 
together are committed to generate  specific organs in response to 
surrounding microenvironment or niche (13) (14) (15) (16) (FIG. 1.2).
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adult life in most males, but whether these stem cells self-renew or 
differentiate is heavily influenced by surrounding somatic cells, in a 
microenvironment often referred to as a stem cell niche. The continuation 
of the spermatogenic process throughout life relies on the proper regulation 
of self-renewal and differentiation of the spermatogonial stem cells.
After birth, male germline stem cells develop into spermatogonial stem 
cells (SSCs). They can self-renew and generate a large number of 
differentiated germ cells. These cells could be reprogrammed to embryonic 
stem cell-like cells and can spontaneously differentiate into derivates of all 
three germ layers in vitro (19). These lines of evidence clearly suggest the 
pluripotency of germ cells in all stages of development.
Although males retain germline stem cells (GSCs) for spermatogenesis 
throughout adult life, oocytes production in females of most mammalian 
species is believed to cease before birth (17) (20). A central dogma of 
mammalian reproductive biology is that females are born with a finite, non­
renewing pool of germ cells, all of which are arrested in meiosis I (oocytes) 
and are enclosed by somatic cells in structures referred to as follicles (17). 
Oocyte numbers decline throughout postnatal life (20) through mechanisms 
involving apoptosis (21), eventually leaving the ovaries devoid of germ 
cells. In humans, exhaustion of the oocyte reserve occurs around the fifth 
decade of life, driving the menopause (22). The process that is believed to 
occur in female mammals with respect to germ-cell development differs 
from that of several invertebrate organisms, including Drosophila 
Melanogaster, in which GSCs maintain oocyte production in adult ovaries
(23) Interestingly, a new line of research has recently established the 
existence of proliferative germ cells that sustain oocyte and follicle 
production in the postnatal mammalian ovary (24) (25).
While diversification of cell types is largely complete at or shortly after 
birth, many tissues in the adult undergo self renewal and accordingly must 
establish a life-long population of relatively pliable stem cells. It is 
generally accepted that adult tissues contain tissue-determined stem cells 
or somatic stem cells responsible for normal tissue renewal (26) (24) (27). 
The effective maintenance of a population of healthy stem cells within a 
particular tissue involves the concurrent operation of multiple genetic and 
epigenetic factors, along with stringent controls within each niche, that 
create perfect harmony among the different cells of various organ system 
(28). It has become apparent that adult stem cells not only reside and 
function in highly regenerative tissues like the bone marrow, intestine and 
epidermis, but are also found in tissues of low cell turnover, such as neural, 
liver, prostate and pancreas.
In adult tissues, somatic stem cells function is the maintenance of tissue 
homeostasis by replenishing functional tissue cells lost by apoptosis (29) 
(30). Following injury, normally quiescent adult stem cells undergo cell 
division producing transit amplifying (TA) cells that rapidly proliferate to 
repair the lost tissue with sufficient numbers of functional differentiated 
cells. In some cases, such as liver and pancreas, fully mature cells have the 
capacity to revert to a proliferative phenotype to effect tissue replacement 
in a poorly understood process (31). It appears that mature cells may de-
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differentiate into stem-like cells with a concomitant change in 
transcriptional profile or fully mature cells have latent stem cell capacities 
(32).
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1.2 Possible origins of cancer stem cells
1.2.1 Concept of cancer stem cells
The term cancer stem cells (CSCs) is used to indicate a tumour-initiating 
cell subset that can give rise to a heterogeneous progeny, similar in 
composition to the tissue from which it was originally isolated.
Like their normal tissue counterparts, tumours are composed of 
heterogeneous populations of cells that vary in their apparent state of 
differentiation. This observation suggests that tumours are not a simple 
monoclonal expansion of cells, but might be similar to abnormal organs 
sustained by a mutated “cancer stem cel!’ population, which is endowed 
with the ability to self-renew and undergo aberrant differentiation (33). 
This hypothesis is further emphasized by the fact that cancer is known to 
result from the accumulation of multiple genetic mutations in a single target 
cell, sometimes over a period of many years (34). Because stem cells are 
the only long-lived cells in many organs, they are the natural candidates in 
which early transforming mutations may accumulate.
How CSCs arise in tissue and progress to give rise to a new organ /  tumour 
is a hot field of investigation. Research over the last decade has tried to 
associate cellular mechanisms with mutagenic effects leading to the 
emergence of CSCs. The possibilities that emerge include: transformation 
of normal stem cells, or transformation of a local pool of early progenitors 
that re-acquire self renewal properties or a series of effective mutations 
that render committed transient-amplifying (TA) progenitor immortal (de­
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differentiation) (35) and, finally, the possible fusion of circulating bone 
marrow derived stem cells with tissue residing cells (36).
The relative abundance of TA progenitor cells makes them likely 
candidates for initial transforming events. Several lines of evidence support 
the concept that a committed progenitor can be the cancer-initiating cell as 
a result of oncogenic transformation (37).
Similarly the preservation of the expression of cell surface markers 
between normal and cancer stem cells suggests that normal tissue stem 
cells may be the targets of oncogenic transformation (37).
Although no direct experimental evidence is currently available for the cell 
fusion origin of CSCs, cell fusion has been shown to be one of the 
mechanisms for the apparent cellular plasticity associated with tissue stem 
cells (38). Conceptually, cell fusion between stem cells and mutated cells 
might lead to regaining of self-renewal capacity to allow further 
accumulation of transforming mutations (39).
Future studies are necessary to provide definitive evidence for identifying 
the origin of CSCs. It is also important to remember that the possible 
origins for CSCs are not mutually exclusive; demonstrating one model for 
the formation of CSCs in a given system does not necessarily exclude other 
mechanisms (FIG. 1.3).
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Figure 1.3' Possible origin of CSCs
The observations that classically define the existence of a CSC population 
are that: 1) only a minority of cancer cells within each tumour are usually 
equipped with tumorigenic potential when transplanted into immunodeficient 
mice; 2) although tumours originate from a single transformed cell, the 
cancer cells within tumours may also display different phenotypes, 
somewhat reminiscent of the normal tissue from which they originate (40) 
and, finally, 3) tumours derived from tumorigenic cells contain mixed 
populations of tumorigenic and non-tumorigenic cancer cells, recreating the 
phenotypic heterogeneity of the parental tumour.
In conclusion, cancer can be thought of as a disease resulting from 
abnormal growth and from chronic activation of stem cells, leading to the 
long term proliferation of these cells. The abnormally dividing stem cell
could be subject to additional genetic events (repression of tumour 
suppressor genes and activation of oncogenes), leading to autonomous 
growth, the loss of cell cycle regulation and resistance to apoptosis, all well 
understood properties of cancer cells (33) (41) (FIG. 1.3).
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1.2.2 Cancer stem cell theory
Although monoclonal in origin, most tumours appear to contain a 
heterogeneous population of cancer cells. This observation is traditionally 
explained by postulating variations in tumour microenvironment and 
coexistence of multiple genetic subclones, created by progressive and 
divergent accumulation of independent somatic mutations.
Two general models of heterogeneity in solid cancer cells have been 
assumed (FIG. 1.4). The stochastic model supposes that each population of 
cells within a heterogeneous tumour has an equal but extremely low 
tumorigenic potential (42) (FIG. 1.4a). In this regard, tumour progression is 
a constant process based on the positive selection of genetically unstable 
clones that guarantees a survival advantage on a tumour within its 
surrounding microenvironment. The stochastic model also accounts for the 
emergence of drug resistance during chemotherapy through selection of 
cells with genotypes that allow survival from the drug insult (43).
The fact that from organ specific stem cells derived all the differentiated 
cell of a given organ has led the proposal of a stem cell hierarchical model 
for tissue development, maintenance and repair. Deriving from this, is the 
hierarchical cancer stem cell model (FIG. 1.4b), which proposes that the 
tumorigenic potential of tumours is limited to a very small clonogenic 
population of cells, the CSCs (1), whereas the large population of cancer 
cells, descendants of CSCs, do not have self renewal capacity and are 
organized in the form of hierarchy. This model postulates that not all cells
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in a tumour are equal and the tumorigenic cells are a rare subset with a 
distinct phenotype.
It was first fully documented for leukaemia and multiple myeloma that only 
a small subset of cancer cells is capable of extensive proliferation (44) 
(45). It has also been shown for solid cancers that the cancer cells are 
phenotypically heterogeneous and that only a small proportion of cells are 
clonogenic in culture and in vivo (46) (47) (48).
Existing therapeutic approaches have been mainly based on the stochastic 
model, but the failure of these therapies to cure most solid cancers 
suggests that the hierarchical CSCs model may be more accurate.
The large number of tumour types with a subpopulation of exclusively 
tumorigenic and therapy resistant cells suggests that, despite the 
unanswered questions, the CSC hypothesis has a rightful role to play in 
tumour biology. At the same time, experimental evidence supporting the 
established alternative theory of clonal evolution can be found as well.
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Figure 1.4: image from (2)
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Therefore, a model that describes cancer initiation and progression should 
combine elements of clonal evolution and CSC theory.
1.2.3 Rethinking the concept of CSCs
The theories proposed by Campbell and Polyak (49) and Adams and 
Strasser (50) have tried to combine the competing models of clonal 
evolution and CSCs. According to these, evidence can be found for both 
models and their prevalence is probably unique to every tumour and may 
essentially change as the tumour progresses. Although CSCs seem to be a 
special subset of cancer cells, recent studies show that CSCs themselves 
are still a heterogeneous population with different biological properties and 
that multiple populations with CSC characteristics can coexist in the same 
tumour. Ma et al. investigated hepatocellular carcinoma (HCC) cell lines and 
were able to separate subpopulations with different tumorigenic potential 
based on CD133 and ALDH expression (51), which however contradicts the 
original CSC hypothesis of just one population with tumour forming 
capabilities. Herman et al found that CD133+CXCR4- and CD133+CXCR4+ 
pancreatic cancer cells do not differ in tumorigenicity, but only the 
CD133+CXCR4+ population migrates and metastasizes (52). The CSC 
hypothesis explains this heterogeneity with the existence of cancer 
progenitor cells, which still possess some residual stem cell traits. Whether 
the heterogeneity of the CSC population is caused by clonal evolution or 
partial differentiation of the cancer initiating cell is difficult to prove.
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It is also becoming clear that several properties, which we thought were 
intrinsic to CSCs, are modulated by the microenvironment of the cancer 
cells (53) (54) and such key traits as metastasizing and growth (39) may 
depend on the normal stromal cells that interact with the cancer cells (55) 
(Table l.A).
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Table 1.A: Evidences supporting and contradicting the stem Cells and Cancer Stem
hypothesis (adapted (5))
E xperim ental ev id en ce  
Supporting the CSC hypothesis Contracdicting the CSC hypothesis
Large number of cells are needed for 
xenotransplantation of tumours
In congenic transplantations substantially 
fewer cells are needed
The required number of putative CSC for 
xenotransplantation of tumours is 
relatively small 
Xenograft tumours can be serially
transplanted, but only with the CSC 
subpopulation 
NON-CSC populations do not initiate
tumour growth in vivo, or require more 
cells than the CSC population to do so
Transplantability of malignancies is not 
restricted to one subpopulation in congenic 
transplantations
A small fraction of tumour cells are 
capable of sustained growth under stem 
cell culturing conditions
CSC markers do not identify a pure CSC 
population
CSCs have higher clonogenicity in vitro
The CSC population is heterogenous in 
itself, with differences in metastatic and 
tumorigenic potential
Cultured CSCs can give rise to progeny 
with non-CSC phenotypes
CSCs have intrinsic in vitro and in vivo 
therapt resistance
24
1.3 Stem cells and cancer stem cell properties: 
similarities and variations
To understand the biology of cancer stem cells, we need to define the 
unique properties of normal stem cells. Adult stem cells play pivotal roles 
in mammalian tissue and are identified through three distinctive properties:
■ SELF-RENEWAL: the ability to undergo division and form new cells 
with a potential identical to the mother cell (56).
■ DIFFERENTIATION: the ability to give rise to a heterogeneous 
population of cells, arranged in a hierarchical manner, includes 
various tissue-specific lineages, thereby building up the requisite 
critical mass toward replenishing the tissue of short-lived, 
differentiated cells (57).
■ HOMEOSTASIS: the ability to regulate and balance differentiation 
and self-renewal in the tissue or organ (58).
This unique combination of properties imparts to stem cells a continuing 
role during the entire life of an organism and ensures that all developed 
tissues harbour stem cells. The regulation of stem cells in an adult is tightly 
controlled, to allow for the growth replenishment of tissue and to permit 
their repair after damage occurred. The critical balance of self renewal and 
differentiation is achieved by specific gene expression programs of stem 
cells, which regulate activation and/or inactivation of mechanism allowing 
the maintenance of the pluripotent state or permitting differentiation into
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more specialized states. A disruption in such homeostatic plan can lead to 
the abnormal state of cancer (59).
In normal tissue three different compartments can be described-' l ) a  self 
renewal compartment with quiescent stem cells. These “reserve” stem 
cells are very few in number as most of the cellular renewal is 
accomplished by tissue determined transit-amplifying cells. 2) A 
proliferative compartment with proliferating TA cells with a limited self­
renewal potential and 3) a terminal compartment with differentiated cells or 
apoptotic cells (30).
Diverse poorly-differentiated adult stem/progenitor cell types, which have 
generally a small size relative to the terminally differentiated cells and 
express specific sternness markers have recently been identified in the 
most mammalian tissues/organs (14) (60) (61) (62). Among the tissues and 
organs harboring a very small number of specific multipotent and 
undifferentiated adult stem/progenitor cells, there are BM, vascular walls, 
adipose tissues, skeletal muscles, heart and brain as well as epithelium of 
lung, liver, pancreas, digestive tract, skin, retina, breast, ovaries, prostate 
and testis (14) (60) (61) (62). All of the multipotent or bipotent adult 
stem/progenitor cell types display a long-term self-renewing capacity and 
can give rise to all of mature and specialized cell types of distinct lineages 
in the tissues/organs from which they originate. Despite certain adult 
stem/progenitor cells found in BM, skin and gastrointestinal tract usually 
show a rapid turnover to replenish the cell loss along lifespan, other adult 
stem/progenitor cell types remain under a quiescent state and rarely divide
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in normal conditions, and undergo only a sustained proliferation after 
intense tissue injuries. Prevailing models assume the existence of a single 
quiescent population of stem cells residing in a specialized niche of a given 
tissue. Emerging evidence indicates that both quiescent (out of cell cycle 
and in a lower metabolic state) and active (in cell cycle and not able to 
retain DNA labels) stem cell subpopulations may coexist in several tissues, 
in separate yet adjoining locations (63) (64) (65). In the zoned stem cell 
model, active stem cells are the primed subpopulation that account for most 
of the replenishment of corresponding tissues, whereas quiescent stem 
cells function as a backup or reserve subpopulation (65) (66). This reserve 
population can be activated either by a stochastic mechanism (65) or by 
feedback upon loss of active stem cells or extensive tissue damage (66). 
The combination of these reciprocal backup systems would provide a 
robust mechanism to ensure a high rate of physiological self-renewal as 
well as flexible damage repair, after which the original hierarchy could be 
re-established.
1.3.1 Self Renewal
The key properties of stem cells , indefinite self-renewal and multilineage 
potential, were first discovered in the bone marrow and described 
experimentally in the 1961 (67).
Self-renewal is the process by which a stem cell divides asymmetrically or 
symmetrically to generate one or two daughter stem cells that have a 
developmental potential similar to the mother cell (68). The ability to self-
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renew is essential for stem cells to expand their numbers during 
development, to be maintained within adult tissues, and to restore the stem 
cell pool after injury (69) (70) (71). Self-renewal is not the same as 
proliferation, although both processes depend on cell division. Proliferation 
is a more general term that incorporates all types of stem and progenitor 
cell divisions, self-renewing and otherwise. Most stem cells can divide by 
either asymmetric or symmetric modes of division, and the balance 
between these two processes is controlled by developmental and 
environmental signals in order to produce appropriate numbers of stem 
cells and differentiated daughters (72) (FIG. 1.5).
Symmetric stem cell division offers a mechanism to increase the stem cell 
population mostly during development and body formation, and it was 
secondarily important during tissue regeneration, where asymmetric 
division is generally preferred. Symmetric stem-cell divisions are common 
in developing tissues, but they can also be observed in adults, as
Symmetrical Asymmetrical Symmetrical
EXPANSIONS STEM CELL POOL — EXHAUSTION
e.g. Often occurs in Normal stem cell e.g. Lack of
neoplastic stem cells homeostasis Wnt signalling
in small intestine
Figure 1.5- image from (3)
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exemplified by the adult Drosophila ovary. Adult Drosophila germline stem 
cells normally divide asymmetrically (73); however, it seems that adult 
Drosophila germline stem cells are regulated to divide asymmetrically or 
symmetrically, depending on their specific location within the niche (74) 
(75).
As in Drosophila, also some mammalian stem cells seem to switch between 
symmetric and asymmetric cell divisions. For example, both neural and 
epidermal progenitors change from primarily symmetric divisions that 
expand stem-cell pools during embryonic development to primarily 
asymmetric divisions that increases differentiated cell numbers in mid to 
late gestation (76) (77) (78) (79). Experimental evidence indicates that at 
least some adult stem cells divide asymmetrically under steady-state 
conditions to maintain population size. Nevertheless they also retain the 
capacity to divide symmetrically to restore stem-cell pools depleted by 
injury or disease, as has been observed in the nervous and haematopoietic 
systems (80) (81) (82) (83).
The role of asymmetric cell division in stem-cell control, coupled with the 
mechanisms that regulate this process, is fundamental for generating 
diversity in multicellular organisms (84) (85). Two main types of 
mechanism govern asymmetric cell divisions. The first, called “intrinsic”, 
relies on the asymmetric partitioning of cell components that determine cell 
fate; the second, indicated as “extrinsic”, involves the asymmetric 
placement of daughter cells relative to external cues (3) (FIG. 1.6). Intrinsic
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mechanisms include regulated assembly of cell polarity factors and 
regulated segregation of cell fate determinants.
6 0  60<60
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Figure 1.6- image from (3)
A classic example of an asymmetric division that is controlled by an 
extrinsic mechanism is provided by the Drosophila germline stem cell, 
which divides with a reproducible orientation to generate one daughter that 
remains in the stem-cell niche and retains stem-cell identity, and one 
daughter that is placed away from the niche and begins to differentiate (85) 
(3) (86) (87) (FIG. 1.4). In conclusion it is important to note that asymmetric 
divisions can be governed by both intrinsic partitioning of fate regulators 
and asymmetric exposure to extrinsic cues (88) (89) (90) (62) (91).
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1.3.2 Multilineage potential and control of stem cell differentiation
The differentiation potential of a stem cell is defined by all the types of 
differentiated progeny it can finally generate. There are different 
possibilities explaining how multipotent stem cells can give rise to a 
repertoire of progenies; one possibility is that multipotent stem cells might 
express a set of transcriptional factors which separately specify different 
lineages or combinations of lineages, such as Ikaros for lymphoid lineages 
(92). Theoretically, the entire developmental potential of a given 
multipotent stem cell could also be determined by a single specific factor, 
which generates a regulatory and hierarchical mechanism of differentiation. 
An example is the forkhead transcriptional regulator F0XL2, which is 
required to prevent trans-differentiation of an adult ovary to a testis (93). 
Competence and multilineage potential may also be specified by expression 
of signal transduction molecules. In several cases the expression of 
specific receptors seems necessary to respond to fate-determining signal, 
leading to activation of specific differentiation pathways (94).
The differentiation of stem cells involves both the exit from the 
uncommitted state and entry into a particular developmental pathway. It is 
not yet discovered whether exit from the stem cell state and initiation of 
differentiation are independently controlled in mammals. From one point of 
view, differentiation might be an obligatory option executed by a stem cell 
after its removal from the niche. On the other extreme, internal and 
external signals might promote differentiation and, as consequence, the exit
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from the stem cell state. In the Central Nervous System (CNS) both 
mechanisms act separately, depending on the presence or the absence of 
basic Fibroblast Growth Factor (bFGF). In vitro, bFGF stimulates self 
renewal of CNS stem cells, but its withdrawal rapidly promotes their 
differentiation (95).
In mammalian system, there is considerable evidence that growth factors 
and cell-cell interactions can influence the outcome of fate decision by 
multipotent progenitors. A single stem cell could be influenced by growth 
factors in a selective or instructive manner. In a selective mechanism, the 
stem cells differentiate into a particular lineage independently of the growth 
factors, which subsequently control the survival and the proliferation of the 
progenitors. For example, forced expression of bcl~2 in immortalized 
hematopoietic progenitor cells leads to differentiation in the absence of 
cytokines, underling that these growth factors are dispensable for their 
differentiation. Conversely in the neural crest, the expression of BMP2,
bFGF and TGFft promotes the differentiation toward the three cell types of 
the CNS (95).
Understanding the interplay between extracellular and intracellular 
regulatory factors in controlling lineage determination remains an important 
challenge for the future.
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1.3.3 Relationship between normal and cancer stem cells' CSC 
plasticity as a stem cell dysfunction
CSCs share many characteristics in common with normal stem cells, 
including self-renewal and differentiation. With the growing evidence that 
cancer stem cells exist in a wide array of tumours, it is becoming 
increasingly important to understand the molecular mechanisms that 
regulate self-renewal and differentiation because corruption of genes 
involved in these pathways likely participates in tumour growth. Studies of 
normal and cancer stem cells from the same tissue have shed light on the 
ontogeny of tumours. Understanding the biology of cancer stem cells will 
contribute to the identification of molecular targets important for future 
therapies.
Many observations suggest that analogies between normal stem cells and
cancer cells may be appropriate. Both normal stem cells and tumorigenic
cells have extensive proliferative potential and the ability to give rise to
new normal or abnormal tissues. Both tumours and normal tissues are
composed of heterogeneous combinations of cells, with different
phenotypic characteristics and different proliferative potentials (96).
Because most tumours have a clonal origin (97), tumorigenic cancer cells
must give rise to phenotypically diverse progeny, including cancer cells
with indefinite proliferative potential. Although some of the heterogeneity in
tumours arises as a result of continuing mutagenesis, it is likely that
heterogeneity also arises through the aberrant differentiation of cancer
stem cells. In other words, both normal and tumorigenic stem cells give rise
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to phenotypically heterogeneous cells that exhibit various degrees of 
differentiation (62).
In contrast to normal stem cells, it has been proved that CSCs undergo 
genomic alterations that allow them to escape cell cycle regulation and 
achieve growth factor and anchorage independence proliferation and 
resistance to apoptosis, besides contributing to dysregulation of self 
renewal and expansion (2). The acquisition of each of these characteristics 
is complementary to the others and requires a suitable microenvironment in 
which the transformed stem cells are believed to proliferate and 
differentiate into an entire tumour (41). The plasticity gained by CSCs is 
regulated by a cooperative effect of cell intrinsic (autocrine) factors, which 
may either involve changes in DNA sequences of genes or gene silencing 
through methylation or altered chromatin architecture (genetic and 
epigenetic effects), together with cell extrinsic (paracrine or derived from 
tumour microenvironment) factors (98). Plasticity makes also possible for 
differentiated cells to acquire cancer stem cell properties in the presence 
of the appropriate oncogenic insults. Thereby, proliferating proto- 
oncogenic stem cells appear to require at least one additional permanent 
genetic mutation to drive them along a trajectory toward transformation 
(99) (100). This could be achieved either through oncogene activation or by 
silencing of tumour suppressor genes, which effectively supplements the 
perturbed shift toward self renewal; continuing mutagenesis would further 
ensure clone amplification and disease progression (91).
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Another common feature of tumour and tissue stem cells is the utilization of 
similar signal pathways that normally control cell fate (101) (102). Such 
regulatory signal molecules, including components of the Notch, Wnt and 
Hedgehog pathways, have been shown to play roles in controlling stem cell 
self renewal and in regulating lineage fate in different systems. In 
numerous tumours, however, the signalling cascades initiated by these 
molecules have recently been demonstrated to be dysregulated. In the skin, 
liver, colorectal and pancreatic cancers, for example, Wnt signalling has 
been demonstrated to be aberrantly activated (103) (104). In ovarian
cancer, the Wnt signal transducer ft-catenin is overexpressed at an
advanced stage of tumour progression (105). The Hedgehog cascade, a 
regulator of patterning during embryonic development, has been shown to 
be associated with breast (106), ovarian (107) and prostatic cancers (107), 
whereas Notch over-stimulation has been strongly implicated in T cell 
malignancies (108). An important difference in the signal between normal 
and transformed states is that those in normal tissue are transiently 
expressed as stem cell activating signals, whereas in cancer these signals 
dominate and lead to a state of long term or permanent activation (106) 
(107) (Table l.B).
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Table l.B: Summary of the common properties between normal and cancer stem
cells
CHARACTERISTICS SHARED BY NORMAL AND CANCER STEM
CELLS
• Capacity for asymmetric division (self renewal), which gives rise to a 
quiescent stem cells and a committed progenitor and contributes toward 
developing a critical mass of cells
• Regulation of self renewal by similar signalling pathways (Wnt, Sonic 
Hedgehog and Notch) and at the epigenetic level by Polycomb genes 
(BMI-1)
• Expression of factors such as 0ct4, Nanog and Sox2, which maintain a 
functional plasticity by promoting pluripotency and immortality
• Extend telomeres and telomerase activity that increases the cellular life 
span
• Expression of ABC transporters, contributing to cellular resistance 
against specific growth-inhibitory drugs
• Expression of similar surface receptors (e.g. CXCR4, CD133 CD117, 
CD44) that are either identified as stem cell markers or associated with 
homing and metastasis.
• Predisposition for growth factors independence and stimulation of 
angiogenesis through secretion of growth factors, cytokines and 
angiopoietic factors.
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1.4 Therapeutic implication of cancer stem cells: 
chemoresistance and radioresistance
1.4.1 Genome integrity and cytoprotective strategies 
As the longest-lived, mitotically active cells in the body, stem cells are 
particularly sensitive to the accumulation of genetic lesions. Preserving 
genomic integrity is important for maintaining normal function as well as 
preventing carcinogenesis. This is more important in stem cells than in 
other cells because stem cells pass mutations on to large numbers of 
progeny, amplifying the risk of cancer. Many mechanisms protect stem 
cells from endogenous and exogenous mutagens or enhance their capacity 
to repair the damage that occurs. In cases where the damage is too 
extensive to be repaired, stem cells may undergo apoptosis or senescence. 
The long-term self-renewal potential of tissue stem cells depends on 
mechanisms that maintain their genomic integrity, such as those involved in 
ROS detoxification, DNA damage repair and telomere maintenance.
Reactive oxygen species (ROS) are toxic products of oxidative metabolism. 
Although important for certain physiological processes such as intracellular 
signal transduction and combating pathogens, excessive levels of ROS 
within cells can damage lipids, proteins, RNA, and DNA, thus impairing 
cellular function.
Stem cells reside in their niches where the oxygen tension is thought to be 
extremely low (1-4%) (109) (110). These hypoxic environments favourably
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support the undifferentiated stem cells to perform anaerobic metabolism. A 
metabolic shift from anaerobic glycolysis to mitochondrial respiration, for a 
more efficient production of ATP, is required for the higher energy demand 
of cells undergoing differentiation. At the same time, the coordinated up- 
regulation of antioxidant enzymes ensures a proper redox environment for 
differentiating cells to prevent excess ROS and oxidative stress resulting 
from the exuberant oxidative phosphorylation.
FoxO family transcription factors are tumour suppressors that protect stem 
cells and other cells from oxidative damage, reducing mutagenesis and 
extending cellular lifespan (111). FoxO transcription factors increase the 
expression of genes required for the detoxification of ROS including 
superoxide dismutase and catalase as well as genes that promote 
quiescence (112). Orciani and collaborators determined the susceptibility to 
oxidative stress of isolated mesenchymal stem cells from human skin (S- 
MSCs) in comparison with keratinocytes (113). Human keratinocytes seem 
to have much greater antioxidant defence to counteract the oxidative injury 
to which they are continuously exposed in the skin. The S-MSCs are 
surrounded by a complex microenvironment that protects them from 
external insults, and so they do not have a particularly efficient defence 
system, and they were generally less responsive to enhanced pro-oxidant 
challenge. As a matter of fact, S-MSCs seem particularly prone to apoptotic 
events, which might thus represent their primary defence mechanism (113).
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The genomic DNA of normal cells is under continuous assault from intrinsic 
insults, such as oxidative stress, and extrinsic insults, such as ultraviolet 
(UV) light and ionizing radiation (IR). In dividing cells, the DNA may also 
suffer from the introduction of errors during the replication required for 
mitosis. Cells have therefore had to evolve mechanisms to maintain 
genomic stability. In response to DNA damage, a cell may trigger a 
checkpoint response that induces cell-cycle arrest and allows the cell time 
to repair the DNA damage before cell-cycle progression is resumed. 
Alternatively, if the DNA damage is too severe, the cell becomes senescent 
or undergoes apoptosis. A defect in a DNA damage checkpoint response 
can result in unchecked mutation and genomic instability.
The consequences of these processes for stem cells can be profound: 
diminution in stem cell pools, or an increased chance for stem cell 
differentiation or malignant transformation (114) (115). In normal stem 
cells, genomic stability is maintained through enhanced DNA damage 
recognition and repair, which provide a robust defence for the cell. Studies 
of gene expression in stem cell populations have established that a small 
number of genes in stem cell populations are consistently over-expressed. 
A surprising number of these are DNA repair genes, including those 
involved in mismatch repair (MMR) and non-homologous end joining (NHEJ) 
repair systems (116) (117).
Little is known about molecular mechanisms implicated in DNA damage 
response in somatic stem cells; however, a peculiar response to DNA 
damage could be observed in stem cells during the transition from
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pluripotency to lineage commitment. It is likely that the DNA damage 
response is different depending on the specific stages along the transition 
from multipotent stem cells to terminally differentiated progenies. A more 
radical solution, such as elimination of repair defective cells by apoptotic 
mechanisms, appears to be adopted by stem cells at earlier stages to 
ensure the genomic stability of their progenies (118) (119) (120). Moreover 
essential players of the DNA damage-activated responses typical of 
proliferating cells, such as ATM, p53, ATR and Chkl, appear involved in 
the regulation of DNA damage response in stem cells during renewal and 
homeostasis (118).
Mechanisms involved in telomere maintenance are also crucial for genomic 
integrity and self renewal potential of stem cells. Mammalian telomeres are 
repetitive DNA sequences (thousands of TTAGGG repeats) along with 
specialized protein complexes that are located at the ends of chromosomes 
(121). Telomeres are required to protect chromosomes from fusing to each 
other, from exonuclease activity, and from the loss of coding sequences 
due to the end replication problem (121). In most somatic cells telomere 
length shortens with each cell division. In cells with a high capacity of self 
renewal, such as stem cells and cancer cells, routine telomere shortening is 
prevented by expression of the telomerase complex. In stem cells 
telomerase expression is necessary for maintaining self renewal potential, 
reducing the rate at which telomeres erode and increasing their replicative 
capacity (109) (122).
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A general conclusion is that differentiation and apoptosis represent the 
major mechanisms adopted by different stem cell types to protect their 
genome integrity. If the damage does not impair the stem cell pool and the 
consequent mutations do not alter progenitor functions, stem cells lead to 
differentiation. In the case of extensive damage, apoptosis and senescence 
represent the only mechanisms avoiding the risk of mutated progeny, 
leading to cancer. In both cases a direct and extreme consequence of this is 
that unrepaired DNA lesions may cause stem cell exhaustion.
Many stem cells have acquired the ability to withstand cytotoxic insults 
through either efficient enzyme-based detoxification systems or by the 
ability to rapidly export potentially harmful xenobiotics. The ABC 
superfamily of membrane transporters is one of the largest protein classes 
known, and is characterized by expression of an ATP-binding cassette 
region functioning to hydrolyse ATP, supporting energy-dependent 
substrate exportation across membranes, principally from the intracellular 
cytoplasm to the extracellular space (123). The large superfamily of ABC 
transporters is portioned in smaller sub-families with functional 
differences. The ABCA sub-family members have been mostly related with 
lipid trafficking in a wide range of body locations, whereas ABCD, ABCE 
and ABCF have roles in very long chain fatty acid transport, initiation of 
gene transcription and protein translation, respectively (124) (125). In 
humans, the three major types of multidrug resistance (MDR) proteins 
include members of the ABCB (ABCBl/MDRl/P-glycoprotein), the ABCC
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(ABCC 1/MRP 1, ABCC2/MRP2, probably also ABCC3-6, and ABCCKHL1), 
and the ABCG (ABCG2/MXR/BCRP) subfamily. Although recognized 
substrates are mostly hydrophobic compounds, MDR pumps are also 
capable of extruding a variety of amphipathic anions and cations. ABCB1 
preferentially extrudes large hydrophobic molecules, while ABCC1 and 
ABCG2 can transport both hydrophobic drugs and large anionic compounds 
(123) (126).
The expression of transport proteins and multidrug resistant proteins 
protect stem cells against toxins and are associated with the efflux of 
xenobiotic toxins, a low rate of cell division and active DNA repair. ABC 
transporters have emerged as an important field of investigation in the 
regulation of stem cell biology (69) and, significantly, ABCG2, an ABC 
transporter found in many stem cells, is up-regulated in hypoxic 
environments, such as the stem cell niches, mediated by H IF l-a (123) (69). 
ABCG2 has a unique function in stem cells and its role is to maintain 
progenitor cells in an undifferentiated state. This hypothesis was supported 
by the results of bone marrow transplantation studies (127). 
Transplantation of ABCG2~overexpressing bone marrow cells into lethally 
irradiated mice resulted in a lower number of mature hematopoietic cells. 
This finding was interpreted as an indication that ABCG2 causes the efflux 
of a substance important for differentiation. In any case, high ABCG2 
expression in stem cells suggested that it has a functional role in stem cell 
survival and that it can be used as a tool for stem cell enrichment (128) 
(129).
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ABC transporters are not the only cytoprotective molecules present in adult 
stem cells; the aldehyde dehydrogenase (ALDH) gene superfamily encodes 
detoxifying enzymes for many pharmaceuticals and environmental 
pollutants (123) (130) (131). Indeed, Aldehyde dehydrogenases are a group 
of NAD (P) + /-  dependent enzymes involved in the metabolism of a wide 
variety of aliphatic and aromatic aldehydes. They serve to detoxify 
xenobiotic aldehydes (e.g. cyclophosphamide) and many other intracellular 
aldehydes, e.g. ethanol and vitamin A (132) (133) (134). In conjunction with 
other markers, high levels of ALDH activity have been shown to 
characterize highly clonogenic, undifferentiated multipotential 
stem/progenitor cells in both human bone marrow (135) and blood (136). 
High ALDH activity has also been used to detect putative stem/progenitor 
cells in a variety of solid organs (137) (138).
In normal human mammary epithelia, the ALDH+ population entirely 
contains the clonogenic cells that can generate both myoepithelial and 
luminal cells (137). This role of ALDH as stem cell marker has also been 
investigated in cancer tissue. A growing body of evidence indicates that 
ALDH activity represents a promising CSC marker (139) (140). Among 
ovarian epithelial tumours the role of ALDH1 as CSC marker is debated. 
Sun and collaborators showed that the isolation of ALDH positive cells had 
greatly enriched for clonogenic, tumorigenic, and metastatic cells in 
adenoid cystic carcinoma (141). Contrarily, in another paper ALDH1 
immunohistochemical staining of a large cohort of ovarian carcinomas 
suggested that high expression of this transporter was a good prognostic
43
factor (142), the opposite of what is found for many tumour types, 
particularly the breast.
A further mechanism that stem cells appear to employ to reduce 
susceptibility to potential toxins is through low expression of certain 
cytochrome P450 enzymes, a superfamily of haemoproteins involved in 
oxidative metabolism, which catalyze largely oxidative reactions, including 
those of pharmacological and toxicological importance (143).
1.4.2 Drug resistance in cancer stem cells and new therapeutic 
strategies
Several mechanisms have been hypothesized as a basis for drug resistance 
in solid tumours, including drug inactivation, quiescence, and increased 
DNA repair in chemoresistant tumour cells (144). The classical drug 
resistant model sustains drug selection of clones possessing mutations that 
confer a survival advantage from various drug insults. From this point of 
view, each cell within the tumour would have an equal probability of gaining 
such mutations (144). However the above mentioned phenotypes also 
characterized normal stem cells, as described in the previous paragraph. 
CSCs are expected to share many of the typical properties of normal stem 
cells, which may underlie their capacity to survive to common therapeutic 
protocols (145).
As a consequence of the CSC theory, it is believed that malignancies, that 
initially undergo complete remission but subsequently relapse to a 
refractory state (146) (147), are expected to possess tumour stem cells
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that have acquired the property to escape clinical treatments. From the 
CSC model point of view, chemotherapeutics preferentially target TA cells, 
causing tumour regression, but fail to eradicate drug-resistance CSCs (FIG. 
1.7).
TA or Differentiated Tumor Cells
Chemotherapy Proliferation
New tumour 
with
Chemoresistant Phenotype
Figure 1.7- Model proposed for drug-resistant CSCs
Following false complete remission of the disease, CSCs proliferate and 
most probably confer the drug resistant phenotype to their progeny, 
resulting in a tumour that is fully refractory to further treatment. Therapies 
are greatly needed that exclusively target the small percentage of tumour 
progenitors in addition to the non-tumorigenic progeny that comprise the 
bulk of the tumour mass.
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In thyroid cancer, resistance to therapy-induced cell death results from the 
high expression of anti-apoptotic proteins and has been connected with the 
autocrine production of interleukin-4 (IL-4) (148). More recently, an IL-4 
antagonist was shown to strongly enhance the anti-tumour efficacy of 
conventional chemotherapeutic drugs through selective sensitisation of 
colon cancer stem cells identified by CD133+ expression (149). It seems 
that the efficacy of conventional chemotherapy regimens may be 
significantly improved when combined with adjuvant treatment, such as 
anti-IL4 (150). Thus, targeted therapies that suppress or destroy tumour 
stem cells directly may synergize with traditional therapies to provide 
increased efficacy in tumour eradication.
Resistance to radiotherapy has been associated with reactive oxygen 
species (ROS), critical mediators of radiation-induced cell killing. Lower 
ROS levels in CSCs results from increased expression of free radical 
scavenging systems; therefore pharmacological depletion of ROS 
detoxifying enzymes could significantly increase radio-sensitization of 
CSCs (151).
Moreover, as tumour stem cells maintain the ability to differentiate, agents 
that induce differentiation may play a therapeutic role against CSCs 
eradication. Both DNA methyltransf erases (DNMTs) and Histone 
deacetylase (HDACs) may have a role in suppressing genes related to 
differentiation. As consequence, HDACs and DNMTs inhibitors, alone or in 
combination with conventional chemotherapies, are strongly anti­
proliferative agents to drug resistant human cancer cells, whereas no
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effects were observed on normal epithelial cells. These date suggest that 
these therapies may hold the potential to directly target tumour stem cells 
(152) (153).
Recently, high-throughput screening for selective CSC inhibitors was 
successfully carried out on EMT-induced breast epithelial cells as an in 
vitro model of mammary CSCs (154). This screen led to the identification of 
a compound, salinomycin that specifically inhibits proliferation of mammary 
CSCs and significantly reduces their relative proportion by more than 100- 
fold relative to paclitaxel, the commonly employed chemotherapeutic drug 
for breast cancer.
The ABCG2 and ABCB1/MDR1 genes are expressed in the majority of stem 
cells and in most of CSCs (145). The combined use of conventional 
chemotherapeutics drugs and ABC transporters inhibitors, such as Apatinib, 
a small-molecule multi-targeted tyrosine kinase inhibitor (155), could be 
used to specifically target CSCs, but this type of therapy may have toxic 
effects on a patient’s normal stem cells. Therefore, this approach needs to 
be adjusted carefully to avoid excessive toxicity.
Another approach to inhibiting CSCs is to target the proteins essential for 
the growth and maintenance of stem cells. For example, Patched (PTCH) is 
the receptor for Hedgehog (HH) molecules, an important pathway 
containing several genes either tumour suppressor genes or oncogenes and 
is mutated or over expressed in several type of cancers (156) (157) (158). 
Constitutive HH expression could be an important component in stem cell 
activation in many tumours and therefore an attractive target for cancer
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therapies. Other pathways critical to embryonic development and 
potentially important in cancer have also been described and include the 
WNT and NOTCH pathways (104) (159). A number of experimental 
inhibitors of these pathways have been developed (160). Inhibition of the 
Notch signalling pathway through pharmacologic and genomic approaches 
prevented sphere formation, proliferation, and/or colony formation in soft 
agar of breast CSCs and could be also useful tool for a combined therapy 
against CSCs in solid tumours.
These targeting strategies still require refinement but the discovery of an 
effective therapy specifically targeting the CSC subpopulation could help 
eradicate the cancer cell subpopulation capable of evading traditional 
therapy and so increase disease free survival. Essential in the optimal 
development of CSC targeted therapies will be the ability to disrupt the 
CSC subpopulation without affecting normal somatic stem cells. Identifying 
regulators of tumour initiating cells that are less critical in normal stem cell 
biology will be important in achieving greater success in control CSC 
growth and tumour relapse.
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1.5 The stem cell niche in health and malignancies
Stem cells are regulated and supported by the surrounding 
microenvironment, referred to as the stem cell niche, which provides stem 
cells with physical anchorage as well as membrane-bound and secreted 
factors that regulate survival, polarity, quiescence and differentiation. The 
concept of the stem cell niche was first introduced in 1978 by Schofield, 
who hypothesized that the stem cell in the multicellular organism is 
regulated by its environment, which imparts to it properties that may be 
altered by removal and isolation of the stem cell from this niche (161). 
Pertinent signals to the stem cell may be direct interactions with resident 
niche cells or extracellular matrix molecules or diffusible autocrine, 
paracrine and even endocrine signals (162), which are all integrated to 
provide the proper regulation and maintenance of the stem cell. The niche 
must be highly specialized and requires specific organization to balance and 
control the self-renewal and differentiation capabilities of the stem cell. 
The niche could be a single cell, as is the case in the Caenorhabditis 
Elegans, or a group of cells, as in the case in the Drosophila Melanogaster 
germline.
The microenvironments regulating the stem cells of higher organisms are
more complicated. In mammals the stem cell niche is composed of a group
of cells in a specific tissue location for the maintenance of stem cells. The
niche’s overall structure is variable, and different cell types can provide the
niche environment. In adults, the niche prevents tumorigenesis by
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controlling stem cells in the arrested state and maintaining the balance 
between self-renewal and differentiation. In this context, any mutation that 
leads stem cells to escape from the niche control may result in 
tumorigenesis (163). It is therefore reasonable to hypothesize that one of 
the differences between normal stem cells and cancer stem cells is that 
cancer stem cells may no longer be dependent on niche signalling (53). 
Some common features, structures, and functions of the stem cell niche in 
different tissues could be summarized as follow*
■ The niche functions as a physical anchor for stem cells. E-cadherin- 
mediated cell adhesion is required for anchoring GSCs and SSCs in 
Drosophila, and N-cadherin may be important for anchoring HSCs in 
the bone marrow niche. Other adhesion molecules, such as integrins, 
may help anchor stem cells to extracellular matrices (164) (90).
■ The niche generates extrinsic factors that control stem cell fate and 
number. Many signal molecules have been shown to be involved in 
regulation of stem cell behaviour, including Sonic Hedgehog (Shh), 
Wnt, Bone Morphogenetic Proteins (BMPs), Fibroblast Growth 
Factors (FGFs), Notch, Stem Cell Factor (SCF), Angiopoietin-1 
(Ang- 1). The BMP and Wnt signal pathways have emerged as 
common pathways for controlling stem cell self-renewal and lineage 
fate from Drosophila to mammals (86) (165).
■ In invertebrates and mammals, the stem cell niche exhibits an
asymmetric structure. Upon division, one daughter cell is maintained
in the niche as a stem cell (self-renewal), whereas the other
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daughter cell leaves the niche to proliferate and differentiate, 
eventually becoming a functionally mature cell (166).
Locating and further identifying stem cell niches in mammals have been 
difficult, owing to their extremely complicated anatomic structures. Studies 
regarding stem cells and their location/niche in other genetic model 
systems, including those of Drosophila and Caenorhabditis Elegans, have 
been fruitful. In Drosophila, GSCs were located in the anterior region of 
ovary germarium. The germarial tip adjacent to GSCs was defined as the 
niche supporting GSCs in the Drosophila ovary (164), whereas the hub, 
located at the tip of Drosophila testis, served this function (167). In C. 
Elegans, a distal tip cell (DTC) located at the tip of the germ line 
organization region was found to function as the niche in supporting GSCs 
(168).
Adult mammalian stem cell niches are more complex due to the presence of 
multiple potential sites for stem cells as well as a number of candidate 
niche cells and extracellular components that are involved in the regulation 
and maintenance of the tissue specific stem cells. In mammals, a stem cell 
niche was successfully identified in the bulge area of hair follicles, in the 
intestinal crypt base, in the mammary gland, in the Subventricular Zone 
(SVZ) of the Nervous Central System (NCS) and in the haematopoietic 
system (110) (169) (170).
Two stem cell niches have been recognized in the mammalian brain, one in
the SVZ and a second in the subgranular zone (SGZ). NSCs isolated from
the SVZ, the best characterized, differentiate into both neurons and glia in
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vitro (171) and are regulated by both contact-dependent factors and 
diffusible signals. In both the SVZ and SGZ structures, endothelial cells that 
form blood vessels and the specialized basal lamina are an essential 
component of the NSC niche. Endothelial cells provide attachment for SVZ 
and SGZ astrocytes and generate a variety of signals that control stem cell 
self-renewal and lineage commitment (172). Brain tumors appear to occupy 
similar niches to normal NSCs. Recent work demonstrate that Nestin+ 
CD133+ brain CSCs associated directly with vascular endothelial tubes, 
and a mouse xenograft model, where co-injection of endothelial cells with 
malignant cells led to more rapid tumor growth (173). Recently, cells 
expressing stem cell markers were found to localize not only to the 
perivascular niche but also to areas of necrosis (174). This raises the 
possibility of a hypoxic niche for brain CSCs, located surrounding vascular 
tubes in strict association with endothelial cells.
From a general point of view, a majority of mutagenic agents described to 
confer a risk for cancer also perturb normal stem cell homeostasis and 
their niche, besides inducing changes in the DNA of some stem cells and 
impairing or enhancing some of their characteristics properties (175).
These mutated stem cells may remain in a state of perpetual activation and 
may be controlled by intercellular communications or by 
autocrine/paracrine factors produced by the niche. The niche could play a 
pivotal role in cancer stem cell self renewal and tumour progression, 
accentuating CSC activation and further differentiation. Another function of 
the tumour niche is the active recruitment of new endothelial and stromal
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cells into tumours that is essential for developing a pro-angiogenic 
environment that enhances tumour survival under adverse conditions (176) 
(177).
In conclusion, it could be possible that sternness is a function of 
microenvironment. The properties of CSCs in different tumours may vary 
significantly, depending on their location within the tumour mass and the 
different cell types or soluble factors characterizing the tumour 
environment. Up to now, several models for the existence and composition 
of CSCs niche have been postulated (178). Firstly, CSCs may not require a 
specific tumour niche and may be capable of surviving in the normal stem 
cell niche. Alternatively CSCs may depend on a pre-activated CSC niche 
for their expansion and survival. Another possibility is that CSCs may 
influence the local microenvironment by secreting different signalling 
molecules, creating their own niche. Finally, CSCs may acquire the ability 
to autonomously provide the necessary factors for expansion and self 
renewal, becoming niche independent.
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1.6 Cancer stem cells and metastasis
In the vast majority of cancers, primary malignancies are responsible for a 
mere 10% of deaths whereas the main cause of mortality is metastases. 
Metastasis is a complex, multi-step process where specific cellular and 
molecular mechanisms are involved. In the case of carcinoma this process 
includes basement membrane destruction and local invasion into adjacent 
tissue, intravasation and survival in the bloodstream, extravasation into 
distant organs and, finally, cancer cell colonization, which implies the cell 
capacity to survive and proliferate at the metastatic site (39). During all 
these steps, tumour cells undergo profound changes in cell adhesion 
properties, involving cell-to-cell contacts and cell-to-extracellular matrix 
adhesion, in addition to the expression of extracellular proteases. Those 
changes lead to the remodelling of cell-cell contacts, degradation of the 
extracellular matrix and migration of the cancer cells into adjacent tissues 
(179).
Epithelial to mesenchymal transition (EMT) is the biological process 
through which epithelial cells acquire a mesenchymal identity (180). EMT is 
a highly conserved process that governs meaningful events during embryo 
development and in the adult life. In the adult organism, EMT is engaged 
during wound healing, tissue regeneration and organ fibrosis (181). In 
cancer, EMT is thought to confer on cancer cells the ability to detach from 
the primary mass and to acquire more motile features. At the metastatic
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site the recapitulation of the primary mass is achieved by the reverse 
process of mesenchymal to epithelial transition (MET) (180).
In general terms, the EMT process involves a complex genetic program 
which is characterised by the repression of epithelial markers and the 
induction of mesenchymal and migration-related markers. Numerous
pathways, such as those triggered by EGF and TGFft growth factors,
activate the EMT program, inducing loss of cell polarity and down- 
regulation of the epithelial marker E-cadherin, whose functional repression 
is considered the hallmark of EMT (180) (182). E-cadherin is a central 
component of cell-cell adherent junctions and is required for the formation 
of epithelia in the embryo and to maintain epithelial homeostasis in the 
adult (183). During tumour progression E-cadherin down regulation is a 
frequent event and its inactivation or silencing can be achieved by different 
mechanisms (184) (185). Most, if not all, well characterised E-cadherin 
repressors are known as EMT inducing developmental regulators. Two of 
the major members of the Snail zinc-finger transcription factors family, 
known as Snail (or Snail 1) and Slug (or Snail2), play an important role 
during EMT, blocking E-cadherin expression. Other important regulators of 
E-cadherin transcription, involved in the EMT process, are SIP1 (or ZEB- 
2), ZEB-1 and Twist (185) (186).
Snail and Slug play crucial roles during EMT, not only repressing E - 
cadherin expression, but also conferring additional properties. Both Snail 
and Slug seem to confer protection against cell death induced by external
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stimuli and resistance to genotoxic agents, including yirradiation and
chemotherapeutic compounds (186). Thus, it is possible that the expression 
of Snail and Slug in cancer cells stimulates not only the EMT process but 
also confer to a tumour cell cancer stem cell properties, such as metastatic 
and chemo/radio resistance attributes. To confirm this hypothesis Bapat 
and co-workers has recently published a brilliant paper (186) where Snail 
and Slug were demonstrated to regulate not only EMT in ovarian cancer 
cells, but also to be involved in the acquisition of stem cell properties 
toward resisting radiotherapy or chemotherapy mediated cellular stress. In 
this study they showed that Snail and Slug directly participate in p53 
mediated pro-survival signalling through active repression of pro-apoptotic 
genes. Furthermore Snail and Slug regulate indirect activation of a self 
renewal program and the expression of sternness genes, such as OCT4, 
NESTIN  and BMI1 (186).
Another character frequently associated with EMT is cadherin switching, 
from the epithelial (E-cadherin) to mesenchymal type (N-cadherin). By 
expressing N-Cadherin on the surface of carcinoma cells, their affinity to 
stromal cells, naturally expressing N-Cadherin, is increased. Malignant 
cells acquire a fibroblastic morphology and the ability to degrade the basal 
lamina, invade through the surrounding tissues and metastasize (FIG. 1.8).
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Figure 1.8' EMT and CSCs
Recent studies support the notion that metastasis capacity is pre­
determined by genetic changes acquired at the initial stages of tumour 
development (187) (188). The biology of CSCs may have important 
implications when applied to the study of cancer metastasis. In many solid 
tumours, both circulating tumours cells (189) and cells at established sites 
of metastasis (190) contain a higher proportions of cells expressing stem 
cell markers, suggesting that CSCs are more capable of metastasizing than 
differentiated tumour cells, and/or that CSCs survive better in metastatic 
sites than the other malignant cells.
Several characteristics of CSCs make them the major candidates able to 
occupy unfamiliar sites and sustain metastatic growth. The inherent 
plasticity of stem cells makes them more adept to survive in a diverse 
environment where growth factors and other signalling molecules are
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different than in the primary tumour site. Moreover, CSC tumour-initiating 
capacity is necessary at any metastasis site to give rise to a new tumour 
mass. Therefore, even if non-CSCs migrate, only the CSC subpopulation is 
able to expand into heterogeneous metastatic lesions.
Numerous molecules and pathways have recently been identified to 
regulate both stem cell migration and cancer metastasis (191). These 
molecules comprise a complex network of cellular interactions that makes 
possible the formation of an organ microenvironment for migrating CSCs. 
Cell surface receptors and their ligands required for their activation, such 
as SDF1 and CXCR4, are expressed during normal stem cell homing and 
mobilization as well as cancer cell metastasis. It is notable that the SDF-1 
chemokine receptor CXCR4 is expressed on immunophenotypically 
identified CSCs in many primary solid tumours, including breast and 
glioblastoma (192). CXCR4 expression may mediate homing of CSCs to 
metastatic sites such as the liver and BM that express high levels of SDF-1 
at baseline.
Also soluble factors participate in directing tumour metastasis and in 
creating a favourable environment for tumour spreading. Cytokines 
produced by the primary tumour may actually create the metastatic 
microenvironment in distant organs (193) (187). For example, VEGFR1+ 
haematopoietic progenitor cells are stimulated by cytokines released from 
the primary tumours and travel to sites of future metastasis. It is thought 
that the presence of these cells changes local microenvironments to make 
them more favourable for metastases (194). Whether this process might
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induce a niche that is particularly helpful for CSCs represents an intriguing 
pathway for investigation. It is believed that these microenvironmental 
changes not only promote tumour progression but also enhance CSC 
survival.
In light of significant advances in metastasis and stem cell research, a 
CSC-based model for both tumorigenesis and metastasis could be 
proposed. During the establishment of the CSC pool, CSCs inherit a unique 
set of genetic and/or epigenetic changes that determine the cancer 
malignancy, metastatic potential and the tissue tropism. Molecular crosstalk 
between the primary tumour and the pre-m etastasis niche through secreted 
stimulatory signals helps manage the homing of metastatic CSCs. 
Trafficking towards favourite tissues and organs of metastatic CSCs is 
guided by cues such as oxygen gradients or other chemo-attractants 
derived from niche sites (120) (195) (171) (172). CSCs and metastatic CSCs 
at primary and secondary sites can either takeover the niches of normal 
stem cells or recruit new components to form a permissive niche. 
Metastatic CSCs may then either proliferate at the new site or stay 
dormant, similar to the quiescent state of normal stem cells (196). 
Stimulatory factors from the niche can lead to reactivation of the CSCs and 
formation of a metastatic lesion, which may partly explain temporal 
patterns of primary tumours versus secondary tumours (197). Metastatic 
CSCs at metastatic sites maintain most of the genetic programs acquired at 
the primary tumour site through self-renewal, which explains the 
phenotypic similarities between primary and metastatic cancers (198).
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However, metastatic CSCs in secondary sites are able to evolve 
independently by accumulating additional genetic alterations that render 
them resistant to treatments that are effective against primary tumours.
1.7 Chemokines in cancer stem cells and metastasis
1.7.1 Roles of chemokines and their receptors in cancer 
Numerous clinical studies have clarified that selected chemokine receptors 
are often up-regulated in a large number of common human cancers, 
including those of the breast, lung, prostate, colon, ovary and melanoma 
(199) (40) (200). Chemokine receptors and their corresponding chemokine 
ligands have been shown to play a number of non-redundant roles in 
cancer metastasis to vital organs as well as regional lymph nodes, the most 
frequent site of cancer metastasis. Indeed, chemokine receptors may 
potentially facilitate tumour dissemination at several key steps of 
metastasis, including adherence of tumour cells to endothelium, 
extravasation, metastatic colonization, angiogenesis, proliferation and 
protection from the host immune response by activation of well known 
survival pathways (201) (202).
The function of chemokines was firstly demonstrated for leukocytes, which
use these proteins to arrest at inflamed blood vessels and as guides to get
to specific sites of inflammation. The specific roles of chemokines for
leukocyte site-specific homing at inflammatory sites also suggest their
possible contribution in several of the key steps of metastasis (39) (199).
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Chemokines are small chemotactic cytokines which bind to G-protein linked 
receptors (203) and are divided into the following four subgroups- CXCL, 
CCL, CX3CL and CL (204).
Homeostatic chemokines are involved in the development and the 
homeostasis of the immune system, whereas inflammatory chemokines are 
released in consequence of special stimuli (injuries, inflammation) and 
induce leukocyte homing to the affected tissue site. They are released 
during inflammation and engage lymphocytes in the course of the immune 
response (203).
In the context of cancer, chemokines regulate tumorigenesis in at least four 
different ways-
■ By acting as homing factors, as well as by autocrine growth 
stimulation (205) (206).
Chemokines secreted by tumours not only draw infiltrating cells into 
tumour sites but they may also contribute to tumour cell growth.
■ By modulation of angiogenesis.
In this regard, a specific set of chemokines act as a direct 
chemotactic factor for endothelial cells and can stimulate the 
creation of new blood vessels within the tumour. CXCL12, the ligand 
of CXCR4, is produced by both stromal cells and cancer cells and 
increases the expression of Vascular Endothelial Growth Factor 
(VEGF) in endothelial cells, thus stimulating neo-angiogenesis 
within the tumour mass (205) (207).
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■ By activating the tumour-specific immune response.
Tumour cells, stromal cells, as well as inflammatory cells contribute 
to the chemokine milieu at the tumour site (208).
Inflammatory cells play positive and negative roles in tumorigenesis 
(209) (210). Tumour associated chemokines may control
inflammation within tumours and as a consequence, inhibit or 
increase the capability of the immune system to eliminate cancer 
cells.
Ovarian cancer cells, for example, produce inflammatory 
chemokines such as CCL2 and CCL5 (211). High levels of CCL2 
stimulate the homing of macrophages in the same area that release 
a variety of factors, including matrix metalloproteinases (MMPs); 
MMPs may increase the invasiveness of cancers and are clinically 
associated with poor outcomes in cancer patients (212). In contrast 
to CCL2, the presence of CCL5 was correlated with infiltration of 
CD8+ T cells and may favour immune responses against tumour 
cells (211).
Tolerance to tumour cells may also be mediated by a subpopulation 
of naturally occurring T regulatory cells (Tregs). Through contact- 
dependent mechanisms, Tregs suppress the cytotoxic ability of 
CD8+ cytolytic T cells (CTL) (213). Ovarian cancer cells and 
tumour-infiltrating macrophages are both able to secrete the CCR4 
ligand, CCL22, and appear to be responsible for the recruitment of 
Tregs (CD4+ CD25+ CD3+ CCR4+) into tumour tissue in a CCL22-
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dependent manner. Thus, CCR4+ Tregs apparently infiltrate into 
tumours in advanced disease and inhibit the activity of tumour 
specific CTL, possibly leading to the poor outcome observed in this 
subset of patients (214).
Another mechanism by which certain tumours escape the immune 
system is through the chemorepulsive activity of high levels of 
CXCL12 (SDF-1). At low concentration, CXCL12 acts as a T cell 
chemo attract ant (215), otherwise can repel T cells both in vitro and 
in vivo via a CXCR4 dependent mechanism (209).
In conclusion, according to which chemokines are released within 
the tumour mass, opposite events may occur: copious production of 
pro-inflammatory chemokines can pilot a strong inflammatory 
response and can potentiate angiogenesis, thus favouring a rapid 
neoplastic growth. Alternatively, high levels of monocytes and/or 
neutrophil infiltration, for example, in response to lower levels of 
pro-inflammatory chemokines, can be associated with angiostasis, 
cytotoxicity, and possible tumour regression (210).
1.7.2 CXCL12/CXCR4 axis plays a pivotal role in CSC metastasis 
CXCR4 is one of the most common chemokine receptors that has been 
demonstrated to be over-expressed in certain human cancers (203) (216). 
The role of the SDF-1-CXCR4 axis was initially studied in haematopoietic 
cells (204), where it regulates the trafficking and homing of CXCR4 positive
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HSCs, p re-B  lymphocytes, and T lymphocytes (217) (218). However, 
besides this role, CXCR4 is also expressed  on the surface of various kinds 
of tissue stem cells (200), supporting their trafficking during development, 
tissue injury, and regeneration.
The binding of CXCL12 to CXCR4 leads to the activation of divergent 
signalling pathways, which can stimulate multiple responses such as 
chemotaxis, cell survival and proliferation and increase intracellular calcium 
concentration or activate transcription of different genes (FIG. 1.9) (4). The 
following figure summarizes some of the key signalling pathways thought to 
be involved in CXCR4 signal transduction. The exact nature of these 
pathways may be tissue-dependen t and thus may diverge between cell 
types.
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Figure 1.9- A schematic picture of the CXCL12/CXCR4 intracellular signal
transduction pathways (4)
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The expression of CXCR4 is regulated at the molecular level by several 
transcription factors associated with organ development as well as those 
related to stress and tissue damage. PAX genes are over-expressed in 
different type of cancers and are responsible for high levels of CXCR4 
expression observed in tumours (219) (220). Beside PAX genes, CXCR4 
expression may also be positively regulated by transcription factors related 
to stress, hypoxia and tissue damage, such as NF-kB (221), hypoxia- 
inducible factor (HIF-1) (222), lysophosphatidylcholine (223), TGF-f31 
(224), VEGF (225), and several interleukins (IL-2, IL-4, and IL-7) (226). 
Thus, it is likely that stress-related conditions, often present in the tumour 
mass or after tissue damage, may up-regulate CXCR4 expression on both 
normal and malignant stem cells. Moreover, the sensitization of normal and 
cancer stem cell chemotaxis to a CXCL12 gradient is reliant on cholesterol 
content in the cell membrane and on the incorporation of the CXCR4 and 
the small GTPase Rac-1 into membrane lipid rafts. This co-localization of 
CXCR4 and Rac-1 in lipid rafts helps the activation of CXCR4 pathway and 
allows normal or cancer stem cells to better sense a CXCL12 gradient 
(227). In this regard, drugs that perturb lipid raft formation by depleting 
cholesterol from cells could negatively influence the metastatic properties 
of cancer stem cells (227).
Preliminary data, together with the reported role of various chemokines in 
metastasis, strongly support the idea that chemokine-mediated metastasis 
could play a key function in migrating CSCs.
65
This implies that the CXCL12-CXCR4 axis may influence the nature of 
tumours and direct the metastasis of CXCR4 positive CSCs by 
chemoattracting them to organs that highly express its ligand. CXCL12 can 
be found on the surface of liver, lung or bone cells, therefore, an increased 
number of metastases in these organs can be observed. Sustaining this 
notion, it has been recently reported that several CXCR4 positive cancers, 
such as breast, ovarian, prostate cancers and neuroblastoma, metastasize 
to the bones in a CXCL 12-dependent manner (228) (229) (230) (207).
It has been experimentally proved, using breast cancer cell lines, that the 
abrogation of CXCL12/CXCR4 signalling impaired breast cancer metastasis 
formation to regional lymph nodes and lung (231). Interestingly, inhibition 
of CXCR4 does not prolong the overall survival in mice with experimental 
lung metastases, but is able to delay or at least impair the proliferation of 
both the primary tumour and metastases (232). Furthermore, the formation 
of the EGFR/Neu heterodimer enhances both the expression of CXCR4, 
required for c-erbB -2 breast cancer cell invasion in vitro and in vivo, and 
inhibits ligand-induced CXCR4 degradation (233) (234). In addition to c- 
erbB-2 (HER2/neu), recent data point out that also CD24 affects CXCR4 
function in breast cancer cells (235). Indeed, CD24 expression reduces 
CXCL12-mediated cell migration and signalling via CXCR4. By contrast, the 
loss of CD24 was correlated with an enhanced CXCR4 lipid raft association 
concomitant with an increased cell migration (235). These results suit well 
to the phenotype of breast cancer stem cells: CD44+ CD24”/low ESA+ (236). 
Thus, if CD24 is truly linked to CXCR4 expression, breast cancer stem cells
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negative for CD24 should express elevated CXCR4 levels, which may be 
responsible for metastatic CSC spreading. However this hypothesis has not 
yet been proven.
The progression and organ-specific spreading of different tumours, such as 
breast, colon, and melanoma has been associated with avR3-integrin 
expression. A lot of data support the evidence of a critical relationship 
between avf33-integrin expression and the CXCL12/CXCR4 axis in prostate 
cancer. Recent findings show that not only CXCR4, but also the expression 
and activation of avf33-integrins is regulated by CXCL12 (237), which 
suggests a positive feedback loop for the adhesion, and subsequent 
prostate cancer metastasis formation in CXCL12 expressing tissues (238) 
(239). Based on these results prostate cancer stem cells, which are 
identified by the phenotype CD44+/ci2f31 integrin hlgh/CD133+, may also 
express CXCR4 and may use this receptor as cellular adhesion components 
and/or as extracellular matrix components for establishing tissue-specific 
metastasis.
Human pancreatic cancer tissue contains CSCs expressing CD 133 that are 
the most tumorigenic and highly chemotherapy resistant cells. Moreover, in 
the invasive front of pancreatic tumours, a distinct subpopulation of 
CD133+/CXCR4+ CSCs was identified as the population responsible for the 
metastatic phenotype of this tumour (240).
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1.7.3 Role of CXCL12/CXCR4 in metastasis of human ovarian cancer 
A central role for the CXCL12/CXCR4 axis in ovarian tumour metastasis 
was also identified and a correlation between the activity of this chemokine 
system and an enhanced intraperitoneal dissemination of Epithelial Ovarian 
Cancer (EOC) was described (241). Recent analysis showed the expression 
of CXCR4 and CXCL12 also in normal ovary, but their localization was 
confined to the follicular cells and it was not detected in normal epithelium 
(242).
Clinical studies also found that the prognosis of patients with a high level of 
CXCR4 is drastically worse than that of the patients with a low CXCR4 
level, indicating that CXCL12-CXCR4 axis plays an important role in the 
biology of ovarian tumours (243) (207) (244).
In vitro studies confirmed that, in the presence of CXCL12, CXCR4 controls 
both ovarian cancer cell proliferation and migration, through the activation 
of the ERK1/2 and Akt pathway (245). In addition it was also reported that 
CXCL12 effects on ovarian cancer cell lines are mediated by EGFR trans­
activation through a mechanism involving the activity of cytosolic tyrosine 
kinases belonging to the c~Src family (246). A possible important "cross­
talk" between CXCR4 and EGFR intracellular pathways might connect 
signals of tumour progression and proliferation and provided a plausible 
explanation for the poor overall survival of patients whose cancer tissue 
co-expressed both CXCR4 and EGFR (246) (207).
Human peritoneal mesothelial cells (HPMCs) coating the peritoneal cavity
bind to EOC cells in the preliminary step of peritoneal metastasis. CXCL12
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is principally expressed in HPMCs rather than in EOC cells, while CXCR4 
was found in both EOC and HPMCs, thus creating an extracellular 
chemotactic milieu for ovarian epithelial cancer cell migration (241) (247). 
The over-expression of HER2/neu in breast cancer enhances the 
metastatic potential through the up-modulation of CXCR4 (234). In a similar 
study performed on a group of ovarian tumour samples (248), HER2/neu 
positive patients did not show a higher CXCR4 expression. Intraperitoneal 
treatment with AMD3100 (CXCR4 inhibitor) resulted in reduced 
dissemination in nude mice inoculated with ES-2 ovarian cancer cell line, 
suggesting that CXCR4 inhibition could suppress the formation of peritoneal 
metastasis (241). Due to the particular way of ovarian cancer spreading and 
metastasis, it is possible that a complex cohort of chemokines, produced by 
different types of cells within the peritoneum, is responsible for the 
invasiveness and the metastatic potential of EOC.
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1.8 CD133 and its potential role as CSC marker
Prominin/CD133 is a 115/120-kDa integral membrane glycoprotein 
specifically associated with plasma membrane protrusions in epithelial and 
non-epithelial cells including neuroepithelial and haematopoietic stem cells 
(249). It displays a unique membrane topology with five membrane- 
spanning domains and eight potential N-glycosylated extracellular sites 
(FIG. 1.10, red circle) (250). CD133 (AC133) was the first identified 
member of the prominin family of pentaspan membrane proteins. The 
specific functions and ligands of the prominins are still relatively unclear, 
but they are distinct in their restricted expression within plasma membrane 
protrusions, such as epithelial microvilli and epididymal ductal epithelial 
sterocilia (FIG. 1.10 from (250) and (251)).
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Figure 1.10: CD 133 structure and cellular localization
A) CD 133 is a pentaspan membrane protein with eight potential N -glycosylated  
extracellular sites. B) CD133 is specifically associated  with plasma m em brane 
protrusions in epithelial and non-epithelial cells.
Due to its location in membranous protrusions of the plasma membrane 
such as the microvilli of epithelial cells, CD133 was attributed a functional 
role as an ‘organizer’ of plasma membrane architecture (250). Interactions 
between CD133 and cholesterol within membrane m icro-domains (250) 
suggested that CD133 might also be essential in maintaining an appropriate 
lipid content within the plasma membrane (252).
Since its expression was found in haematopoietic progenitor cells (253), 
much attention has been focused on the potential role of CD 133 as a cell 
surface marker of adult stem cells. Indeed, in human haematopoietic 
lineages, CD133 antigen expression is restric ted  to CD34+ cells, although 
CD 133 transcripts have been found in many human cell lines and 
differentiated cells (254).
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Human AC 133+ cells, isolated from human peripheral blood and 
manipulated in vitro to undergo myogenesis, were shown to improve 
disease through a direct contribution to muscular regeneration when 
transplanted into a lineage of dystrophic mice, a model of Duchenne’s 
muscular dystrophy (255). Bussolati et al showed that a population of 
CD 133+ cells isolated from the adult human kidney were capable of both 
self-renewal and multi-lineage differentiation in vitro and in vivo, and could 
contribute to renal tissue regeneration by differentiation to form both 
epithelial and endothelial lineages (256).
Expanding evidence highlights the role of CD 133 as a marker of CSCs in 
various human tumours (257) (258). This assertion was supported not only 
by the fact that CSCs isolated from numerous tumours expressed this 
marker (259) (260) (261) (262) (263), but also by the fact that CD133 
expression is regulated by several pathways generally mutated in different 
types of cancer (264) (265) (266).
CD 133 was expressed in combination with CD44+ and (12P1 hlgh in 
approximately 0.1% of cells within a large series of prostate tumours, 
irrespective of their grade or metastatic state (262). These cells were able 
to self-renew and to proliferate and showed multi-lineage differentiation 
capabilities in vitro in order to recapitulate the original tumour phenotype 
(267) (262).
CSCs are significantly enriched in CD133+ subpopulations derived from 
human colon cancer and hepatocellular carcinomas, as shown by their
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potential to both self-renew  and differentiate, to form colonies and 
proliferate in vitro, and by their ability to reform the original tumour 
phenotype when transplanted either subcutaneously or into the renal 
capsule of immunodeficient mice (263).
Ovarian cancer CD133 expressing cells were able to self renew, giving rise 
to both CD 133 positive and negative cells, and were associated with 
enhanced resistance to platinum-based therapy (260). CD 133 positive cells 
in ovarian cancer were also shown to be involved in the establishment of 
tumour vasculature that is critical for tumour cell survival during disease 
progression (268). A controversy exists regarding the potential tumorigenic 
capability of ovarian CD 133 positive cells. Only one paper has 
demonstrated that CD 133 + ovarian tumour cells have increased
tumorigenic capability over CD133-cells and have the ability to regenerate 
a heterogeneous tumour similar to that found in the original patient (261).
A recent study assessed the changes in human cord blood-derived CD 133+ 
cells following culture in medium conditioned by cells that stably expressed 
specific Wnt signalling molecules (264). Regulation of the differentiation 
and proliferation status of CD 133+ cells by Wnt signalling matches with the 
role of CD 133 as a CSC marker. Indeed, Wnt signalling dysregulation 
through genetic alterations of its downstream components, such as APC or 
J3-catenin, is a common event in the pathogenesis of several cancer types 
(265).
A recent paper asserted that the sternness of medulloblastoma-derived 
CD133+ cells was related with the Notch signalling pathway (269). Notch
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blockade resulted in a 5-fold loss in the CD 133+ sub-population and in 
elimination of the CD 133+ side-population featuring high Hoechst dye 
exclusion (270). Moreover, in the highly aggressive brain tumour, 
glioblastoma multiforme, the HEDGEHOG (HH)-GLI pathway has been 
shown to regulate the self-renewal of the CD 133+ cells and, importantly, 
expression of the ‘sternness- associated gene signature’ (266).
A major problem with CSCs is their resistance to current therapies such as 
chemo- or radiotherapy (271) (272) (273). CD133+ TICs are resistant to 
therapy (273), consistent with their stem-like nature as reported both for 
chemotherapy (271) and radiation treatment (272). However, since the 
function of CD133 is unknown, it is not obvious if CD133 is just a marker of 
resistant cells or whether high expression of CD 133 in TICs could 
contribute to the resistance to therapy. Frank et al. (272) recently showed 
that CD133+/ABCG5+ melanoma cells were resistant to doxorubicin 
treatment and that melanoma tissue isolated from patients expressed high 
levels of both CD 133 and ABCG5. Moreover, CD 133+ glioma cells are also 
resistant to radiation therapy (271). Following radiation, glioma cells 
acquired a higher level of resistance, associated with increased CD133 
expression.
A lot of research strongly links high expression of the surface marker 
CD133 with tumour-initiating capacity and greater resistance to chemo- 
and radio-therapy, suggesting potential methods for selectively eradicating 
the TICs by targeting associated signaling pathways (265) (269) or the cell 
cycle machinery (271).
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Cervical cancer and ovarian cancer
1.9 Squamous cell carcinoma of the cervix: an overview
1.9.1 Epidemiology and aetiology
Cervical cancer is the second most common malignancy in women 
worldwide. Squamous cell carcinoma (SCC) remains the most frequent form 
of cervical cancer. However, the incidence of cervical adenocarcinoma has 
increased significantly over recent years (274).
Cervical cancer offers a unique opportunity for prevention because it is 
preceded by a well recognized pre-malignant form: cervical intra-epithelial 
neoplasia (CIN) in the case of squamous cell carcinoma and cervical 
glandular epithelial neoplasia in the case of adenocarcinoma. The 
introduction of cervical screening programs, based on the Papanicolaou 
smear, has significantly decreased the incidence of SCC of the cervix in 
developed countries. In contrast, the incidence of adenocarcinoma has 
continued to rise, even in developing countries, despite the introduction of 
screening programs (275). The reason of this discrepancy is partially due 
to difficulties in detecting the precursor lesions with conventional screening
(276).
Human papilloma virus (HPV) has been demonstrated to be the main 
aetiological agent in both squamous and adenocarcinoma of the cervix, with 
high-risk HPV types 16 and 18, detected in more than 95% of cervical 
cancers (277). Other cofactors may influence the progression from
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infection to cancer. These cofactors can either be specific to the host, to 
the virus itself or to the environment. Tobacco, Chlamydia infection in 
HPV-positive patients, multiparity, family history of cervical cancer, 
immunosuppression and HIV infection are statistically associated with 
cervical cancer, whereas the effects of oral contraceptives are 
controversial (278).
The human papillomavirus is organised into two groups- the low-risk types 
that include HPV 6, 11, 31, 33, 35, 42, 43 and 44, and high-risk forms that 
include HPV 16, 18, 45 and 46. The high-risk viruses cause lesions which 
more frequently progress to malignancy, and are present in 70% of 
invasive squamous cell carcinomas. 90% of squamous cell dysplastic 
lesions are caused by HPV 16, and more than 50% of the invasive 
squamous intraepithelial tumours contain HPV 16. In contrast, HPV 18 is 
implicated in small cell undifferentiated tumours and adenocarcinomas
(277).
Of the three causative molecular mechanisms of cervical cancer, two are 
associated with HPV: firstly, the effect of the viral oncogenes, E6 and E7 
and secondly, integration of the viral DNA into chromosomal regions of 
tumour DNA. The third process involved is the repetitive loss of 
heterozygosity in some chromosomal regions.
E6 and E7 influence pathways involved in cell cycle control by interacting 
with two important tumour suppressor proteins, p53 and RB (277). Binding 
of E6 protein with p53 results in a loss of p53 activity within the cells. The 
infected cells, expressing a mutant form of p53, fail to exhibit cell cycle
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arrest in G1 phase after DNA damage and acquire the ability to escape 
apoptosis induced cell death (277). The E7 viral protein binds to the 
retinoblastoma protein (RB), which negatively regulates cell growth and 
proliferation, and inactivates RB function within the cells. E7 expression 
inactivates not only RB but also its related proteins, such as p21 and PCNA, 
therefore avoiding cell cycle arrest after DNA damage. However, evidence 
suggests that HPV alone is not sufficient to induce malignant 
transformation and other host genetic and epigenetic variations are equally 
important in the development of cervical cancer (279) (280).
1.9.2 Evidence for the existence of CSCs in squamous cell carcinoma
The vertebrate skin is composed of an epidermis and a dermis which
derive from embryonic ectoderm and mesoderm, respectively. The
epidermis is a stratified squamous epithelium made up of multiple layers of
keratinocytes resting on a basement membrane that separates it from the
underlying dermis. The basal layer of epidermis is a heterogeneous
population of proliferative and differentiating cells. A subpopulation in the
basal layer, known as epidermal stem (EPS) cells, give rise to transit
amplifying (TA) cells by symmetric or asymmetric division (281). The
interfollicular epidermis, hair follicle, and sebaceous gland all arise from
TA cells (282). The EPS cells are characterized by unlimited capacity for
self-renewal, high expression of 131-integrins, and rapid adhesion to
extracellular matrix (ECM) proteins (283). The TA cells are programmed to
undergo terminal differentiation after a few cell divisions. They also
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express lower levels of f31-integrins and adhere more slowly on ECM 
proteins than the stem cells (283) (284). Like stem cells of other tissues, 
EPS cells are important because they not only play a central role in 
homeostasis and wound repair but also represent a major target of tumor 
initiation.
The mechanism by which HPV alters cell cycle regulation and may drive 
cervical EPS into carcinogenesis, remain the main questions to be 
answered. The self renewal of normal stem cells is tightly regulated and 
responds to feedback mechanisms which regulate cell division and 
differentiation. HPV infection could involve normal cervical stem cells and 
via E6 and E7 viral proteins effects could be responsible for their malignant 
transformation. In this scenario infected cervical stem cells may directly 
acquire CSC properties, such as abnormal proliferation, cell cycle de­
regulation and evasion from apoptosis and senescence mechanisms (277). 
These considerations, combined with the existing evidence obtained from 
analysis of human epidermal tumours and genetically modified mice, 
suggest that the stem cell populations in different epidermal compartments 
may be the targets of tumorigenesis. Tumours, including squamous cell 
carcinomas, sebaceous adenomas and basal cell carcinomas display 
characteristics of multilineage differentiation, an aspect of the normal 
parental stem cell. This evidence supports the theory that these types of 
tumours are propagated and maintained by a population of cancer stem 
cells (285).
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In work published in 2008 it was demonstrated that markers that are co­
expressed in normal stem cells were not co-expressed in the tumour mass 
of poorly differentiated human SCCs and immortalized SCC cell lines (oral 
cavity and cervix). Down-regulation of two markers, Lrigl and MAP4, and 
up-regulation of a third, MCSP, were correlated with poor differentiation 
status and increased proliferation in primary tumours (286). However, this 
does not correlate solely to an extension of the epidermal stem cell 
compartment, but it is probably due to TA cell amplification. This suggests 
that SCC cells assume certain properties of the normal epidermal stem 
cells, but also down-regulate the pathways involved in stem cell 
quiescence (286).
Particular attention in the epidermal cancer stem cell field has been given 
to Head and Neck Squamous Cell Carcinoma (HNSCC), which are often 
invasive, recurrent and chemotherapy-resistant (287). The cancer stem 
cell subpopulation of HNSCC was characterized using methods previously 
adopted to typify breast cancer stem cells (236).
Prince et al. demonstrated that both SCC primary tumours and secondary 
xenografted tumours expressed the CSC marker CD44 to a variable degree. 
Only cancer cells positive for CD44 were tumorigenic and showed an 
undifferentiated basal-cell like phenotype. The tumours formed by purified 
CD44+ cells reproduced the original tumour heterogeneity and could be 
serially propagated, demonstrating two crucial properties of stem cells: the 
ability to self-renew and to differentiate. Furthermore, the tumorigenic
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CD44+ cells differentially expressed the BMI1 gene, at both the RNA and 
protein levels (288).
In another work, cultured cell lines derived from HNSCC were also shown 
to contain a cell subpopulation with stem cell properties (287). All cell lines 
had a fraction of cells able to export Hoechst dye but the rate of exclusion 
varied distinctly from one cell line to the other. Similarly, all cell lines 
formed cancer spheres when grown in suspension but there was difference 
in the size of spheres and in their patterns of formation. High expression 
levels of sternness markers, such as |3-catenin, CD44, R-integrin and 
CD133, were limited to the surface region of holoclone cells, which 
characterize the undifferentiated fraction of tumour cells. Interestingly SCC 
cells sorted for CD44/CD133 are clonogenic, but the double positive 
population was very small and not yet functionally characterized (287). 
Another interesting paper published in 2009 identified a subpopulation of 
CD44+/CK17+ cells with stem-like properties in patient primary 
carcinoma of the cervix uteri. From the 50% of tumour samples analyzed 
they were able to obtained primary cultures of spheres, which self renew 
and proliferate extensively both in vitro and in vivo. CD44+/CK7+ sphere 
cells were partially inhibited by chemotherapeutic drugs and expressed 
sternness-related genes, such as Oct-4, Stat3, C-myc and Sox2 (289). 
These in vivo and in vitro studies support the hypothesis that SCC cancer 
stem cells are enriched in a subpopulation of CD44 positive cells. The 
heterogeneity of CD44 expression is not sufficient alone to identify the
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tumour initiating cells subpopulation within this type of cancer and 
therefore other markers need to be discovered.
Recently, podoplanin was identified as another putative marker for tumour- 
initiating cells in one SCC cell line, A431 (290). Podoplanin positive cells 
also expressed CD44, had higher colony-forming potential in vitro and 
induced tumours more rapidly than unsorted or podoplanin negative cells
(290). In addition podoplanin has been previously shown to promote EMT
(291), suggesting its possible role in the SCC stem cell phenotype. 
However, like CD44, podoplanin appears to only enrich for the population 
of SCC stem cells, because the dose of cells required for tumorigenesis in 
vivo was still too high (290). In light of these studies, it appears that there 
is still a need to identify more SCC cancer stem cell/tumour initiating cell 
markers to more precisely identify the apparent hierarchy of cancer cell 
populations within the tumours.
An alternative approach to identify SCC cancer stem cells has been to 
discover and characterize the SP cells by their ability to efficiently pump 
out Hoechst 33342 dye. Because SP cells of normal epidermis show 
characteristics of epidermal stem/progenitor cells (31), SP cells may be 
also potential candidates for the identification of cancer stem cells in SCC. 
In one study, three different oral SCC cell lines were shown to contain a SP 
(287) and a subsequent study using a different set of SCC cell lines 
revealed that the SP has a higher clonogenic ability and proliferation rate 
than their parental cell lines (292). After serial in vitro propagation, these 
cells maintain elevated expression levels of the epidermal stem cell marker
CSPG4/MCSP. Significantly, purified SP cells also showed increased 
tumorigenicity, even though the injected tumour cell dose was 
comparatively high (292). Thus, SCC SP cells display characteristics of 
cancer stem cells and could be combined with CD44 and podoplanin 
expression for further analysis of SCC tumour initiating cells.
We have also contributed in this field of research, investigating the tumour 
fraction with cancer stem/tumour initiating cell characteristics in three 
human cervical carcinoma cell lines A431, Caski and SiHa (293). 
Considering the already published data, our primary approaches for the 
isolation of SCC stem cells were the growth as non-adherent spheres in 
specific media and aldehyde dehydrogenase (ALDH) enzymatic activity. A 
good correlation between the two parameters was observed and the 
highest levels were observed in the A431 cell line that was selected for 
characterization of the CSC/TIC fraction (see Results chapter for more 
details). Together our results indicated that the growth of A431 cells as a 
non-adherent sphere was not sufficient by itself to define a stem-like 
population, but it was essential for the emergence of a small population of 
tumour cells with CSC properties.
In conclusion, a lot of data have highlighted the possible phenotypes 
associated with SCC cancer stem cells both in vitro and in vivo, but it 
remains to be established the specific marker profile of this subpopulation 
in SCC and how to translate this knowledge for patient benefit.
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1.10 Human ovarian cancer
1.10.1 Epidemiology and aetiology
Ovarian cancer is the major cause of mortality among gynecological 
malignancies, and represents the fifth most common cause of cancer death 
in women in the Western World. The age at diagnosis, degree of disease, 
success of primary surgery, and the histopathological features of the 
tumour are important prognostic markers (294). Over the last decades, 
ovarian cancer incidence has remained stable and, despite recent 
advancements in treatment, the overall five-year survival rate continues to 
be low, probably because over 70% of ovarian tumours are diagnosed when 
regional or distant involvement has already occurred (295).
The aetiology of ovarian cancer is poorly understood. Factors associated 
with an increased risk for invasive epithelial ovarian cancer include age, 
race, nulliparity and family history of ovarian cancer, endometrial or breast 
cancer. Factors associated with a reduced risk are history of one or more 
full-term pregnancies, use of oral contraceptives, history of breast feeding, 
tubal ligation, and hysterectomy. Other factors such as infertility drugs, 
hormone replacement therapy, age at menarche, age at menopause, dietary 
factors, lactose intolerance, talc use, coffee and alcohol consumption have 
been suggested, but their role is still inconclusive (296).
Depending on the cell and anatomic structures from which the tumour 
presumably originates, most of the ovarian cancers can be placed into one 
of three major categories (297):
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1. Epithelial ovarian carcinoma' ovarian surface epithelial cells (OSE) 
are organized as a single cell layer on a sheet of basement membrane. In 
ovarian carcinoma (EOC), genetic and epigenetic changes enable OSE 
cells to escape positional control and proliferate in a disorganized 
fashion. Two type of ovarian surface epithelial lesion have been 
described as a possible precursor of carcinoma (297).
2. Stromal tumours- are ovarian tumours that probably originate from 
theca cells and/or granulosa cells. These two types of cells are located 
within the stroma of the organ, surrounding the germinal cells that form 
the follicles. Some of these tumours have a fibrous appearance and 
therefore are named fibromas or thecomas. Most of the stromal tumours 
are benign and surgical excision is curative (297).
3. Germ cell tumours: are ovarian tumours originating from cells 
believed to derive from primordial germ cells. More than half of the 
ovarian neoplasms that develop in children and adolescents are of germ 
cell origin, with one-third of these being malignant. Conversely, in 
adults, germ cell tumours are relatively infrequent, and the great 
majority of them are benign (297).
1.10.2 Epithelial ovarian cancer
It is broadly accepted that the bulk of ovarian cancer arises from ovarian 
epithelial cells of the surface or inclusion cyst epithelium, which represent 
some 90% of all ovarian malignancies (298). Recently it has been suggested
84
that the fallopian tube epithelium may play a more important role in the 
development of Epithelial Ovarian Cancer (EOC) (299) (300).
Ovarian epithelium is derived from the coelomic epithelium and this 
developmental heritage of pluripotency might have conferred to OSE cells 
the potential to differentiate into a variety of structures seen in their 
respective forms of cancer.
EOC are classified as benign if they lack exuberant cellular proliferation 
and invasive behaviour, as borderline if there is exuberant cellular 
proliferation but no invasive behaviour and as malignant if there is invasive 
behaviour (297).
The high mortality of this tumour is largely explained by the fact that the 
majority (75%) of patients present at an advanced stage, with widely 
disseminated metastatic disease within the peritoneal cavity.
Ovarian carcinoma metastasizes either by direct extension from the 
ovarian/fallopian tumour to neighbouring organs (bladder/colon) or when 
cancer cells detach from the primary tumour. Exfoliated tumour cells are 
transported throughout the peritoneum by physiological peritoneal fluid and 
disseminate within the abdominal cavity. Extensive seeding of the 
peritoneal cavity by tumour cells is often associated with ascites, 
particularly in advanced, high-grade serous carcinomas. These cancers 
grow rapidly, metastasize early, and have a very aggressive disease 
course. Unlike most other cancers, ovarian carcinoma rarely disseminates 
through the vasculature. However, pelvic and/or para-aortic lymph nodes 
can be involved.
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Current treatment strategies for advanced EOC consist of aggressive 
surgery (“cytoreduction” or “tumour debulking”). Postoperatively, all 
women, except those with very well-differentiated early stage cancer, 
receive chemotherapy with platinum (carboplatin, rarely cisplatin) and a 
taxane (Taxol, rarely taxotere). Although patients respond initially to the 
standard combination of surgery and chemotherapy, a large majority 
succumb later through development of recurrent, therapy-resistant disease 
(301).
EOC are classified into five major subtypes* serous, mucinous, 
endometrioid and clear cell (299).
Highly malignant epithelial ovarian tumours lacking any specific 
differentiation are classified as undifferentiated. Serous or mucinous 
tumours identical to those occurring in the ovary may arise in multiple 
locations within the pelvic and abdominal cavities. By convention, when the 
ovaries appear to be incidentally involved and do not appear to be the 
primary origin of the tumour, the tumour is recorded as an extra-ovarian 
peritoneal carcinoma (297).
Serous Epithelial Ovarian Cancer
This type of EOC is formed by cells that resemble those of the internal 
lining of the fallopian tube. They represent the majority of EOC and two- 
thirds are bilateral. Serous carcinoma is widely disseminated at the time of 
diagnosis, often invades through the ovarian capsule and grows on the 
surface of the ovary (297) (298).
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Mucinous Epithelial Ovarian Cancer
Mucinous tumours are epithelial ovarian cancers formed by cells that 
resemble either those of the endocervical epithelium (endocervical or 
Mullerian type) or, more frequently, those of the intestinal epithelium 
(intestinal type). Malignant mucinous tumours represent 5-10% of all 
malignant ovarian neoplasms and one-third are bilateral. Late extra- 
peritoneal recurrences, particularly in the lungs, are characteristic of 
malignant mucinous tumours (297) (298).
Endometrioid Ovarian Cancer
Endometrioid tumours are epithelial ovarian tumours formed by cells that 
resemble those of the endometrium. They may be associated with the 
aberrant presence of endometrium outside the uterus (endometriosis) and 
with overgrowth (hyperplasia) or cancer of the endometrium. These 
tumours make up the second most common malignant ovarian surface 
epithelial tumour type and are rarely bilateral. Most malignant endometrioid 
tumours are confined to the ovaries and adjacent pelvic structures. 
Malignant ovarian endometrioid carcinomas are considered to have a better 
prognosis than either mucinous or serous carcinomas (302).
Clear Cell Ovarian Cancer
Little is known about the development and progression of this type of EOC. 
Most of them are malignant and studies have shown that 5-10% of cases 
are associated with endometriod lesions. Two-thirds of all women with 
malignant clear cell tumours have never given birth, and 50-70% have
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endometriosis. They can be predominantly solid or cystic with one or more 
polypoid masses protruding into the lumen. Survival rates for clear cell 
carcinomas are poorer than for other surface epithelial carcinomas (303).
Studies of ovarian carcinoma have successfully connected genetics to 
tumour behaviour, giving a good explanation to such variety within the 
same subtype of ovarian cancer. Indeed, the four major histopathologic 
types of ovarian carcinoma are characterized by rather distinctive, though 
not necessarily unique, genetic abnormalities (299) (304). Low grade 
serous carcinoma carry activating mutation in KRAS and BRAF genes, 
whereas deregulation of the tumour suppressing pathway p53 and BRCA1/2 
is more common in high grade serous tumours, even if they may be present 
in their low grade counterparts. Moreover KRAS mutation is supposed to be 
an early event also in ovarian mucinous carcinogenesis.
Silencing mutations of PTEN tumour suppressor and concomitant activation 
of the PI3/Akt cascade, as well as deregulation of the Wnt/|3-catenin/Tcf 
pathway, are highly specific to endometrioid carcinoma. The profiles of 
clear cell carcinomas showed that they were similar to those of renal and 
endometrioid carcinomas, implying that certain molecular events are 
common to clear cell tumours, regardless of the organ of origin. In this type 
of EOC, p53 mutation is rare, but Her2/Neu expression is two times higher 
than that observed for the other subtypes. (304)
More recently, a comparison of the gene expression profiles of serous,
endometrioid, and clear cell types of ovarian cancer with that of normal
ovarian surface epithelium revealed 43 genes that were common to all
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types of EOC (305), suggesting that the process of ovarian tumorigenesis 
involves a common pathway (306).
1.10.3 Human ovarian cancer stem cells
A clear correlation with surface markers that leads to the identification of
specific stem and progenitor subsets have been adequately achieved in the
haematopoietic system, or in organs such as breast and brain. Using the
same markers, CSCs were thereby isolated and studied in the
corresponding tumours. Over the last few years, several studies have
focused on the isolation, identification, and characterization of stem cells
from normal ovarian tissue as well as from ovarian tumour samples.
Differentiation potential in the ovary has been connected with the ovarian
surface epithelium. OSE has retained properties of relatively uncommitted
pluripotential cells as reflected by its growth potential, its capacity to
reverse their phenotype in response to environmental changes, and its
ability to differentiate along numerous pathways. These properties make
OSE cells responsible of wound repair after post ovulatory rupture. This
immature state may be responsible, in part, for the propensity of OSE to
undergo neoplastic transformation, and may be the principle cause that
makes OSE cells the possible source of ovarian cancer stem cells (299).
Bukovsky et al. maintained that mesenchymal cells in human ovarian tunica
albuginea are capable of differentiating into OSE cells by a mesenchymal-
epithelial transition in vivo. Through this transition, mesenchymal cells in
the tunica albuginea give rise to primitive granulosa cells in the ovarian
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cortex and to primitive germ cells which differentiate into oocytes and 
assemble with granulosa cell nests to form new primary follicles (16). 
Another study showed that granulosa cells may undergo a de- 
differentiation process which revert these cells to a stem cell state, 
supported by the expression of 0CT4 and by their ability to differentiate 
into neuronal, chondrocytic and osteoblastic lineages (307) (FIG. 1.11). Up 
to now, a unique source of normal and cancer ovarian stem cells is not yet 
defined and future studies need to be undertaken to clarify this issue.
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Figure 1.11: Possible origin of normal and cancer ovarian stem cells
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Lack of accurate information regarding the origin and biology of normal 
ovarian stem cells, has been a restrictive factor in the identification of 
ovarian CSCs. For the isolation of putative ovarian CSCs from the bulk of 
an ovarian malignancy a number of different approaches have been used.
In the first study, the authors used tumour cells isolated from ascitic fluid 
from patients with advanced stage ovarian carcinomas (308). 
Characterization led to the identification of two spontaneously immortalized 
clones, among nineteen, that showed characteristics of CSCs. All the clones 
were positive for the presence of cell surface markers such as c-kit, stem 
cell factor (SCF), CD44, EGFR and E-cadherin, but only the two CSC clones 
had the ability to form spheroids in suspension, multicellular colonies in 
soft agar and were associated with in vivo tumorigenicity. This study was 
the first to support the association of cancer stem cells with serous ovarian 
cancer.
Another work performed in the same laboratory showed, through 
mitochondrial genome profiling, that the ovarian CSCs are probably derived 
from a single mutant stem cell clone (309).
Beside the ability to grow in vitro as spheres, in an anchorage-independent 
manner, another common approach used to isolate and identify the CSC 
subpopulation is based on the cell surface phenotype. A lot of efforts were 
spent on the identification of a specific surface-marker profile for ovarian 
CSCs. In this context, CD 133 antigen has proved to be a marker of tumour 
cells with sternness features in several human malignancies (310).
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Upon comparing the percentage of CD 133 positive cells between normal 
ovaries, benign ovarian tumours, primary ovarian carcinoma and omental 
metastasis, Ferrandina et al. found that the primary tumours expressed the 
highest levels of the two CD133 epitopes (AC133-1 and AC133-2) (259). 
The CD 133+ cells represented less than 1% of the total population, which 
is one of the defining characteristics of CSCs. The CD133+ cells were able 
to form colonies and had a higher proliferation potential than CD 133- cells 
in vitro. A limitation in this work is that the authors did not identify a strict 
connection between CD 133 and the functional criteria for defining the CSC 
subpopulation, such as in vivo self renewal and chemoresistance. 
Subsequently, another study supported the putative role of CD 133 positive 
cells in ovarian tumours and additionally identified that epigenetic 
dysregulation of CD133 may be connected with neoplastic transformation 
(260). This research demonstrated that ovarian cancer CD 133 expressing 
cells were able to self renewal, giving rise to both CD 133 positive and 
negative cells, and were associated with enhanced resistance to platinum- 
based therapy. However, the fact that ovarian CD 133 + cells showed a 
gene expression signature similar to that of other cancer-initiating cells 
seemed to be an indirect support of the hypothesis. Another limitation to 
the idea that CD 133 + cells represent ovarian CSCs arises from the fact 
that CD 133 negative cells could also generate tumours in mouse models. 
This anomaly was more recently clarified by Curley et al. They 
demonstrated that CD 133 + ovarian tumour cells have more tumorigenic
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capability than CD 133-cells and have the ability to regenerate a 
heterogeneous tumour similar to that found in the original patient (261).
CD 133 positive cells in ovarian cancer were also shown to be involved in 
the establishment of tumour vasculature that is critical for tumour cell 
survival during disease progression (268). Using mouse models, the authors 
demonstrated that endothelial cells are actively recruited by functional 
CSCs for tumour neovasculogenesis, but, conversely to Curley’s reports but 
similar to Baba et al., they did not observe any difference in terms of 
tumorigenic potential between CD133 + and CD133- cells.
In conclusion, although CD 133 initially has appeared to be a weak candidate 
for the identification of ovarian CSCs now there is increasing evidence 
supporting its role as an ovarian CSC marker.
Another putative ovarian CSC marker that has emerged in the last few 
years is CD44, the hyaluronic acid receptor. This molecule is expressed in 
numerous tumours and was also described as CSC marker in breast, colon 
and squamous head and neck cancers. Two major papers have been 
published supporting this role for CD44 in EOC (311) (312). In the first 
report an initial enrichment of cancer stem cells from ovarian tumour 
samples was obtained through their ability to grow in suspension as 
spheres. Sphere cells expressed stem cell markers, such as Bmi-1, Nanog, 
Oct4, ABCG2, and were characterized by the surface phenotype CD44 and 
CD117 (c-Kit). Similar to ovarian cancer spheroids, injection of 100 
CD44+/CD117+ cells were able to propagate the original tumour, whereas 
the double negative subpopulation remained non- tumorigenic even when
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injected at a much higher cell dose (311). Alvero et al. added new insight 
into the role of CD44 in ovarian CSCs. CD44 positive ovarian cancer cells 
had distinct genetic and miRNA profiles, are responsible for the ability to 
recapitulate the original tumour and are able to proliferate in presence of 
chemotherapeutic compounds. Moreover CD44+/MyD88+ cells showed 
constitutive NF-kB activity and cytokine and chemokine production, high 
capacity for repair, resistance to TNFa-mediated apoptosis, capacity to 
form sphere in vitro and self renewal/tumorigenicity in vivo (312).
The involvement of MyD88 may connect ovarian CSCs to tissue repair 
process dependent on TLR4 (Toll Like Receptor-4)/MyD88 pathway (313) 
(314). Thus, CD44+/MyD88+/TLR4+ EOC cells could respond to TLR4 
ligand by activating the NF-kB pathway, sustaining the process of 
repair/differentiation triggered by the cancer stem cells.
The same group also demonstrated that CD44 + EOC cells are able to form 
vessel-like structures in vitro and are able to acquire an endothelial- 
specific phenotype (CD44+/VE-Cadherin+/CD34+) dependent on 
IKKP/NF-kB pathway and not on the Vascular Endothelial Growth Factor 
(VEGF) (315). Finally, Bourguignon et al. demonstrated the involvement of 
CD44 positive cells in the drug resistance mechanism, using an ovarian 
cancer cell line SKOV3.ipl, established from ascites developed in nude mice 
after an intraperitoneal injection of SK0V3 cells. The binding of hyaluronan 
(HA) to its receptor CD44 promotes Nanog association with CD44, Nanog 
nuclear translocation and subsequent expression of Nanog target genes, 
such as R exl and Sox2, pluripotent stem cell regulators. Therefore, it is
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likely that the HA-CD44 interaction serves as an upstream activator of 
Nanog signaling. Moreover hyaluronan-CD44 interaction recruits Nanog 
and favours its functional association with Stat3. This complex enhanced 
the transcription of Stat3 specific target genes, leading to MDR1 gene 
expression and tumour cell growth, as well as multidrug resistance (316).
To complete the spectrum of ovarian CSCs markers, two other papers have 
to be mentioned. The first published by Gao et al. identified CD24 positive 
EOC cells as those that possessed sternness properties. Conversely to what 
has been observed in breast CSCs, ovarian CD24 positive cells seem to 
possess stem cell-like characteristics, such as quiescence and 
chemoresistance, as well as a specific capacity for self-renewal and 
differentiation. In addition, CD24 + cells were more tumorigenic than an 
equal number of CD24 -  cells and expressed higher mRNA levels of some 
'sternness' genes, including NESTIN , fi-CATENIN, BMI-1, OCT3/4, 
NOTCH1 and NOTCH4. Furthermore CD24 + cells possessed a 
mesenchymal phenotype, as suggested by their lower E-Cadherin mRNA 
level than the CD24- cells (317).
In another work, Lin28 and 0ct4 human embryonic stem cell markers were 
suggested as putative ovarian CSC markers. In this report, Lin28 and Oct4 
co-expression was found both in ovarian cancer cell lines and patient 
tumour samples and was correlated with advanced tumour grade. When the 
expression of these two proteins was repressed in the same cells, there 
was a significant reduction in cell growth and survival. Consequently the 
authors proposed that Lin28 and 0ct4 may have an important role in the
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initiation and progression of EOC, and may serve as an important molecular 
and therapeutic target for future treatment strategies (318).
The capacity to extrude Hoechst dye has also been used to identify ovarian 
cancer stem-like cells (319) (320). This dye-excluding side-population 
(SP) ability in used in various normal and cancer tissues to select for 
presumptive stem-like cells. It is reasonable that the SP phenotype coupled 
with specific marker expression may be the most functional assay to isolate 
and characterize the CSC subpopulations from tumour samples. In this 
regard Szotek et al. identified and characterized SP cells from genetically 
engineered mouse ovarian cancer cell lines, human ovarian cancer cell lines 
and human ovarian patient tumours. SP cells from both mouse and human 
ovarian cancer showed the ability to regenerate tumours with lower latency 
and higher frequency than the non-SP cells that remain responsive to 
doxorubicin and to Mullerian Inhibiting Substance (MIS) (321). The finding 
that SP-derived CSCs were highly resistant to doxorubicin, through ABCG2 
expression, accounts for evasion mechanisms under chemotherapy; it 
further supports the candidature of these cells as being CSCs.
Recently, another exhaustive study addressed the optimization parameters 
essential to identify and isolate the SP in ovarian cancer, using the human 
ovarian cancer cell line OVCAR3 as an in vitro model (322). In this study 
only 0.9% of the whole population was isolated as SP and these cells had 
the capacity to form holoclones and to express the self-renewal marker 
Oct4.
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Similarly Hu L et al. showed that SP of ovarian cancer cells, collected from 
primary ovarian cancer patient ascites and from different types of epithelial 
ovarian cancer cell lines, expressed the stem cell markers Nanog, Stellar, 
Oct4 and ABCG2. SP cells were more tumorigenic than non-SP cells 
showed an extensive cell proliferation capacity and were more resistant to 
chemotherapy in vitro and in vivo, compared with non-SP (323).
The tumorigenic and chemoresistant phenotype of ovarian SP were 
confirmed by another study. In collaboration with our group, Moserle et al. 
investigated the presence of SP in epithelial ovarian cancer and found it to 
be present in 33% of primary tumour samples analyzed, as well as in 4 of 6 
cultures from xenotransplants (324). They found that SP cells had higher 
proliferation rates, were much less apoptotic compared with non-SP cells, 
and gave rise to tumours faster than non-SP cells. Moreover, IFN-alpha 
treatment was followed by a marked reduction in SP size in tumour cell 
lines of different origin. Isolated SP cells treated with IFN-alpha were 
associated with a peculiar change in their transcriptional profile. These 
findings could have important clinical implications because they imply that 
tumours bearing large SP numbers, albeit rare, could be sensitive to IFN- 
alpha treatment.
Together these reports have emphasized the role of SP in CSC enrichment 
and have tried to optimize the technical procedures for identifying the SP 
within heterogeneous cancer cell populations.
Drug resistance is a hallmark of CSC subpopulations and a lot of effort and
experimental approaches have been developed for the identification of this
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property. Besides the isolation of the SP, the analysis of ALDH1 activity 
has also been used to identify the tumour initiating and drug resistant 
cancer cell population within different type of cancer (134). In the field of 
ovarian CSCs, three different and partially opposite examples were 
reported. In 2009, Chang et al. analyzed a large cohort of ovarian 
carcinomas using tissue microarrays to identify a possible correlation 
between ALDH1 expression and clinical factors, such as diagnosis, tumour 
grade and stage, and clinical response to chemotherapy. The results 
showed that ALDH1 was a favourable prognostic factor in ovarian cancer 
patients, contrary to what was observed in breast cancer where it is 
associated with poor patient prognosis. Probably ALDH1 may have a 
different function in ovarian cancer and its functional role in normal and 
neoplastic ovarian tissue needs to be determined with more efficiency 
(142).
On the other hand, Deng et al. showed that the percentage of ALDH1 
positive cells in different types of tumour is significantly correlated with 
the level of ALDH1 expression in the corresponding normal tissue. In 
normal ovary the expression of this marker is limited compared to that 
observed in ovarian cancer samples and is significantly associated with 
poor clinical outcome in serous ovarian cancer (325).
A recent paper, published in October 2010 by Landen and co-workers 
(326), confirmed that ALDH positivity correlated negatively with 
progression-free survival of patients with EOC. Additionally, ALDH positive 
ovarian cancer cells, isolated from two pairs of ovarian parental and
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chemoresistant cell lines (SKOV3ipl/SKOV3TRip2 and A2780ip2/ 
A2780cp20), had increased but not absolute tumorigenicity. ALDH1A1 in 
vitro down-regulation sensitized ovarian cancer cells to chemotherapy 
whereas in vivo its down-modulation had an effect on tumour growth only if 
it was combined with chemotherapeutic treatments. These results suggest 
that the ALDH1 positive population had properties of CSCs and it is 
associated with ovarian cancer cell chemoresistance. Ovarian cancer cell 
lines can be re-sensitized to chemotherapy by down-regulation of ALDH1 
both in vivo and in vitro.
In summary, these data indicate that the prognostic value of ALDH1 in 
ovarian cancer, although potent, may be histotype-specific. Indeed, based 
on clinic-pathological and molecular studies, different histotypes of EOC 
have remarkably individual molecular backgrounds and biological 
behaviours. They may be considered as different diseases, even though 
they are located in the same anatomic location. Consequently, the 
prognostic value of ALDH1 in different types of ovarian epithelial cancers 
still needs to be further investigated in large-scale independent sample 
sets.
A number of studies have contributed to the knowledge about the various
phenotypes associated with ovarian cancer-initiating cells both in vitro and
in vivo, but there remains a paucity of information about how to translate
this knowledge for patient benefit. The ongoing characterization of these
cells, combined with new technologies in sequencing, microarrays and
imaging, will soon allow us to highlight the pathways and mechanisms
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driving ovarian cancer-initiating cell function as well as the potential 
vulnerabilities that can be exploited for targeting these cells.
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CHAPTER 2
MATERIALS and METHODS
2.1 Experimental approaches commonly used for cancer stem  
cell identification and isolation
2.1.1 Isolation assays
Marker expression- Fluorescence Activated Cell Sorting (FACS) or magnetic 
beads selection
There are several concerns regarding the isolation of stem cells based on 
marker expression, such as the enzyme treatment, loss of cell viability 
during the sorting procedure and the purity of the isolated fraction. 
Treatment of the tissue sample with enzymes, such as trypsin, would 
destroy the surface antigens and not only affects the ability to sort the 
suspension into specific populations, but might also influence the ability of 
these molecules to play a role in the early stages of repopulation in vivo or 
in vitro. Thus, techniques for dissociating cells must be carefully 
developed.
In addition, phenotypes, based on marker selection, often use terms, such 
as high, middle, low, and non-expression, to describe the properties of the
1 0 1
sorted cells for each marker; these terms are subjective and can vary 
depending on the method used for cell preparation. Additionally gate setting 
and the antibody preparation used could affect the efficiency of the 
approach. Although flow cytometry offers a sensitive, specific, and robust 
method of cell isolation and purification, some of its technical limitations 
make its application to stem cell purification a high risk. An alternative and 
common approach for the isolation of CSC is the immuno-magnetic beads 
selection/depletion. This system is based on super-paramagnetic particles 
of approximately 50 nanometers in diameter directly conjugated with a 
specific antibody or able to detect the fluorochrome of the primary antibody 
(anti-fluorochrome micro bead). After the staining, the magnetically labeled 
cells are separated over a specific column placed in a magnetic field— 
separator. The cells are retained on the column, while unlabeled cells pass 
through. The retained cells can then be eluted from the column and 
analysed by FACS.
Sphere assay
Several in vitro assays have been used to identify stem cells and CSC, 
including sphere assays and serial colony-forming unit (CFU) assays 
(replating assays).
Forced growth in suspension in the presence of specific growth factors was 
found a useful tool for isolation of undifferentiated multipotent neural and 
breast stem cells (327). Under these conditions, most of the cells die and 
surviving cells give rise to floating spherical colonies (spheres). One of the
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most important characteristics of stem/progenitor cells is the ability to 
self-renew; only cells with self-renewal capability are able to sustain the 
growth in suspension, giving rise to non-adherent colonies. The growth in 
suspension has also been applied to the isolation and propagation of 
putative tumour stem cells from tumour cell lines and from patient tumour 
specimens (308) (328). However the rapidity of sphere growth in many 
systems makes it unlikely that they arose from single cells solely through 
clonal expansion. The complexity of distinguishing the relative 
contributions of aggregation and proliferation in sphere formation poses a 
major impediment to their use in isolating this subpopulation of cells.
Side Population and Aldefluor assays
Another phenotype used to distinguish cancer stem cells within a tumour is 
their presence within the side population (SP) fraction defined by Hoechst 
dye efflux properties. SP is a distinct, small cell population composed of 
unstained cells in the left lower quadrant of a Flow Activated Cell Sorter 
(FACS) profile. SP cells are identified and electronically gated on a cell 
sorter station after excitation of the Hoechst dye with 150 mW of 350 nm 
UV light. SP fluorescence emissions are directed toward a 610-nm dichroic 
filter and captured simultaneously through both a blue (450-nm) band-pass 
and a red (675-nm) long-pass filter on a linearly amplified fluorescence 
scale. Goodell et al. (329) have demonstrated that the exclusion of Hoechst 
33342 by SP cells is an active process involving multidrug resistance 
transporters, such as MDR1 and ABCG2. SP has been used to isolate,
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characterize and study malignant stem cells, because their ability to 
exclude nuclear dyes correlates with multidrug resistance, such as the 
expulsion of cytotoxic drugs (330).
SP has been identified in many normal tissues, including mammary glands 
(331), lung (332), brain (333) and skin (334) in both human and animal 
models. In addition to the identification of SP in normal cells, SP cells have 
been characterized in various tumours and cancer cell lines (293) (335) 
(336). However, as with cell surface markers, the existence of a SP 
phenotype is not a universal property of stem cells, and in some tissues, 
the SP fraction may not contain the stem cells. Experiments that identified 
normal breast stem cells by their ability to generate mammary glands in 
cleared fat pads showed that the majority of these cells are not included 
within the SP fraction. Possible toxicity of the dye should also be 
considered when interpreting functional assays based on SP cells.
The aldehyde dehydrogenase (ALDH) family is a group of cytosolic 
isoenzymes responsible for oxidizing intracellular aldehydes, thus 
contributing to the oxidation of retinol to retinoic acid in early stem cell 
differentiation (337). Specific ALDH activity is evaluated using the 
ALDEFLUOR assay based on the different staining in the presence or in the 
absence of the Aldefluor inhibitor diethylaminobenzaldehyde (DEAB). 
Aldefluor assay followed by FACS analysis assesses the presence and size 
of the cell population with ALDH enzymatic activity.
Isolated cancer cells from several types of tumour with relatively high 
aldehyde dehydrogenase 1 (ALDH1) activity display in vitro features of
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CSCs, including capacities for proliferation, self-renewal and 
differentiation, resistance to chemotherapy and CSC marker expression 
(338) (339) (340). As for SP approach or for specific marker expression 
commonly used to isolate cancer stem cells, the Aldefluor assay may give 
misleading results, due to the fact that a high percentage of heterogeneous 
cancer cells show an elevated level of ALDH activity. For these reasons 
both SP and Aldefluor assays must be followed by a functional evaluation. 
Because of these complicating factors, it is safer to first isolate stem cells 
using other methods and then ask whether that particular stem cell 
population is indeed included within the SP and or ALDH positive 
population.
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2.1.2 Functional assays
Self-renewal, tumorigenic and differentiation potential
Self-renewal and lineage capacity are the hallmarks of any stem cell. 
Therefore, as with normal stem cells, assays for cancer stem cell activity 
should include self-renewal and tumour propagation abilities.
The main approach used to examine the self renewal ability and, in 
particular, to monitor the type of division, as symmetric or asymmetric, is 
based on the staining with specific dyes. PKH or FCSE fluorescent cell 
linkers are lipophilic dyes that enable fluorescent labelling of live cells over 
an extended period of time, with no apparent toxic effects. During 
symmetric cell divisions the dye is portioned among the daughter cells, so 
that, after a number of mitotic divisions it is diluted and all the cells are no 
longer stained. On the contrary, as consequence of asymmetric division, the 
dye is retained by the daughter cell that remains a stem cell because it is 
mainly quiescent. Thus, label retention may be used as a marker of stem 
cells if they are relatively slow cycling. Since asymmetric division 
correlates with asymmetric partitioning of cell fate determinants, the 
analysis of the intracellular localization of a specific protein such as Numb 
after the first division, is another method to discriminate between 
symmetric or asymmetric cell division (91).
Up to now, the gold standard assay that is commonly accepted to 
discriminate between bulk cancer cells and CSCs is the serial
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transplantation in animal models that, although imperfect, is considered as 
the best functional assay, because it demonstrates both self renewal and 
differentiation potential of the selected CSCs.
Recipients are immune-deficient mice with different grades of 
immunological defects- nude mice (B cell deficient), severe combined 
immunodeficient (SCID) and non-obese diabetic (NOD) mice (B cells and T 
cell deficient). More recently many investigators have turned to 
N0D/SCID/Il-2rY_ (341) and Rag2~/_YC_/_ mice (342) as these mice lack the 
entire immune system.
In transplantation assays, cells are xenografted in immune-compromised 
mice that are monitored at various time points for tumour formation. To 
show self-renewal, cells isolated from the tumours are grafted into a 
second animal for more passages.
Issues complicating transplantation assays include potential effects of the 
grafting site. It is well known that normal stem cells are greatly dependent 
on signals from the surrounding stromal cells but it is not still clear what 
the effect may be on separating cancer stem cells from any supporting cells 
during the course of the assay.
Moreover the extraordinarily high level of genetic and epigenetic changes 
that take place within most cancer cells, may allow some cells to generate 
diverse cell types not because they are stem cells per se but because of 
their genetic/epigenetic instability.
Although serial transplantation assays remain the best developed method 
for identifying cells with properties of cancer stem cells, more precise and
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simpler assays are likely to emerge as the favourite technique for their 
identification.
Another useful approach for the characterization of normal and therefore 
cancer stem cells is the capacity to undergo differentiation processes both 
in vivo and in vitro. After asymmetric division, one of two stem daughter 
cells gives rise to a proliferating transit-amplifying cell destined to terminal 
differentiation. Differentiation potential in vivo is usually assessed by the 
ability of isolated cancer stem cells to give rise to a heterogeneous tumour 
that resembles the original one. On the other hand, differentiation potential 
of cancer stem cells could be also evaluated by culturing cells under 
conditions favourable for tissue-specific differentiation. After culture in 
lineage specific conditions, the expanded cancer stem cells may be highly 
differentiated in to their tissue-specific lineages, as assessed on the basis 
of phenotypic characterization and histological analysis.
When analyzed in vitro, normal human skin keratinocytes give rise to three 
subpopulations based on their patterns of clonal expansion (343). Colonies 
with a round compact form, termed holoclones, are considered to be 
derived from stem cells, while clones with initial or advanced differentiation 
are called meroclones and paraclones respectively, being representative of 
early and late TA progenitor cells (344). The presence of these stem cell 
derived hierarchies is a functional and simple method to characterize 
cancer stem cell multilineage potential (293), but it is also an indication of 
the heterogeneous composition of the CSC subpopulation.
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All the considerations listed above indicate that the cancer cell population 
is heterogeneous with respect to one of the key criteria that define stem 
cells and cancer stem cell isolation. As a result, it remains to be elucidated 
whether the term CSCs defines a specific state or, alternatively, indicates a 
gradient of phenotypic features along a spectrum of sternness and 
commitment that is permissive to self renewal.
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2.2 General procedures and reagents
All the solutions were made using double-distilled H2O stored in sterile 
containers. Details of all the general reagents used for experimental work 
of this thesis are tabulated below. Chemicals were supplied by Sigma- 
Aldrich (UK) or Merck (Germany).
Table 2.A: List of reagents
P B S
5 .8 4 g  NaCI, 4 .7 2 g  N a2H P 0 4) 2 .6 4 g  N aH 2P 0 4, 2  H20  
(pH =7.2) in 1 L
P B S  C aC I2 (10x)
7 9 ,4g  NaCI, 2g  KCI, 2g  KH2P 0 4, 14 ,2g  N a2H P 0 4- 2 
H20 ,  1g MgCI2' 6H 20  in 1L +1, 32 g  C aC I2 2H 20  in 1L
TAE (T ris  A c e ta te  EDTA)-50X 2M Tris, 2M glacial ac e tic  acid , 50m M  EDTA, pH =8.0
TB E  (T ris  B o ra te  EDTA) 10X 0.5M  Tris, 0.5M  boric acid , 13mM  EDTA, pH= 8 .0
G el lo a d in g  d y e  b u f fe r  (6x):
2 5m g b rom opheno l blue, 1 ,25m l S D S 1 0 % , 12,5m l 
glycerol
M PB S
dried  sk im m ed  milk p o w d er M arvel in P B S  (M arvel is 
d ried  sk im m ed  milk pow der) a t  d ifferen t %
P B S T  0 .1% P B S  - 0 .1 % T w een  20
1 1 0
Table 2.B: Western Blot reagents
L y s is  b u f fe r  (RIPA  b u ffe r)
50mM Tris-HCI (pH=7.4), 150mM NaCI, 
1% NP40, 0.1% SDS, 0.5% NaDOC, 
protease inhibitor (complete mini, Roche)
R u n n in g  b u ffe r  (M O PS)
50mM sodium acetate, 10mM EDTA, and 
10mM EGTA, treated with DEPC 
(INVITROGEN)
B lo ttin g  b u ffe r
39mM glycine, 48mM Tris , 0.037% SDS 
and 20% methanol
Table 2.(T List of antibodies and isotype controls
ANTIBODY
SPEC IFIC ITY
C O N JU G A T E H O ST S P E C IE S S U P P L IE R
Mouse anti-human 
CD44
APC Mouse lgG2b Becton Dickinson 
(Franklin Lakes, NJ)
Mouse anti-human 
CD45
FITC Mouse lgG2a MACS Miltenyi 
(Germany)
Mouse anti-human 
CD133
PE Mouse lgG1 MACS Miltenyi 
(Germany)
Mouse anti-human 
CD117
PerCP-Cy5.5 Mouse lgG1 Becton Dickinson 
(Franklin Lakes, NJ)
Mouse anti-human 
CD 184 (CXCR4)
APC Mouse lgG2a Becton Dickinson 
(Franklin Lakes, NJ)
Mouse anti-human 
EpCAM
PE Mouse lgG1 eBioscience (San 
Diego, CA)
Mouse anti-human 
CD133
/ Mouse lgG1 MACS Miltenyi 
(Germany)
Mouse anti-human 
Folate Receptor
/ Mouse IgG Home made
Mouse anti-human 
CD44
/ Mouse lgG1 DAKO (Denmark)
Mouse anti-human 
Vimentin
/ Mouse lgG1 Novocastra/Leyca
Microsystem
(Germany)
111
R abbit an ti-h u m an  N- 
C ad h erin
/ R abbit IgG 
polyclonal
S a n ta  C ruz ( S a n ta  
C ruz, CA)
M ouse an ti-h u m an  
Ki67
/ M ouse lgG1 C hem ico n  (T em ecu la , 
CA)
M ouse an ti-h u m an  E- 
C ad h erin
/ M ouse lgG1 Z ym ed  L ab o ra to ries 
(C arlsb ad , CA)
M ouse  an ti-h u m an  
C ytokeratin  8 /18
/ M ouse lgG1 N o v o castra /L ey ca
M icrosystem
(G erm any)
M ouse anti h u m an  
SSEA 1
/ M ouse IgM
(E S  cell m ark e r 
sa m p le  kit)
C h em ico n  (T em ecu la , 
CA)
M o u se  anti h u m an  
SSEA 1
/ M ouse  IgM Z ym ed  L ab o ra to ries  
(C arlsb ad , CA)
M o u se  an ti-h u m an  
O C T 4
/ M ouse IgG
(E S  cell m ark e r 
sa m p le  kit)
C h em ico n  (T em ecu la , 
CA)
R abb it an ti-h u m an  
O C T 4
R abbit IgG 
(polyclonal)
ABCAM (C am bridge , 
UK)
M ouse an ti-H um an 
P odop lan in
/ M ouse  lgG1 ABCAM (C am b rid g e , 
UK)
M o u se  an ti-h u m an  
C X C R4
/ M ouse  lgG 2 R&D S y s te m  
(M inneapolis, MN)
R abbit an ti-h u m an  
C X C R4
/ R abbit IgG B iotrend (G erm an y )
M o u se  an ti-h u m an  
C D 117
/ M ouse  lgG1 C h em ico n  (T em ecu la , 
CA)
M o u se  an ti-h u m an  
N anog
/ M o u se  lgG 2 Sigm a-A ldrich  (St. 
Louis, MO)
R abbit an ti-acety l- 
H istone H3
/ R abbit IgG U pstate/M illipore 
(Billerica, MA)
R abbit an ti-acety l- 
H istone H4
/ R abbit IgG U pstate/M illipore 
(Billerica, MA)
Iso type control FITC M o u se  lgG 2 M ACS Miltenyi 
(G erm an y )
Iso type control P E M o u se  lgG1 M ACS Miltenyi 
(G erm an y )
Iso type control P erC P -C y 5 .5 M o u se  lgG1 B ecton  D ickinson
1 1 2
(Franklin L akes, NJ)
Iso type control A P C M ouse  lgG 2 B ecton  D ickinson 
(Franklin L akes, NJ)
A lexa F luor 546 / g o a t anti- rabbit 
IgG
INVITROGEN (P ais ley  
, UK)
A lexa F luor 4 8 8 / G o a t an ti-m o u se  
IgG
INVITROGEN (P ais ley  
, UK)
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Table 2.D: list of probes for REAL TIME assay (APPLIED BIOSYSTEM)
GENES PROBES
O C T 4 (PO U 5F1) H s01895061_v1
NANOG H s02 3 8 7 4 0 0 _ g 1
NESTIN H s0 0 7 0 7 1 2 0 _ s1
C D 133 H s0 1 0 0 9 2 6 1_m1
C X C R 4 H s00237052_m 1
E G F R H s0 0 193306_m 1
GAPDH (VICMGB) 4 3 2 5 7 9 2
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Cell lines used in this research and their culture conditions
The following cell lines were purchased from the American Type Culture 
Collection ATCC (Rockville, MD).
• A431 (ATCC, cat. No. CRL-1555) a squamous epidermoid carcinoma cell 
line, established from an epidermoid carcinoma of the vulva of an 85 year 
old female patient by D.J Giard, et al. (345).
• CaSki (ATCC, cat. No. CRL-1550) a cervical epidermoid carcinoma cell 
line, established from a metastasis in the small bowel mesentery.
• SiHa (ATCC cat. No. HTB-35) a cervical squamous cell carcinoma cell 
line, established from fragments of a primary tumour sample.
These cell lines were maintained in adherent conditions in RPMI-1640 
medium (Sigma-Aldrich, St. Louis, MO) containing 10% fetal bovine serum 
(FBS) (Lonza, Walkersville, MD), and 1% glutamine (Lonza) at 37°C in 5% 
C02 and sub-cultured by trypsin/EDTA (Lonza) detachment.
General procedures for maintenance of eukaryotic cancer cell lines
All manipulations involving cell culture were performed in a sterile 
environment provided by a laminar flow sterile hood. All liquid reagents 
were either purchased sterile or filtered through a 0.22 pm filter. Routine 
culturing was performed at 37°C in humidified incubators in the presence of 
5% CO2. All cell lines were routinely tested for mycoplasma infection using 
the MycoAlert Mycoplasma detection Kit (Cambrex) and positive cells were 
then excluded. Centrifugation of cells was usually achieved at 1200 or 1500 
rpm for 5 minutes. Fetal bovine serum (FBS) (Gibco, CA) was heat
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inactivated at 56°C for 40 minutes before using as supplement in the 
growth media.
Generally cell counts were obtained using a Burker’s chamber visualized 
through an inverted microscope and cell viability was checked by Trypan 
blue exclusion. When a more precise count was needed, cells were 
counted with Countess ™ automated cell counter (Invitrogen, Italy) that 
performs cell count and viability measurements using trypan blue stain.
All cell lines were propagated in adherent conditions for different passages, 
using the following methods. After removing the culture medium, the cell 
layer was briefly rinsed with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution 
to remove all traces of serum. Trypsin-EDTA solution was added to the 
cell culture and incubated for 5 minutes at 37°C in a humidified incubator in 
the presence of 5% CO2. After cell detachment, 10 ml of complete medium 
was added to the flask in order to inactivate the Trypsin solution. The cell 
suspension was then centrifuged for 5 minute at 1500 rpm, resuspended in 
an appropriate volume of complete medium, counted when needed, and 
seeded to new culture vessels.
Spheres from parental cell lines were obtained by plating the cells at low
density (1,000 cells/ml) in MEGM serum free medium, supplemented with
0.4% BPE, 0.1% hEGF, 0.1% hydrocortisone, 0.1% GA-1000, 0.1% insulin,
1% glutamine (MEGM BulletKit) (Lonza). The in vitro maintenance of
spheres was performed in Ultra Low Attachment Plates (Corning, NY, NY)
and spheres were trypsinized with TrypLE™ Express (Invitrogen, Carlsbad,
CA). Spheres with a mean diameter of 50-150 pm, were monitored and
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trypsinized every 4/5 days. Spheres re-seeded in adherent conditions were 
cultured in the same culture conditions of the relative parental cell line.
Storage and recovery of eukaryotic cells from liquid nitrogen
Harvested cells were pelleted by centrifugation and resuspended at 
approximately 106 cells /ml in FBS containing 10% v/v dimethylsulphoxide 
(DMSO), which prevents the formation of ice crystals. Aliquots of 1 ml were 
transferred to 1.5 ml cryotubes and stored overnight at -80°C. Frozen cells 
were transferred the following day to liquid nitrogen tanks (-196°C). 
Recovery of cells from storage was performed by rapidly thawing in a 37°C 
H2O bath. Thawed cells were washed in 10 ml fresh and pre-warmed 
medium, pelleted by centrifugation and then transferred to the appropriate 
culturing conditions for the cell type of interest.
Processing ovarian tumour samples
Many solid tumours contain a heterogeneous population of normal and 
cancerous cells. Separation of these cell populations is the key to an 
accurate assessment of the true genotypic and phenotypic characterization 
of cancer cells. In order to isolate a subpopulation of cancer cells with 
characteristic of CSCs we developed different methods to obtain a single 
cell suspension, starting from surgical ovarian tumours (FIG 2.1).
Clinical specimens were obtained from a series of consenting patients 
according to the Internal Review and the Ethics Boards of the Istituto 
Nazionale Tumori of Milan.
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All manipulations involving tumour samples were performed under a laminar 
flow sterile hood. All liquid reagents were either purchased sterile or 
filtered through a 0.22 pm filter.
Cancer samples were firstly mechanically processed using a scalpel and 
scissors. Blood, floating fat and necrotic fragments were discarded. 
Recovered tumour fragments were then re-suspended in specific medium 
and shredded in to smaller pieces. Single cell suspensions were filtered 
with 70pc or 100 pc cell strainers (Becton Dickinson) and checked for their 
vitality. At least one purification step, usually by Ficoll gradient, was 
applied to eliminate lymphocytes and red cells. Frequently, after 
processing, samples did not contain tumour cells sufficient to be 
immediately characterized and sorted for specific markers.
Depending on the consistency of the tumour samples, mechanical shredding 
alone was not sufficient to obtain and isolate a single cancer cell 
suspension. For this reason we set up and performed different enzymatic 
approaches. After the mechanical process, tumour fragments were 
suspended in the enzymatic solution and digested for different periods of 
time depending of the tissue consistency and on the reagents used.
Initially tumour fragments were suspended in the Triple Express Trypsin 
(GIBCO). Digestion was performed at 37°C in a humidified incubator in the 
presence of 5% CO2 for a period of time ranging from 2h to overnight 
incubation. The cell suspension was then filtered with 70 pc or 100 pc cell 
strainers and checked for vitality. A purification step was required for the 
presence of lymphocytes and red cells. Using this approach the yield of
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tumour cells was generally low and again, after processing, the available 
samples often did not contain sufficient tumour cells to be immediately 
characterized and sorted by specific marker expression.
In order to achieve a complete digestion of tumour fragments, we 
subsequently used the Accumax solution (Millipore), which is a proprietary 
solution that contains collagenolytic, proteolytic, and DNAse enzymes and 
is provided as a ready-to use solution. As an added benefit, Accumax 
solution does not contain any mammalian or bacterial components. 
Digestion was performed at room temperature with rotation for one or two 
hours and cell viability was generally checked every thirty minutes. Also in 
this case, after digestion, the tumour cell suspension was filtered and 
purified but again the yield of tumour cells was commonly insufficient for a 
phenotypic characterization by FACS analysis.
To limit the difficulties encountered with the procurement of high purity 
primary tumour cells and the low yield of purified cells, we used the 
Panomics’ Cancer Cell Isolation Kit (Panomics, CA), which combines 
specific reagent compositions and handling processes to successfully 
isolate purified tumour cells. Firstly non-tumour and necrotic tumour tissue 
were picked out with sterile ophthalmological tweezers and tumour 
fragments were cut in small pieces. The pelleted material was then 
resuspended in Tumour Cell Digestion Solution and incubated at 37°C for 
2-4 hour with agitation. The heterogeneous cell mixture was then purified 
with the Tumour Cell Purification solution, filtered with a 100 pc filter and 
analyzed for viability. With this method we obtained a purified tumour cell
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suspension, as validated by FACS analysis, but the number of total cancer 
cells recovered was again not sufficient for a sorting procedure based on 
expression of a specific marker (FIG. 2.2).
As for the ovarian solid tumours, we set up different methodologies in 
order to isolate a purified cancer cell suspension from ascitic samples. 
Using enzymatic dissociation with the ACCUMAX solution we usually 
obtained a satisfactory yield of a viable single cell suspension. Digestion 
was carried out at room temperature with rotation for one or two hours 
depending of the size of tumour cell population, and cell viability was 
generally checked every thirty minutes. The tumour cell suspension was 
filtered and purified to eliminate necrotic tumour cells and inflammatory 
cells such as leukocytes and lymphocytes.
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Discard blood and floating fat
Collect the tissue and discarded 
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Figure 2.1: Processing ovarian tumour samples
ovarian solid tumours were cut in small pieces and processed with the methods described 
in the text. Fat and necrotic fragments were discarded. After processing, viable single 
cells were, when possible, seeded in different culture conditions and phenotypically 
characterized. Examples of ovarian tumour samples in vitro culture and phenotypic
characterization are reported.
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Figure 2.2: Experiment layout
after surgery, ovarian tumour samples, solid m asses or ascites, w ere collected  and 
mechanically and/or enzymatically processed. Tumour cells recovered  w ere phenotypically 
characterized and expanded in vivo in a murine model. In vivo expansion could guarantee 
a continued source of material. After in vivo growth, cancer sam ples w ere again collected 
and processed, and the purified tumour cells w ere characterized for stem  cell p roperties.
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Culture conditions of ovarian cancer cells recovered from surgical specimens 
All manipulations involving tumour cells were performed under a laminar
flow sterile hood. All liquid reagents were either purchased sterile or
filtered through a 0.22 pm filter. Routine culturing was performed at 37°C in
humidified incubators in the presence of 5% CO2.
Following solid tumour or ascitic clump digestion the isolated cells were 
seeded in adhesion for two hours in RMPI 1640 or MCDB 105/MEDIUM 
199 U2 (Sigma-Aldrich, St. Louis, MO), containing 10% fetal bovine serum 
(FBS) (Lonza, Walkersville, MD), and 1% glutamine (Lonza) to allow 
inflammatory and/or stromal cells adhesion to the plastic. The supernatant 
was then collected and cells were seeded in different culture conditions. 
Aliquots were plated in the presence of different concentrations of serum 
(10%, 1% and 0.1%) (Lonza, Walkersville, MD) and in different media (RMPI 
1640 or MCDB 105/MEDIUM 199 1-2), as described above. Adherent cells 
were routinely checked and fresh medium added every 5 days. Cell 
detachment was performed after removing the culture medium; the 
Trypsin-EDTA solution was then added to the cell culture and incubated 
for 5 minutes at 37°C in humidified incubators in the presence of 5% CO2. 
After complete detachment, 10 ml of complete medium were added to the 
flask in order to inactivate the Trypsin solution. The cell suspension was 
then centrifuged for 5 minutes at 1500 rpm, resuspended in an appropriate 
volume of complete medium, counted when needed, and seeded to new 
culture vessels.
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Following ovarian cancer surgical specimen digestion, cells were seeded in 
suspension at low cell-density (1,000 cells/well or 5,000 cells/well) in 
MEGM BulletKit serum free medium, supplemented with 0.4% BPE, 0.1% 
hEGF, 0.1% hydrocortisone, 0.1% GA-1000, 0.1% insulin, 1% glutamine 
(Sphere medium) (Lonza). Sphere growth was monitored every two/three 
days and in vitro maintenance was performed in Ultra Low Attachment 
Plates (Corning, NY, NY). Spheres were trypsinized with TrypLE™ Express 
(Invitrogen, Carlsbad, CA), as described for the culture of A431 spheroids.
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2.3 General methods 
RNA extraction
Total RNA was isolated with the RNAspin Mini RNA Isolation Kit (GE 
Healthcare, Piscataway, NJ). Approximately 107 cells were harvested and 
pelleted by centrifugation at 1200 rpm for 5 minutes. The pellet was lysed 
in 350 pi of lysis solution RA1 + 3.5pl |3-mercaptoethanol. Then the lysates 
were mixed vigorously and filtered with RNAspin Mini filter units by 
centrifugation for 1 min at 13400 rpm. The same volume of 70% ethanol 
was added to the samples and mixed vigorously. The lysates were then 
filtered through a RNAspin Mini column, which binds and captures the RNA, 
and centrifuged for 1 min at 12300 rpm. After washing with Membrane 
Desalting Buffer (MDB), DNasel solution was loaded on to the column to 
avoid possible DNA contamination and incubated for 15 min at RT. The 
RNA was then washed with RA2 buffer that inactivates DNasel and twice 
with buffer RA3. Finally the RNA was eluted by applying 40 pi of RNeasy 
free H2O to each mini-column 
Agarose gel electrophoresis of nucleic acids
Gels were prepared by adding agarose (1 to 1.5% w/v) to 30 ml 0.5x TAE
buffer and heated to boiling point in a microwave oven. After cooling, 1 pi
of ethidium bromide stock solution (lOmg/ml) (Sigma) was added. Gels
were poured into a gel tray with a well-comb of the desired number of
wells. After setting, the gel was submerged into the electrophoresis tank
containing 0.5x TAE buffer. Loading dye (1/6 volume of 6x stock solution)
was added to the nucleic acid solutions which were then loaded into the
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wells. Electrophoresis was performed at a constant voltage (100-120 volts) 
for at least 40 minutes or until the desired resolution was obtained. Nucleic 
acids were visualized with short-wave ultraviolet light. In the case of 
electrophoresis of DNA fragments, molecular sizes were calculated with 
respect to a reference DNA Ladder (MBI Fermentas, Germany) run 
together with the samples.
Determination of nucleic acid concentration
DNA and RNA quantification was performed using the spectrophotometric 
measurement (Ultraspec 2100 pro, Amersham Biosciences, Sweden) of UV 
absorption at wavelengths 260 and 280nm. Measures of DNA/RNA purity 
were determined by the A260/A280 ratio. For DNA this ratio provides 
indications of protein contamination. A pure DNA solution has an A260/A280 
ratio around 1.8. For RNA the ratio A260/A280 should be greater than 1.6.
Concentration calculations are based on the principle that A26O =1 is 
equivalent to 50pg/ml of double stranded DNA and 40pg/ml of RNA.
Reverse transcription PCR
First strand cDNA was generated from a RNA template using a High 
Capacity cDNA reverse Transcription Kit (AB Applied Biosystem). The 
cDNA reactions prepared using the High Capacity cDNA Reverse 
Transcription Kits can be used in a variety of applications, including- 
quantitatively converting up to 2 pg (for a 20-pl reaction) of total RNA to 
cDNA, generating single-stranded cDNA suitable for quantitative PCR
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applications and generating single-stranded cDNA suitable for short- or 
long-term storage.
1 pg of total RNA per 50-pl reaction was used and eluted with sterile DEPC 
water to a final volume of 25 pi. 2X Reverse Transcription Master Mix for a 
final volume of 25 pi was prepared as followed’. 5 pi of 10X RT Buffer + 5 
pi of 10X RT Random Primers + 2 pi of 25X dNTP Mix (100 mM) + 2.5 pi 
MultiScribe™ Reverse Transcriptase + 10.5 pi Nuclease-free H20. The 
reverse transcription reaction was carried out using the following 
conditions^ 1st step at 25°C for lOmin; 2nd step at 37°C for 3 hours; 3rd step 
at 85°C 5 min; 4th step 4°C.
The quality and yield of cDNA reverse transcription was checked by normal 
amplification of GAPDH (see next paragraph for details). Amplified 
GAPDH-PCR product were controlled by mixing 5 pi of the reaction 
mixture with 1 pi of 6x loading dye stock solution and subsequently run on 
an agarose gel.
Real time PCR
Quantitative real-time PCR was performed by an ABI Prism 7900 HT 
Sequence detection System (Applied Biosystem) using: TaqMan® Gold RT- 
PCR reagents, probes for EGFR, OCT4, NANOG, NESTIN, and GAPDH 
(endogenous control) (Applied Biosystem). The PCR reaction exploits the 5' 
nuclease activity of AmpliTaq Gold® DNA polymerase to cleave a 
TaqMan® probe during PCR. The TaqMan probe contains a reporter dye at 
the 5' end of the probe and a quencher dye at the 3" end of the probe. 
During the reaction, cleavage of the probe separates the reporter dye and
127
the quencher dye, which results in increased fluorescence of the reporter. 
Accumulation of PCR products is detected directly by monitoring the 
increase in fluorescence of the reporter dye. When the probe is intact, the 
proximity of the reporter dye to the quencher dye results in suppression of 
the reporter fluorescence.
For each gene and cell line the analysis was performed in triplicate. The 
final volume for every single reaction was 20 pi. For each gene the mix for 
triplicate samples consist of: 3 pi of cDNA (25ng/pL) + 30 pi TaqMan 
Universal PCR Master Mix (2X) + 9 pi of sterile water. The samples were 
then loaded onto the MicroAmp® Optical 96-Well Reaction Plate and finally 
covered with Optical Caps. Analyses were performed using data analysis 
software (SDS software 2.2.2) with the AACT method for relative 
quantification (Applied Biosystems).
For gene expression analyses of ABC transporters we mixed 2 pi of single­
stranded cDNA (equivalent to around 100 ng of total RNA) with 48 pi of 
nuclease-free water and 50 pi of TaqMan Universal PCR Master Mix. After 
loading 100 pi of the sample-specific PCR mixture into one sample port of 
the microfluidic cards (Human ABC Transporter Panel; Applied 
Biosystems), the cards were centrifuged twice for 1 min at 1500rpm and 
sealed to prevent well-to-well contamination.
The cards were placed in the microfluidic card Sample Block of an ABI 
Prism 7900 HT Sequence Detection System (Applied Biosystems). The 
thermal cycling conditions were 2 min at 50°C and 10 min at 95°C, followed 
by 40 cycles of 30 sec at 97°C and 1 min at 59.7°C. The assay for each
1 2 8
gene on the microfluidic card was carried out in triplicate, due to the design 
of this specific panel. The calculation of the threshold cycle (Ct) values was 
performed using the SDS 2.2 software (Applied Biosystems), after 
automatically setting the baseline and the threshold.
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2.4 Biological and biochemical assays 
In vitro proliferation rate
A431WT and A431SPH were seeded in standard medium in standard 6 well 
culture dishes and in sphere medium in 6 well low attachment culture 
dishes (Corning), respectively (10,000 cells/well in triplicate). Cell 
proliferation rate was monitored at day 4 and 7 after the seeding by cell 
counting. Proliferation of A431SPH was also performed in sphere medium 
in the absence of EGF (Sigma-Aldrich).
Cell cycle analysis
Cells were harvested and pelleted as described above. Collected cells were 
spun at 1200 or 1500 rpm for 5 minutes and the supernatant was removed. 
Ice-cold 70% ethanol was added dropwise to the pellet and the tube was 
flicked in order to resuspend and permeabilize the cell pellet. Generally 1ml 
for lx lO 6 cells was sufficient. Permeabilized cells were stored at 20°C for 
at least 24 hours. Before sample analyses, cells were pelleted to remove 
ethanol and washed twice in ice cold PBS IX. The pellets were then 
resuspended in PBS IX with 0.5mg RNAse A (Sigma-Aldrich) and 50mg/ml 
Propidium Iodide (Sigma-Aldrich) and incubated at 37°C for 3 hours. Cells 
were spun and resuspended in cold PBS IX. Flow cytometric analysis was 
performed using a FACS SCAN cytometer (Becton Dickinson, Franklin 
Lakes, NJ) and results were analysed with ModFit.
Western blot analysis
For preparation of total cell lysates of A431WT and A431SPH, cells were
washed with ice-cold PBS and lysed in RIPA buffer (See Table 2.B)
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containing 2% SDS and a protease inhibitor cocktail (Boehringer, Milan, IT) 
for 40 minutes in ice. After clearing by centrifugation (15 min at 13,000 
rpm), lysates were quantified by the BCA Protein Assay Kit (Pierce, 
Rockford, IL). Aliquots containing 40 pg of protein were separated on 
precasted 4%-12% gels (Invitrogen) and transferred onto nitrocellulose 
membranes (Amersham Bioscience-GE Healthcare). After blocking with 5% 
non-fat dried milk (MERCK, New York, NY) in PBS plus 0.1% Tween 20, 
membranes were incubated with a rabbit monoclonal antibody anti-EGFR 
(Cell Signaling, Danvers, MA), a rabbit polyclonal antibody anti-Oct4 
(Abeam, Cambridge, UK), a mouse monoclonal antibody anti-Nanog 
(Sigma-Aldrich) or a rabbit polyclonal antibody anti-Actin (Sigma-Aldrich). 
Binding of primary antibodies to membranes was detected by a peroxidase- 
conjugated secondary antibody and developed by ECL (Pierce, Rockford, 
IL). As a positive control for stem-protein expression we used MEL-1 (a 
human embryonic male stem cell line) whole cell lysates (ab27198, Abeam). 
Flow cytometry
The expression of cell surface or intracellular molecules was evaluated by 
flow cytometry. For each sample, approximately lx lO 6 tumour cells were 
harvested, washed twice in ice-cold PBS and resuspended in 200pl PBS IX 
-0.03% BSA.
For nuclear or cytoplasmic staining, cells were permeabilized for 30 
minutes on ice in 70% ethanol. Only live cells were used for the detection 
of molecules and 10 pg/ml of primary monoclonal antibody, or antibody 
concentration suggested by the manufacturer was added to each cell
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suspension. As a negative control, 200 pi of PBS IX with isotype matched 
control antibody was added in place of the primary antibody (See Table 
2.C). Incubation was carried out for 30 minutes or 1 hour on ice depending 
on the characteristics of the antigen. Cells were washed twice with 300 pi 
PBS IX by centrifuging at 1400 rpm for 5 minutes at 4°C. Anti-human 
primary antibody staining was detected with a fluorescein-labeled goat 
anti-mouse IgG + IgM (H + L) secondary antibody (KPL, Gaithersburg, 
MD). Samples were incubated in PBS IX in the dark for 30 minutes on ice. 
For double staining with the ALDEFLUOR assay and CD44 APC (APC 
mouse anti human CD44, BD Bioscience) the CD44 antibody was added 
after 30 minutes of incubation with ALDH substrate + /-  ALDH inhibitor. 
Stained cells were washed and resuspended in 0.3 ml PBS IX + 1% 
formalin. Flow cytometry was performed using a FACS Calibur or a FACS 
ARIA or a FACS CANTO (Becton Dickinson) and the collected data were 
analyzed with Winmdi Software or FACS DIVA software (Becton Dickinson, 
CA).
Immunohistochemistry (on paraffin embedded and on frozen (cryostat-cut) 
tissues)
Immunohistochemistry on formalin-fixed paraffin-embedded sections was 
performed using the UltraVision LP large volume Detection System HRP 
Polymer kit (Thermo Scientific, Waltham MA). Formalin-fixed paraffin- 
embedded sections were de-paraffinized at 60°C (30-60min), treated twice 
with xylol for 1 min and hydrated by incubation with 99%, 95% and 75%
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ethanol twice for 3 min each and then immersed in H2O for 5 min. To block 
endogenous peroxidase, sections were incubated with methanol + 0.3% 
hydrogen peroxide solution for 30 min at RT. Antigen retrieval was carried 
out in lOmM citrate buffer pH=6 for 15 min at 95°C in a steam-cooker, then 
left at RT for 30 min.
Sections were washed 3 times with PBS (5 min each). Blocking solution 
BLOCK LP (UltraVision) was applied for 10 min at RT in a humidified 
chamber. Sections were then incubated with the primary rabbit polyclonal 
antibody anti-human CXCR4 (Biotrend) for lh  at RT in a humidified 
chamber and then washed 3 times with PBS (5 min each). The ENHANCER 
(UltraVision) was added and incubated for 30 min at RT in a humidified 
chamber. After 3 PBS washes, slides were incubated with HRP POLYMER 
(UltraVision) for 30 min at RT in a humidified chamber.
Slides were washed with PBS and the peroxidase activity was revealed by 
incubating sections in DAB (3-3 diaminobenzidine) (Sigma) for 5 min.
After washing with water, sections were counterstained with Gill’s 
haematoxylin solution for 5 sec and washed again with water. Sections 
were passed through an ascending series of alcohols (75%, 80%, 95% and 
100%), followed by xylol 5 min for 4 times, and then mounted with EUKIT 
resin.
Frozen sections were washed 3 times with PBS (5 min each). To block 
endogenous peroxidase, sections were incubated with PBSIX + 3%
hydrogen peroxide solution for 30 min at RT. After PBS washing, sections
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were incubated with PBS IX + 2% normal blocking serum (depending on 
the animal species for secondary antibodies) or PBS IX + 1% BSA for 30 
min. After 3 washes with PBS IX, sections were then incubated with the 
primary monoclonal antibody (overnight at 4°C) or with a primary 
polyclonal antibody (lh  at RT) in PBS IX + BSA 0.1% in a humidified 
chamber (EpCAM 1:35, Novocastra; FR lOpg/ml, homemade; CD44 10pg/ml, 
DAKO; CD 133 1:10, Becton Dickinson; SSEA1 1:100, Chemicon). Sections 
were washed 3 times with PBS (5 min each) and incubated with either a 
polyclonal goat anti-mouse IgG/biotinylated secondary antibody 1:100 or 
with a polyclonal goat anti-rabbit IgG/biotinylated secondary antibody 
1:200 (DAKO) in PBS IX + BSA 0.1% 30 min at RT. After 3 washing with 
PBS IX, sections were then incubated with Streptavidin/HRP 1:300 in PBS 
IX for 30 min at RT. Sections were washed 3 times with PBS IX (5 min 
each) and incubated with DAB for 5min. After washing with water, sections 
were counterstained with Gill’s haematoxylin solution for 5 sec, washed 
again with water and then mounted with EUKIT resin.
Epifluorescence
A431SPH were collected after 3 or 4 days of culture, when the mean 
diameter was approximately 50yc, washed with PBS IX to eliminate the 
entire culture medium and fixed with 4% formaldehyde in PBS IX. Sphere 
cells were permeabilized with PBS IX + BSA 1% and Triton-X 100 0.1% 
(Sigma-Aldrich) for 20min at RT. To mark the nuclei, spheres were firstly 
incubated with a rabbit polyclonal antibody anti-acetyl-Histone H3 or anti- 
acetyl-Histone H4 (Upstate) for 1 h at RT. After washing the cells 3 times
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with PBS IX, Alexa Fluor 546 goat anti- rabbit IgG was used as the 
secondary labelled antibody and incubated in PBS IX and BSA 0.1% for 
30min at RT in the dark. Spheres were then washed and incubated with one 
of the primary mouse monoclonal antibodies (see Table 2.C) in PBS IX and 
BSA 0.1% for 1 hour at RT and then washed 3 times with PBS IX. The 
Alexa Fluor 488 goat anti—mouse IgG secondary antibody was incubated in 
PBS IX and BSA 0.1% for 30 min, at RT in the dark. Finally spheres were 
washed with PBS IX and resuspended in lOyl of ProLong Antifade Reagent 
(Invitrogen), spread on glass slides and covered with a glass coverslip. 
After one night at RT, the mounting media was dry and confocal analyses 
were performed.
Animals and tumour models for in vivo assays
All protocols were approved by the Ethics Committee for Animal 
Experimentation of the National Cancer Institute of Milan and carried out 
according to institutional and international guidelines (347). Female SCID 
mice were obtained at 5-6 weeks of age from Charles River Laboratories 
(Calco, Italy) and left untreated for at least one week for acclimatization. 
After 1 week of stabilization, mice were xenografted subcutaneously in the 
flank region with 1 x 105 or 3 x 105 A431WT or A431SPH cells in a single 
cell suspension in 0.1 ml saline. Tumour growth was monitored on a regular 
basis and three dimension measurements were used to calculate tumour 
volume (V) using the formula V = 1/6 it D3, where D is the mean of the 
three diameters of the tumour. Animals were humanely sacrificed when the
o
tumour volume reached 1 cm or when the physical appearance of the
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mouse was compromised. The explanted tumours were frozen at -80°C. 
From frozen tumours, 5 ym-thick sections were cut and stained with 
haematoxylin/eosin for histological analysis.
Tumours coming from patients either as solid masses or as ascitic fluids 
were disaggregated with the appropriate method (previously described). 
For the subcutaneous (s.c.) model, mice were xenografted in the flank 
region with either 0.5 x 106, 1x10s, 2x l06, 3x l06 or 9x l06 tumour cells in 
0.1 ml of saline, and tumour growth was monitored on a regular basis and 
three dimension measurements were used to calculate tumour volume (V) 
using the formula V = 1/6 it D3, where D is the mean of the three diameters 
of the tumour. For the intraperitoneal (i.p.) models, mice were xenografted 
with different doses of tumour cells (see Result and Discussion, Chapter 3 
and 4 for details) in 0.5 ml of saline. For each mouse, ascites growth was 
evaluated as percentage of body weight increment: the body weight 
measured at each time point after cell transplantation was related to the 
initial animal body weight at the time of cell injection [(Body Weight 
Measured/Body Weight at Day 0) x 100]. The humane end-points 
considered were: for s.c. models a tumour volume > 750 mm3 and/or a body 
weight loss > 20%; for i.p. models a body weight increase > 20% or an i.p. 
tumour mass with an estimated volume > 500 mm3. In these cases animals 
were humanely euthanized and tumours/ascites characterized.
Side population
A431WT and A431SPH cells were stained with 2.5 yg/ml of the DNA 
intercalating Hoechst 33342 dye (Invitrogen) in the absence or in the
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presence of 50 yg/ml of verapamil, a BCRP inhibitor, for 90 min at 37°C, 
washed, and resuspended in cold PBS. Before flow cytometry analysis, 1 
yg/ml propidium iodide (Sigma-Aldrich) was added to exclude non-viable 
cells. Side population (SP) cells were identified and electronically gated on 
a Digital Vantage or FACS ARIA cell sorter (Becton Dickinson) after 
excitation of the Hoechst dye with 150 mW of 350 nm UV light. SP 
fluorescence emissions were directed toward a 610-nm dichroic filter and 
captured simultaneously through both a blue (450-nm) band-pass and a red 
(675-nm) long-pass filter on a linearly amplified fluorescence scale. 
Aldefluor assay
(ALDEFLUOR KIT, Stem Cells Technologies, Vancouver, BC).
Prior to the start, all necessary supplies were assembled and kit reagents 
were allowed to come to a room temperature (RT) of 18 to 22°C before 
use. Activation of the ALDEFLUOR reagent BAAA (BodipyTM- 
aminoacetaldehyde) was performed by adding 25 yl of DMSO (1.5 ml 
supplied by the kit) to the vial of dry ALDEFLUOR reagent (50 yg supplied 
by the kit), mixing well and incubating for 1 min at RT. Dry ALDEFLUOR 
reagent is an orange-red powder that changes to a bright yellow-green 
upon addition of DMSO. 25 yl of 2N Hydrochloric Acid (HC1) (1.5 ml 
supplied by the kit) was added and the new solution mixed well. This 
mixture was then incubated for 15 min at RT. The final step was the 
addition of 360 yl of ALDEFLUOR Assay Buffer (4 bottles of 25 ml each 
supplied by the kit) to the vial and mix. The activated reagent was kept at 2 
to 8°C during use and at -20°C for its routine storage. For sample
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preparation, cells were firstly detached, counted and then resuspended in 
ALDEFLUOR Assay Buffer to a concentration of lx lO 6 cells/ml, and 5 yL of 
the activated ALDEFLUOR substrate was added to the cell suspension, 
mixed very well and immediately half of the mixture was transferred to the 
tube-control. The ALDH enzymatic reaction begins immediately upon 
addition of the activated substrate to the cell suspension. It is imperative 
that an aliquot of the ALDEFLUOR-reacted cells be added to the control- 
tube without delay. Five yl of the specific ALDH inhibitor 
diethylaminobenzaldehyde (DEAB) (1.5 mM in 95% ethanol stock solution 
supplied by the kit) was rapidly added to the tube-control, in order to 
inhibit the reaction. Both samples, the test-tube and the control-tube, were 
incubated for 60 min at 37°C in humidified incubators in the presence of 5% 
CO2. Following incubation, all tubes were centrifuged for 5 min at 1200 rpm 
and supernatants were removed. Cell pellets were resuspended in 0.5ml of 
ALDEFLUOR assay buffer. Cells incubated with ALDEFLUOR substrate 
(BAAA) and the specific inhibitor of ALDH, DEAB, were used to establish 
the baseline fluorescence of these cells and to define the ALDEFLUOR 
positive region. After staining, cells were maintained on ice during all 
subsequent procedures. Flow cytometric analysis was performed using a 
FACS ARIA (Becton Dickinson, Franklin Lakes, NJ).
PKH assay
A431SPH cells were separately stained, using PKH26 Red Fluorescent or 
PKH67 Green Fluorescent Cell Linker Kit for General Cell Membrane 
Labeling (Sigma-Aldrich). Protocol was performed to obtain a final
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concentration of 2 x 106 M PKH26 or PKH67 dye and 1 x 107 cells in 
Diluent C in 2 ml. All the steps ware performed at RT in polypropylene 
conical centrifuge tubes.
THV/TPrior to the start, sphere cells were disaggregated using TrypLE Express 
trypsin at 37°C for five minutes in humidified incubators in the presence of 
5% CO2. Approximately 20 x 107 cells obtained from a single cell 
suspension solution were washed once with complete medium and once 
using medium without serum and centrifuged five minutes at 1500 rpm. 
After centrifuging the cells, the supernatant was carefully aspirated, leaving 
no more than 25pl of supernatant on the pellet. Cells were resuspended, 
without vortexing in the residual medium and then diluted in 1ml of Diluent 
C (supplied by the kit). This will be a 2X cell solution. Prior to the staining, 
PKH26 RED or PKH67 GREEN 2X stock solutions were prepared- the 
mother solution dye lx lO -3 M (supplied by the kit in ethanol) was diluted in 
Diluent C P250. One ml of 2x cell solution was then rapidly added into 1 ml 
of 2X 4xl0~6 M dye solution and mixed immediately by gentle pipetting. 
Cells were stained in the tube for 5 minutes at 25°C and periodically 
inverted. The reaction was stopped using 1% of BSA (Sigma-Aldrich). Cells 
were washed three times with complete medium and plated at 1,000 
cells/ml in sphere medium (Lonza), in Ultra Low Attachment 6 well Plates 
(Corning) and monitored at the 4th and 7th days after seeding.
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Morphological assay- analysis of cloning experiments in adherent conditions
For morphological analysis of adherent clones, single cells were collected, 
counted and seeded in standard medium in adherent conditions at 10 cells/ 
well in 24 well plates (Corning-Costar). After 7 days, the clones were 
counted and the percentage of each class of clone morphology (holo-, mero 
and para-clone) was determined, using the formula: (# clone type/ # total 
clones) x 100.
Sphere Forming efficiency (SFE)
Sphere forming efficiency of cancer cells (A431, SiHa and CaSki cell lines) 
was evaluated by low-density sub-cloning. Cells were detached and 
seeded in sphere medium at 1 cell/well in 96 well low attachment plates 
(Corning). Spheres with a mean diameter of 50-150 pm, were counted after 
4/10 days, depending on the cancer cell line. Sphere Forming Efficiency 
(SFE) was determined using the formula: (# of spheres/# of cells plated) x 
100.
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CHAPTER 3
RESULTS and DISCUSSION
3.1 Tumour initiating cells: development and critical 
characterization of a model derived from the A431 
carcinoma cell line forming spheres in suspension
Numerous tumours, including squamous cell carcinomas of the cervix, 
display characteristics of multilineage differentiation, an aspect of the 
normal stem cell compartments. This evidence supports the theory that 
these types of tumours are propagated and maintained by a population of 
Cancer Stem Cells/Tumour Initiating Cells (CSCs/TICs).
Very limited research is at present focused on cervical cancer CSC/TIC. 
The field is therefore open to new investigation.
To investigate the tumour fraction with CSC/TIC characteristics in this kind 
of tumour, we started with the A431 cancer cell line and we extended the 
study to two other cervical carcinoma cell lines, Caski and SiHa.
3.1.1 Sphere formation and ALDH activity of cell lines from squamous 
cell carcinomas of the cervix.
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We compared three different cervical cancer cell lines, A431 and SiHa, both 
derived from primary SCC of the cervix, and CaSki, which is conversely 
established from a metastasis in the small bowel mesentery, for sphere 
forming efficiency and intrinsic ALDH enzymatic activity.
Cells from the three cell lines were grown in suspension at low density in 
serum-free sphere medium for 7-10 days. A431 and Caski but not SiHa 
cells were able to grow forming spheres in suspension (FIG. 3.1 A). When 
tested in limiting dilution assay (1 cell/well), A431 cells showed a higher 
sphere forming efficiency (SFE; mean 65.5% ± SE 1.7 of four independent 
experiments) as compared to Caski (SFE ; mean 32.8 ± SE 6.8 of two 
independent experiments) (FIG. 3.IB).
To assess the presence and size of a stem-like population we tested the 
ALDH enzymatic activity of the same cell lines. The fluorescent 
ALDEFLUOR reagent freely diffuses into cells and is a non-toxic substrate 
for ALDH. The amount of fluorescent ALDH reaction product that 
accumulates in cells directly correlates to the ALDH activity in these cells. 
The cells incubated with ALDEFLUOR substrate together with the specific 
ALDH inhibitor were used to establish the baseline fluorescence and to 
define the ALDEFLUOR positive region. As shown in Figure 3.1C, A431 
showed the highest fraction of ALDEFLUOR positive cells (mean % ± SE = 
45.7 ± 6) as compared with Caski (mean % + SE = 30.6 ± 10.7) and SiHa 
cells (mean % ± SE = 24.3 ± 6.7). On the basis of these results the A431 
cell line was selected for further analyses (FIG. 3.1C and FIG. 3.ID).
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Figure 3.1* Sphere formation and ALDH activity of cell lines from squamous cell
carcinomas of the cervix.
A) Example of spheres formed by A431, Caski and SiHa cells plated at limiting dilution in 
suspension and analyzed at day 7-10 after seeding. B) SFE of A431, Caski and SiHa cancer 
cell lines plated at 1 cell/well (A43L mean % ± SD of 4 independent experiments; Caski: 
mean % ± SD of two independent experiments). C) Percent of ALDEFLUOR positive cells 
evaluated in 3 independent experiments (mean % ±  SD of 3 independent experiments).
The difference in ALDH activity between the A431 and Caski were not statistically 
significant (p = 0.2510) but between A431 and SiHa they were statistically significant (p = 
0.0473). D) Representative images of Aldefluor assay on Caski (lOp vitro) and SiHa (lOp 
vitro) cell lines. Aldefluor assay of A431 cell line was reported in FIG. 3.3A.
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3.1.2 A431 sphere characterization: clonogenic and proliferative 
potential.
Single-cell suspensions of A431 sphere (A431SPH) cells were able to give 
rise to new spheres with a SFE similar to that of the parental A431 
(A431WT) cells, but with a wider range of variability among the three 
different experiments performed (mean 55.5% ± SE 12.2). To demonstrate 
that spheres were derived from single cells and not from cell-aggregation, 
A431SPH cells were stained with PKH26RED or PKH67GREEN fluorescent 
dyes, mixed and plated at limiting dilution; this culture gives rise only to 
completely red or green spheres (FIG. 3.2A).
Cloning experiments, performed to evaluate the morphology of adherent 
clones derived from A431WT and A431SPH cells plated in FBS-containing 
medium, indicated that both parental and sphere cells were able to form 
holoclones. The number of holoclones, possibly derived from cells with 
stem-like characteristics, was higher in A431WT than A431SPH (mean % ± 
SE = 47.9 ± 7 .1  and 36.4 ± 6.4, respectively). On the contrary, the number 
of more differentiated paraclones was significatively higher in A431SPH as 
compared to A431WT (mean % ± SE = 22.7 ± 4.3 and 4.85 ± 2.9, 
respectively). The number of clones with intermediate characteristics, 
called meroclones, was more or less similar in the two cell populations 
(mean % ± SE = 47.3 ± 4.3 and 40.95 ± 8.5, for A431WT and A431 SPH, 
respectively) (FIG. 3.2B and FIG. 3.2C).
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These results indicated that A431 cells have a high capability to grow in 
suspension as spheres and sphere-forming cells, and like TIC, displayed 
again consistent sphere-forming efficiency and therefore self-renewal 
capability in culture. However, the higher proportion of differentiated 
paraclones observed in A431SPH suggests that differentiation takes place 
in A431 cells in suspension much more than in adherent growth conditions. 
Long-term cultures grown in suspension (more than 40 serial passages) 
were obtained from A431SPH cells, indicating that these cells maintain high 
proliferative potential. When compared both at early and late passages, the 
growth of A431SPH cells in suspension was exponential both at day 4 and 
7, whereas A431WT cells proliferated more rapidly during the first 4 days 
and then more slowly, reaching a probable plateau phase of growth after 7 
days of culture (FIG. 3.2D). Analysis of the cell cycle by staining the cells 
for DNA content revealed that the suspension cell culture seemed to select 
cells which had a better ability to proliferate. In contrast with the adherent 
parental cell, A431 spheres did not accumulate in the G1 phase of the cell 
cycle, with concomitant decrease in the S and G2/M phases (FIG. 3.2E).
The A431 cell line over-expresses EGFR due to amplification of the EGFR 
gene. Since sphere medium is supplemented by 20 nM EGF, this factor 
might be important to sustain A431 proliferation in non-adherent 
conditions. To verify the role of EGF, A431SPH were grown in sphere 
medium in the presence or absence of EGF. No difference in the 
proliferation rate was observed (FIG. 3.2F) suggesting that non-adherent 
growth of A431 cells is not dependent on EGFR stimulation.
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Figure 3.2: A431WT and A431SPH clonogenic and proliferative potentials.
A) PKH67 green and PKH26 red staining of A431SPH, seeded in suspension at limiting 
dilution (1000 cell/mL) after the assay. B) Examples of clonal morphology from single-cell 
cloning in standard medium (Bar = 100 pm). C) Relative percentage of different clones 
from A431WT and A431SPH cells (mean + SD). For A431WT cells, results are from 2 
independent experiments, for A431SPH cells results are from 4 independent experiments. 
(*p = 0.0407 Paraclone). D) Proliferation rate of A431WT and A431SPH cells, at early and 
late passages. E) Cell cycle analysis of A431 WT and A431 SPH. (F) A431SPH were grown 
in sphere medium in the presence or absence of EGF. Mean ± SD of 3 different in vitro
passages (lp, 5p, 13p).
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3.1.3 Monitoring of ALDH expression and Side Population in A431SPH.
The ALDH enzymatic activity and Side Population (SP) phenotype of the 
A431WT and A431SPH cells were compared. Representative experiments 
for ALDH and SP are shown in Figure 3.3A and in Figure 3.3D, 
respectively. A431WT showed a sizeable fraction of ALDEFLUOR positive 
cells (mean % ± SE = 45.7 ± 6), but the proportion of ALDEFLUOR positive 
cells was significantly increased in A431SPH cells (mean % ± SE = 64.9 ± 
7.5) (FIG. 3.3A and FIG. 3.3B). Since the CD44 marker was found to be 
associated to the Podoplanin positive stem cell-like subpopulation in the 
A431 cell line (290), we evaluated the possible correlation between 
CD44hlgh and ALDH-positive cells. We found a high CD44 positivity both in 
A431WT and A431SPH cells, ranging from 88 to 95%. Moreover, in double 
staining experiments and FACS analysis, we observed a direct relationship 
and a clear overlapping between the two tested markers in both cell types 
(representative images are shown in FIG. 3.3C), suggesting that CD44 and 
ALDH do not identify in A431 cells a specific subpopulation with TIC 
properties.
SP is defined by Hoechst dye exclusion in flow cytometry. To determine 
the region containing Hoechstlow cells (SP), corresponding to cells able to 
extrude Hoechst 33342 dye, A431WT and A431SPH cells were incubated 
with the dye alone or in combination with verapamil, a drug inhibiting the 
activity of ABC pumps. As consequence of verapamil treatment the SP 
positive fraction is expected to disappear.
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Repeated FACS analyses demonstrated that the small fraction of Hoechst 
low gp ceps present in A431WT (mean % + SE = 0.13 + 0.03) increased 
following sphere formation (mean % ± SE = 1.3 ± 0.32). Verapamil 
treatment reduced by 90% the A431SPH SP (0.08 + 0.012) (FIG. 3.3D and 
FIG. 3.3E). These results indicate that the growth in suspension as spheres 
enriched the A431 cell lines in cells with detoxifying abilities that are 
hallmarks of the sternness phenotype.
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Figure 3.3' Monitoring of ALDH expression and Side Population.
A431WT and A431SPH cells were analyzed for the activity of ALDH1 (A and B) and for 
the side population (SP) phenotype (D and E). A) Plots from a representative experiment in 
presence (upper plots) and in absence (lower plots) of DEAB inhibitor. Baseline 
fluorescence is indicated as region P3 and the ALDEFLUOR positive region as region P4.
B) Percent of ALDEFLUOR positive cells evaluated in 3 independent experiments (mean % 
± SD of 3 independent experiments): the increase in ALDH1 positive cells was statistically 
significant (p = 0.0002). C) Representative images of A431SPH cells (at different in vitro 
passages) analyzed for the activity of ALDH1 and expression of CD44. D) SP plots from a 
representative experiment in absence (middle plots, -ver) or in presence (right plots,
+ ver) of verapamil. Morphological parameters of each population are described in left 
plots. E) Percentage of SP cells as evaluated in three independent experiments (mean % + 
SD of 3 independent experiments). The differences between A431WT and A431SPH SP 
without verapamil and between A431SPH SP with and without verapamil were statistically
significant (p < 0.05).
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3.1.4 Modulation of sternness markers.
The expression of stem and differentiation markers in A431SPH cells was 
analyzed by Real Time PCR at the 4th, 7th, 10th and 12th in vitro passages 
using the A431WT as a calibrator (FIG. 3.4A). The growth in non-adherent 
conditions was found to up-regulate the expression of NANOG and 
NESTIN, with a less pronounced rise of OCT4. The EGFR levels were 
concurrently slightly up and down-regulated.
To verify if the RNA analyses correlated with the protein levels we 
analyzed whole protein cell extracts from A431WT and A431SPH cells, 
using as internal control a male embryonic cell extract. The results showed 
an increased Oct4 protein level in A431SPH as compared to the parental 
cells, whereas a similar Nanog protein level was detected in both cells (FIG. 
3.4B, lanes 2 and 3). Overall, it seemed that the protein expression was not 
strictly related to mRNA level. Indeed the expression of genes linked to 
self-renewal was initially promoted at the RNA level by the cell grown as 
spheres, whereas their transcription became down-regulated in later 
passages.
We also evaluated expression levels and localization of epithelial, 
mesenchymal and sternness markers in A431SPH, using 
immunofluorescence analysis (FIG. 3.4C). Confocal analysis showed that 
CD44, a well known CSC marker in different solid tumours, was expressed 
homogeneously at a high level by all of the sphere-cells. The proliferation 
marker Ki67 seemed to mark few cells located at the external face of the
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sphere, suggesting that the bulk of the spheroid could be composed of 
quiescent cells, which do not undergo asymmetric division, leading to the 
differentiation. We observed a weak or absent expression of N-Cadherin 
and vimentin, mesenchymal markers, but a strong expression of epithelial 
markers, such as E-Cadherin and Cytokeratin 8/18. We also tested the 
expression of the stem-germinal cell marker SSEA1, which was weakly 
expressed, and the expression of the POU-FAMILY factor 0CT4 which was 
weakly expressed by a limited number of sphere-cells.
Expression of Podoplanin, a marker recently described to be associated 
with the stem-like population of A431 cells, was evaluated in A431SPH 
cells by FACS analysis. Based on the histograms shown in Figure 3.4D, 
Podoplanin is expressed in A431WT cells at very low levels. In contrast, 
sphere-derived cells displayed a distinct population of Podoplanin-positive 
cells, around 5.5%, as evaluated in two different sphere passages. This 
sub-population of Podoplanin positive cells increased during in vitro culture 
and they were distinctly smaller than the bulk sphere population. Moreover, 
a population of cells with this characteristic was not evident in A431WT 
(FIG. 3.4D, black arrow).
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Figure 3.4: Modulation of “sternness” markers and evaluation of podoplanin 
expression in A431WT and A431SPH.
A) The expression levels of multiple “stem” genes in various (as indicated) in vitro 
passages of A431SPH cells were assessed by Real Time PCR using the A431WT cells as a 
reference. Results from 2 to 5 separate experiments, depending on the gene analysed, are 
shown. 4p, 7p, lOp, 12p indicates passage numbers. B) A representative Western Blot 
analysis of whole protein cell extracts of A431WT (WT) and A431SPH (SPH) using as 
positive control a male embryonic cell extract (C+). C) Representative pictures of 
confocal analysis on A431 sphere, after immunofluorescence for selected markers as 
indicated. Red fluorescence marked the nuclei whereas green fluorescence was specific 
for the annotated markers. D) Flow cytometry analysis of podoplanin expression in 
A431WT and A431SPH cells. Notice the presence of a subpopulation of podoplanin- 
positive cells composed of smaller cells, as demonstrated by their lower FCS parameter, in 
A431SPH cells (indicated by black arrow). Please note that black arrow also indicates the 
region where cells should appear on A431WT graph, but they are largely missing.
(Abbreviations: NC = negative control; PDPN = podoplanin).
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3.1.5 In vivo tumorigenicity.
The tumorigenic potential of A431SPH in comparison with A431WT cells 
was evaluated in vivo by s.c. injection of cells into athymic nude mice. At a 
dose of 3 x 105 cells, tumours developed in all A431SPH injected mice 
(100% take) (FIG. 3.5A). At this dose, the tumour onset was earlier and the 
growth faster than in tumours derived from A431WT cells, which also 
showed a lower tumour take (50%) (FIG. 3.5A and FIG. 3.5B). Indeed, the 
tumour volume doubling time was approximately 2 and 10 days for 
A431SPH and A431WT, respectively. At the lower dose of 1 x 105 cells, 
tumours from A431SPH cells grew in 2 out of 6 mice (33% take). In 
contrast, no tumours were observed in six mice injected with the same 
dose of A431WT cells (FIG. 3.5A). A431SPH tumours could be serially 
transplanted for at least four in vivo passages at the dose of 3 x 105, 
propagating their original tumour phenotype and in vitro they gave rise to 
new sphere formation. Histologically, the parental A431WT-derived 
tumours were poorly differentiated squamous epidermoid carcinomas (FIG. 
3.5C). A431SPH-derived tumours initially maintained the same histological 
characteristics but became much more undifferentiated after a few in vivo 
passages. These results indicate that, despite the modest increase in 
tumorigenic potential of A431SPH as compared to A431WT, A431SPH cells 
demonstrated a higher proliferative potential that strongly contributed to 
the rapid development of the tumour mass.
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Figure 3.5: In vivo tumorigenicity.
Two doses (1 x 10° and 3 x 10°) of A431WT and A431SPH cells w ere s.c. injected in nude 
mice and tumour developm ent evaluated as A) take rate  at the two doses of cells; B) 
tumour volume at different times after injection of 3 x 10a cells; C) H&E staining of 
represen tative frozen sections from A431WT and A431SPH tumours.
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3.2 Discussion
Established tumour cell lines, even after long-term propagation in vitro, can 
maintain the heterogeneity of the original tumour, including cells with 
different morphological phenotypes, variable proliferative and clonogenic 
potential together with the presence of cells with stem-like characteristics. 
For these reasons, tumour cell lines may also represent useful models to 
study the CSC/TIC component in vitro. In this study, among three cell lines 
derived from squamous cervical carcinoma, A431 cells exhibited the 
highest fraction of ALDH-positive cells and a good correlation between 
ALDH positivity and sphere forming efficiency (FIG. 3.1). Therefore, we 
selected the A431 cell line as a model suitable for a critical evaluation of 
the experimental procedures adopted for the characterization of CSCs in 
tumour cell lines.
Forced growth in suspension in the presence of specific growth factors was
found to be a useful tool for the isolation of undifferentiated multipotent
neural and breast stem cells (348) (327). Under these conditions, most of
the cells die and surviving cells give rise to floating spherical colonies
(spheres). One of the most important characteristics of stem/progenitor
cells is the ability to self-renew. Only cells with a self-renewal capability
are able to sustain the growth in suspension giving rise to non-adherent
colonies. The growth in suspension has also been applied to the isolation
and propagation of putative tumour stem cells from tumour cell lines and
from patient tumour specimens (349) (308) (350) (351). In suspension, the
A431 parental cells (A431WT) showed a very high SFE, which was
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essentially maintained by the cells derived from single sphere cloning, 
indicating that both the A431WT and sphere-derived cells have self­
renewal properties (FIG 3.IB).
Increased ALDH activity has been found in stem cell populations in multiple 
myeloma and acute myeloid leukaemia (351), and also in normal and cancer 
stem cells of the breast (1371352). Our analysis on cervical cancer cell 
lines showed the presence of ALDH positive cells in all tested cell lines in a 
range between 30 to 49%, and a good correlation between ALDH activity 
and sphere forming efficiency was also observed, especially in the A431 
cell line (FIG. 3.IB and 3.1C). Moreover, in the A431 model, cells exhibited 
a high fraction of ALDH-positive cells (49%) which increased up to 80% in 
sphere cells (FIG. 3.3A). Overall, our data are in agreement with the wide 
range of ALDH enzymatic activity recently reported in breast cancer cell 
lines, where ALDEFLUOR positive cells showed higher sphere-forming 
capacity compared to ALDEFLUOR-negative cells (353).
The high ALDH activity and SFE of the selected cell line correlated with 
the formation, upon cell adhesion, of a high number of clones with compact 
round morphology (holoclones) both by A431WT and A431SPH. Clones with 
these characteristics are considered enriched in stem cells not only in 
keratinocytes, where they were originally described (343), but also in 
several carcinoma cell lines (285) (354) where a holoclone fraction, ranging 
from less than 5% to about 30%, has been described. Interestingly, the 
percent of holoclones formed by A431WT approached 50%, representing 
the highest among those reported (285). Holoclones are characterized by a
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high proliferative potential (355) and this property can explain why 
A431WT and spheres showed quite similar proliferation rates when 
evaluated in the exponential growth phase (seven days growth) and also the 
maintenance of the proliferative potential for more than 40 passages (FIG. 
3.2D). However, as evaluated after a few passages in suspension, A431 
sphere-derived cells formed slightly lower numbers of undifferentiated 
holoclones as compared to parental A431 cells, whereas the number of 
differentiated irregular colonies (paraclones) appeared significantly 
increased (FIG. 3.2B and 3.2C). We conclude that, in agreement with that 
described in other tumour models (308), in our model system the growth in 
suspension sustained the cell fraction with stem-like characteristics but at 
the same time also induced differentiation inside the spheres.
We found that the SP, originally representing a very small fraction of A431 
parental cells (0.2%), increased to about 1.2% in sphere-derived cells but 
remained far smaller than the percentage of ALDH-positive cells (FIG. 3.3 
A, B, D and E). Similarly, in human haematopoietic cells, ALDH-positive 
cells only partially overlapped with the SP (356). The SP fraction, identified 
by Hoechst dye exclusion, represents only 0.16% of the main population on 
short-term  culture of human keratinocytes (31), whereas in oral squamous 
cell carcinoma cell lines and primary tumours, the SP was highly variable 
(from 0.1 to about 10%) (357).
Podoplanin, in association with CD44hlgh has been recently reported as a 
new marker of epidermal carcinoma cancer stem cells in the A431 cell line 
(290). Our FACS analysis revealed that a population of small sized cells,
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representing about 5% of the total count, emerged in sphere cells with a 
higher Podoplanin mean fluorescence (FIG. 3.4D). Interestingly, by flow 
cytometric analysis we also observed that small-sized cells constitute the 
SP fraction of A431SPH cells (FIG. 3.3D). Similar to murine keratinocytes, 
where SP is suggested to constitute the most primitive blast-like subset of 
any epidermal population (358), small sized Podoplanin-positive and SP 
cells might represent the real stem-like cell component of A431 cells, 
which was highlighted by the growth in suspension. CD44 was highly 
expressed in both A431WT and A431SPH cells, suggesting that this 
molecule does not identify in A431 cells a specific subpopulation with TIC 
properties.
Since the CD44 marker was found to be associated with the Podoplanin 
positive stem cell-like subpopulation in the A431 cell line (290), we 
evaluated the possible correlation between CD44hlgh and ALDH-positive 
cells. We found a high CD44 positivity both in A431WT and A431SPH cells, 
ranging from 88 to 95% (FIG. 3.3C). Moreover, in double staining 
experiments and FACS analysis, we observed a direct relationship and a 
clear overlap between the two tested markers in both cell types, suggesting 
that both CD44 and ALDH do not identify in A431 cells a specific 
subpopulation with TIC properties.
By epifluorescence analyses, the expression pattern of the proliferation 
marker Ki67 indicates that the more quiescent cells, which do not undergo 
asymmetric division, leading to their differentiation, are located in the bulk 
of the spheroid, whereas proliferating TA-cells are placed at the external
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face of the sphere. The absence of vimentin expression, the low levels of 
N-Cad and the homogeneous expression of epithelial markers, such as E- 
Cad and cytokeratins, indicated that spheres may be more prone to acquire 
an epithelial phenotype than a mesenchymal one (FIG. 3.4C). We also tested 
the expression of the stem-germ cell marker SSEA1, which is weakly 
expressed in the spheres, and the expression of the POTJ-FAMILY factor 
0CT4 which is only weakly expressed by sphere-cells located at the 
external face of the spheroids (FIG. 3.4C). These data confirm our previous 
Western Blot and Real time analyses and highlight the potential sternness 
phenotype of A431 spheres.
The presence of a subpopulation with stem-like properties was confirmed 
by Real Time PCR analysis. mRNA levels of ‘sternness’ genes, in particular 
NANOG and NESTIN, were initially up-regulated during growth of spheres 
in suspension, supporting the notion that this kind of growth allowed the 
initial expansion of a pool of cells with stem-like properties (FIG. 3.4A). 
These data have been partially confirmed by protein analysis of selected 
markers. In particular, since no change in Nanog protein expression had 
been detected by Western blot analysis, we suppose that other mechanisms 
of post-transcriptional regulation could affect the protein production in 
A431SPH cells and in the A431WT cells (FIG. 3.4B). The observed 
transcriptional activation of stem cell markers tended to be down-regulated 
in higher passages, in agreement with the observed increase in more 
differentiated paraclone formation in adherent conditions.
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The tumorigenic potential in vivo defines the intrinsic ‘sternness’ of cancer 
cells, and we found that A431WT cells, which were 100% tumorigenic at 1 
x 106 cells dose (data not shown), were unable to establish tumours after 
injection of 0.1 x 106 cells. A431SPH, fully tumorigenic at 0.3 x 106 cells, 
developed rapidly growing tumour masses in a shorter period of time than 
parental cells, but were only partially able to form tumours (2/6) after 
injection of 0.1 x 106 cells (FIG. 3.5). The number of A431SPH cells 
required for tumour formation was quite high when compared to that 
sufficient to induce tumours in other tumour models (263) (349). However, 
the assays were carried out in not completely immunocompromised animals 
and without Matrigel support. Nevertheless, we suggest that the increased 
tumorigenic potential, transplantability and aggressiveness of the sphere- 
growing population support our contention that we are enriching for cells 
with stem/progenitor-like properties.
In conclusion, this study has illustrated that A431 cells represent a useful 
tool for studying many aspects of cancer stem cell biology that are 
probably applicable to most, if not all, human cancers. Together our results 
support the hypothesis that the growth in suspension is essential for the 
emergence of a small population of tumour cells with CSC properties (SP, 
presence of Podoplanin positive cell, small cellular dimension) inside a 
wider “sphere” cell population characterized by “less stringent” stem cell 
features, such as high ALDH activity and high levels of expression of 
putative sternness markers, such as CD44, that, as in the case of A431, 
were frequently already present in adherent parental cells.
163
CHAPTER 4: 
RESULTS and DISCUSSION
4.1 Isolation of cells with characteristics of stem/progenitor cells 
from epithelial ovarian cancer.
Recent studies have shown that epithelial ovarian CSCs could be isolated on 
the basis of their ability to grow in suspension as spheres, or by their 
capacity to exclude the Hoechst dye (Side Population phenotype), or by the 
expression of CD44/CD117 or CD133 markers (See Chapter 1.10.3).
To identify and isolate ovarian CSCs, we applied different experimental 
procedures 1) establishment of in vitro cultures from solid tumour 
specimens or ascitic cells in non-adherent condition using a specific culture 
medium (See Chapter ‘Material and Methods’), 2) establishment of 
transplantable in vivo tumour cell lines, starting from solid tumour 
specimens or ascitic cells and their characterization by identification of 
specific marker expression and their possible correlation with a more 
aggressive phenotype; 3) Sorting of subpopulations expressing the selected 
markers and phenotypic and functional characterization of the sorted 
subpopulation for sternness properties (See Chapter Material and Methods).
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4.1.1 Setting up the culture conditions for in vitro expansion of 
ovarian cancer cells
In vitro culture of ovarian cancer cells isolated from solid tumour 
specimens or ascites was adopted for two main reasons’, the expansion of 
tumour cells in adherent conditions in order to obtain sufficient material for 
further characterization and the selection of tumour cells able to grow in 
suspension as spheres.
Following solid tumour or ascitic cell aggregate digestion, the isolated cells 
were seeded in adherent conditions for two hours to allow inflammatory 
and/or stromal cell adhesion to the plastic. After this initial adhesion- 
purification step, the supernatant was collected and cells were seeded in 
different culture conditions.
Aliquots were plated in the presence of different concentrations of serum in 
standard conditions. The use of different media (RMPI 1640 or MCDB 
105/MEDIUM 199 1:2) and different concentrations of serum (10%, 1% and 
0.1%) did not improve the growth of ovarian cancer cells, recovered from 
both solid tumours and ascites. Often a strong contamination of normal- 
stromal infiltrating cells was present in tumour cultures and this became 
predominant during the passages (representative examples are shown in 
FIG. 4.1A). When tumour cells survive, after several weeks of culture they 
form small colonies, composed of slow cycling tumour cells, which do not 
proliferate even after the addition of different growth factors.
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We have also tried to plate the purified tumour cells in Sphere medium, 
using appropriate low attachment culture flasks, which permit the selection 
of those cells able to grow in suspension as spheres (See Chapter 2 
‘Material and Methods’). From both solid tumours and ascites, some 
spheroids or cell aggregates appeared after a few days of culture. After the 
mechanical or enzymatic disaggregation of spheroids, growth of new 
spheroids was observed only for one or two in vitro passages. The poor 
sphere formation and the lack of proliferation or self-renewal were not 
improved by the addition to the culture media of different growth factors, 
such as Lysophosphatidic acid (LPA) (359) and bFGF (representative 
examples are shown in FIG. 4. IB). On the contrary, LPA did not stimulate 
cell proliferation and seemed to induce cell death. Similarly tumour cells 
seeded in the sphere medium plus bFGF were not able to form spheroids 
and showed a highly vacuolated cytoplasm.
The establishment of in vitro culture of cells derived from thirty-eight 
tumours and thirty ascitic samples was not achieved either in adherent 
conditions or in specific stem cell medium.
Therefore our efforts were directed towards stabilization of in vivo 
transplantable cell lines from patient-derived tumour cells. This alternative 
approach led us to obtain three transplantable ovarian cancer cell lines, 
which were further characterized for potential sternness properties.
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Figure 4.1: Setting up the culture conditions for expanding cancer cells:
A) R epresentative images of tumour cells, obtained after digestion of solid tum ours or 
ascites clumps and in vitro m aintenance in adherent conditions. After a few in vitro 
passages tumour cells did not proliferate and strom al cells becam e predom inant. B) 
R epresentative images of tumour cells obtained after digestion of solid tum ours or ascitic 
clumps and in vitro m aintenance in suspension in Sphere medium. Growth of new  spheroids 
was observed only for a few in vitro passages and was not improved by the p resence  of
LPA (10 pM) and bFGF (lOnM).
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4.1.2 Ovarian cancer sample characterization: evaluation of specific 
marker expression
The expression of specific antigens, correlated with a sternness phenotype, 
is the principle approach adopted to isolate and characterize the CSCs/TICs 
from a wide range of haematopoietic and solid tumour types.
The chemokine receptor CXCR4, expressed by CSCs of different solid 
tumours, has been reported on a subset of ovarian tumour cells, but not yet 
described as a CSC marker in EOC. We aimed to investigate whether, like 
CD133, CXCR4 expressing cells would also identify a subpopulation with 
characteristics of cancer stem/progenitor cells in human primary EOC and 
ascites.
In the period from January 2007 to June 2010, we obtained at the time of 
surgery 69 ovarian solid tumour specimens and 106 ovarian carcinoma 
ascites.
Fifty-five cases of solid tumours were processed as described in the 
Chapter ‘Material and Methods’. After processing, depending on FACS 
limiting factors, such as cell viability, the number of available cells and 
CD45 positivity, the cells obtained from 39 tumour samples were 
phenotypically characterized by FACS analysis. The expression level of 
CD45 was evaluated for monitoring the percentage of inflammatory cells 
present in the samples. Nine cases with a low percentage of CD45 positive 
cells (median 4.2%) were selected and used for further analysis (FIG. 4.2A).
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In these cases, EpCAM expression was high (median 74.6%) while CD44 
and CXCR4 showed a variable degree of expression (median 12.9% and 
26.6% respectively) with a low mean fluorescence. CD 133 expression was 
found on a low number of the cells in the tumour samples with a range of 
expression between 0-16.4% (median 1.4%) (FIG. 4.2A).
To confirm these results and to verify expression and localization of 
sternness markers, we analyzed, by immunocytochemistry on cryostat 
samples collected at the time of surgery, 18 ovarian carcinomas that were 
poorly differentiated. All the samples were positive for the epithelial 
marker EpCAM and for the ovarian carcinoma marker Folate Receptor (FR). 
All cases showed a focal reactivity for CD44, indicating that this antigen is 
expressed by a subpopulation of tumours cells. Among 17 cases analysed 
for CD 133 expression, 10 showed focal tumour positivity, this being small 
groups of cancer cells positive for this marker. Interestingly, in one case 
we noted that CD 133 positive cells were located near endothelial cells, 
surrounding blood vessels. For two cases we were able to monitor CXCR4 
expression on paraffin embedded tumour samples (FFPE), depending on the 
specificity and immuno-reactivity of the CXCR4 monoclonal antibody used 
for this approach. As with CD44 and CD 133 expression, CXCR4 positive 
cells were organized in small groups of tumour cells, close to the tumour 
invasive front (representative images are shown in FIG.4.2B).
Among 106 cases of ovarian carcinoma ascites, most of which were derived 
from ovarian serous adenocarcinoma, almost half (51) of the samples were 
characterized by the absence of tumour cells. The other 50% were
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classified either as samples with a high or low number of cancer cells. 
These cases were phenotypically characterized by FACS analyses. FIG 
4.2C illustrates some of these cases, depending on FACS limiting factors, 
such as cell viability, the number of available cells and CD45 positivity. The 
expression level of CD45 was assessed to check the range of inflammatory 
cells present in the samples. Only cases with a low percentage of CD45 
positive cells were chosen and considered for further analysis (median 
8.5%).
In these cases EpCAM positivity ranged from 15% to 82% (median 35.2%). 
CD44 and CXCR4 expression levels were similar to those observed in solid 
tumour samples. Both markers had a variable degree of expression with a 
low mean fluorescence, suggesting that most of the ascitic cells expressed 
few levels of these two molecules (median 7.3% and 24.2% respectively). 
Also the expression level of CD 133 was similar to that observed in solid 
tumour samples with a range of positivity from 1% to 20% (median 2.7%) 
(FIG. 4.2C).
Cells obtained from four solid tumour cases were intraperitoneally injected 
in SCID mice and from none of them did we obtain a transplantable tumour 
cell line.
On the other hand, 18 cases of cells obtained from patient ascitic tumours 
were injected intraperitoneally in SCID mice and 33% (6) were able to grow 
in vivo for at least one passage. From three of them we obtained a 
transplantable primary ascites tumour cell line which could be 
phenotypically and functionally characterized for sternness properties.
170
These results indicated that in a wide range of EOC primary tumours and 
ascitic samples the expression of CD 133, CD44 and CXCR4 was restricted 
to a subpopulation of ovarian cancer cells. We thus focused on CD133 and 
CXCR4, both found expressed in other solid tumours, as potential ovarian 
CSC/TIC markers.
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Figure 4.2: Ovarian cancer sample characterization: identification of specific marker
expression.
A) and C) The table and graph summarize the % of positive cells (mean) for the indicated 
m arkers among ovarian tumours A) and ascites C) analyzed by FACS analysis. B) IHC 
represen tative images of tumours sam ples for specified m arkers
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4.2 Isolation of cells with characteristics of stem/progenitor cells 
from epithelial ovarian cancer: selected case
characterization
4.2.1 Clinical features and in vivo transplantability of selected cases
From three cases of ovarian carcinoma ascites (named ascites #1, ascites 
#2 and ascites #3) we were able to establish by intraperitoneal injection of 
ascitic cells, transplantable primary ascites tumour cell lines that were 
phenotypically and functionally characterized for CSC properties.
Ascites #1 was derived from a 47 year-old woman, with a poorly 
differentiated serous adenocarcinoma. The cells were transplanted in 
Nu/Nu mice for two in vivo passages but then its tumorigenic potential 
decreased (FIG. 4.3A). We received the sample at the time of primary 
surgery. The patient underwent a front-line treatment of standard 
chemotherapy and was lost at the follow-up.
Ascites #2 gave rise to a stable transplantable cell line for up to 9 in vivo 
passages in SCID mice. It originated from a 61 year-old patient with a 
serous adenocarcinoma stage IIIC, who had primary surgery followed by a 
debulking surgery within two months. We received the sample at the 
debulking surgery. At this time point the tumour had spread to the 
peritoneal cavity, most of the lymph nodes were positive and the ascites 
was characterized by a large number of tumour cell nests. After surgery 
the patient underwent a front-line treatment of six cycles standard
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platinum-taxane based chemotherapy and was lost at the follow-up (FIG 
4.3B).
The third case, ascites #3, was successfully transplanted for five in vivo 
passages in SCID mice. The patient had a previous clinical history of breast 
cancer. At 34 years old she was diagnosed with a triple negative breast 
cancer, which was chemotherapeutically treated. After three years she 
developed an endometrioid ovarian cancer stage III and received a standard 
neo-adjuvant treatment for three months and primary debulking surgery. 
After surgery the patient underwent a front-line treatment (six cycles of 
platinum-taxane based chemotherapy). After a disease-free period of about 
two years (platinum-sensitive) the tumour relapsed and we received the 
sample at the time of the second surgery. At this time point the tumour had 
spread into the peritoneal cavity, and the ascites was characterized by a 
large number of cancer cells and most of the lymph nodes were infiltrated 
by tumour cells (FIG 4.3C).
Among these three cases we could observe diversity in terms of 
histopathology, response to treatment and clinical features. Nevertheless 
all of them shared some common properties related to a sternness profile, 
as reported in the following chapters.
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Clinical features of selected cases. Clinical history of patients from whom ascites #1 A),
#2 B) and #3 C) were collected.
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4.2.2 Ascites #1- stem cell-like phenotype of xenograft-derived 
ascites.
The first attempt to isolate a subpopulation of CSCs/TICs with stem-like 
properties was based on culture selection of cancer cells able to grow in 
vitro as spheres. Tumour cells derived from Ascites #1 and from 
xenograft-derived tumours/ascites were cultured in vitro in specific media, 
as described previously. We did not observe sphere formation in 
suspension culture or cancer cell growth in adherent conditions.
FACS analyses of ascites #1 revealed a strong positivity for the epithelial 
markers EpCAM and for CD44 (% positive cells 90.04% and 30.55% 
respectively). Positivity was also observed for the stem cell antigen CD 133 
(15.85%) and the embryonal stem cell antigen SSEA1 (15.27%) (FIG. 4.4A). 
These results were then confirmed by immunocytochemistry analyses on 
ascites #1 cryostat-cut solid tumour collected at the time of surgery. The 
patient tumour expressed high levels of EpCAM and CD44, showed a focal 
positivity for both CD 133 and SSEA1 while CXCR4 expression was absent 
(FIG.4.4B).
Tumour cells from ascites #1 were injected intraperitoneally (i.p) in Nu/Nu 
mice and were successfully transplanted for 2 in vivo passages. Xenograft 
-derived tumours and ascites from the first and second transplantations 
were phenotypically characterized. We analyzed the xenograft-derived 
ascitic cells by FACS analysis and the xenograft-derived solid masses by 
immunocytochemistry on cryostat-cut sections (FIG. 4.4C and FIG. 4.4D).
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The epithelial origin was confirmed by high expression of the EpCAM 
marker both in the xenograft ascitic cells (% positive cells: 95.9%) and the 
xenograft tumour. CD44 expression decreased in xenografted ascitic cells 
(% positive cells: 12.1%), whereas it seemed to be maintained at the same 
levels in xenograft-derived tumours.
On the contrary, the expression levels of CD133 (% positive cells: 96.7%) 
and SSEA1 (% positive cells: 96.6%) strongly increased in the xenograft- 
derived tumour and ascites. CXCR4 expression was found in a small 
subpopulation of ascitic cells (% positive cells: 4.1%). Its expression was 
not analyzed on cryostat sections from xenograft-derived solid masses 
(FIG. 4.4C and FIG. 4.4D).
The high expression level of stem cell markers observed in ascites #1 
xenograft-derived sample was not sufficient to guarantee the in vivo 
transplantability of this case. Nevertheless, these results suggested that 
ovarian tumour samples could be characterized by the presence of a 
subpopulation with a stem cell-like phenotype.
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Figure 4.4'- ascites #1- phenotypic characterization and stem  cell-lik e  phenotype of 
xenograft-derived solid tumours and ascites.
A) and C) FACS and B) and D) im m unocytochemistry analyses of patien t’s surgical sample 
(A and B) and xenograft derived sam ples (C and D). The percentage of positive tumour 
cells for the indicated m arkers are shown; CN= negative control.
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4.2.3 Ascites #2: stem  cell-like phenotype of xenograft-derived 
ascites and in vivo tumorigenicity
As reported in Figure 4.5A and 4.5B, the patient’s solid tumour showed a 
strong positivity for the epithelial marker EpCAM, while the ascitic cells 
were only partially positive for this antigen (% positive cells- 34%). CXCR4 
expression was localized in a few tumour cell foci (FIG. 4.5A) whereas it 
was highly expressed in ascitic tumour cells (% of positive cells: 40.6%) 
(FIG. 4.5B). In both tumour and ascites, the CD44 antigen was expressed at 
a very low level. In the tumour sample, focal expression of CD44 was 
observed and only 1.4% of ascitic cells were positive for this marker.
CD 133 showed a peculiar expression range. In the solid tumour we did not 
detect any CD133-positive cells while in ascitic cells its expression was 
present on 22.7% of tumour cells. Finally SSEA1 expression was detected 
only in ascitic cells at a very low level (% positive cells: 1%).
These results revealed that, in the same patient, the solid tumour and the 
ascitic cells may have a different CSC marker profile, suggesting further 
heterogeneity within the same population of cancer cells. Alternatively, 
some protein expression could be acquired late during tumour development, 
possibly as an effect of growth in non-adherent conditions in the ascitic 
fluid, such as CD133, or could indicate specific features of the 
subpopulation of positive cancer cells, such as CD44 and CXCR4.
To identify another possible marker for ovarian CSC characterization and 
isolation, we performed the Aldefluor assay, which is based on the
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expression of the ALDH enzymes. This analysis revealed that only 1.9% of 
the ascitic cancer cells possessed the ability to metabolize the Aldefluor 
reagent. This subpopulation of ALDH+ cells was only partially inhibited by 
the presence of the DEAB inhibitor (0.6%) (FIG. 4.5C). Notably we detected 
a high mortality of tumour cells after the Aldefluor staining procedure, 
suggesting that the low ALDH positivity observed may have been due to 
the high percentage of dead cancer cells.
Ascites #2 was successfully transplanted in SCID mice for more than eight 
in vivo passages, developing mainly xenograft-derived ascites and showing 
a high tumorigenic potential. The tumorigenic potential of ascites #2 was 
evaluated in vivo by both intraperitoneal and subcutaneous injection in SCID 
mice.
After i.p injection, the xenograft-derived ascitic cell growth was assessed 
as a body weight increment (g) and compared to same age non-xenografted 
mice, used as control. Initially high tumour cell doses were injected to 
ensure tumour engraftment. At a high dose of 60xl06 cells, ascites 
developed in all mice treated (100% tumour take) and in all in vivo 
passages analyzed (FIG. 4.6A). Moreover the body weight increment was 
exponential, suggesting that the in vivo growth may have selected for a 
subpopulation of tumour cells with a higher proliferative potential. These 
data were also confirmed by the decrement observed in the tumour onset. 
At the 5th in vivo passage ascitic cells grew more rapidly than at the 1st in 
vivo passage, as the time necessary for ascites growth decreased from 75 
days (1st passage) to 40 days (5th passage) (FIG 4.6A and FIG. 4.6B). These
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results indicated that cancer ascitic cells with a higher tumorigenic and 
proliferative potential were selected during in vivo transplantation.
To better evaluate cancer cell growth and confirm the tumorigenic potential 
of ascites #2 s.c injections in SCID mice were performed.
As shown in Figure 4.6C, injection of 9 and 3 x 106 cell doses induced 
weight loss and cachexia in treated mice, causing animal death within 20 
days after injection. The injection of lower cell doses of 2x l06, lx lO 6 and 
0, 5 x 106 cells generated xenograft-derived solid tumours in almost all 
mice treated (tumour take- 100% at 2x l06, 66% at lx lO 6 and 66% at 0, 5 x 
106). Tumour take increased in proportion to cell dose but tumour masses 
were not easily measurable, these being characterized by small volumes 
even after three months from injection. Xenografted solid tumours showed 
a cystic morphology, with the presence of necrotic or inflammatory 
infiltrate (FIG. 4.6C).
These data indicate that, injection of ovarian cancer cells isolated from 
ascites #2 was able to propagate cancer cells much more efficiently if 
injected intraperitoneally instead of subcutaneously. After i.p. injection of 
patient’s ascites we did not detect the formation of solid tumour masses, 
since it only developed xenograft-derived ascites in all in vivo passages. 
Moreover these results suggest that within the heterogeneous cancer cell 
population, there may exist a pool of CSCs that strongly contributed to the 
rapid development of the tumour mass.
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Figure 4.5: ascites #2  phenotypic characterization.
A) Immunocytochemistry analyses of the patien t’s solid tumour (Bar: 50|JC, 20X Epcam,
40X CD44, CXCR4, CD133). B) FACS analysis of ascites #2. The percen tage of positive 
tumour cells for indicated m arkers are shown. C) Aldefluor analysis of a sc ites  #2 trea ted  
or not with ALDH inhibitor DEAB. The percentage of ALDH positive tumour cells is
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Figure 4.6: ascites #2 in vivo tumorigenicity 
A) One cell dose (60xl06) of ascites #2 was intraperitoneally (i.p) injected in SCID mice 
and xenograft-derived ascites growth was evaluated as % of body weight increment. Non­
treated mice were reported as control for normal body weight increment. Ascites #2 
tumour up-take and tumorigenic potential increased during in vivo transplantation. B) 
Statistical analysis (linear regression) at different in vivo passages of ascites #2 at 
decreasing cell doses. C) Ascites #2 subcutaneously (s.c) injected at decreasing cell doses 
in SCID mice. Tumour growth was evaluated as tumour volume (mm3).
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4.2.4 Ascites #3' Stem cell-like phenotype of xenograft-derived 
ascites and in vivo tumorigenicity
Ascites #3 was phenotypically characterized for sternness properties and 
successfully transplanted in SCID mice for five in vivo passages.
FACS analysis of the patient’s sample revealed that only 16% of ascitic 
cells expressed the epithelial marker EpCAM and the 8.6 % of tumour cells 
were positive for CD44. Ascites #3 CXCR4 positivity was lower than that 
observed for the previous case (ascites #2), but more or less similar to 
those of ascites #1. We did not detect any significant positivity for SSEA1 
and CD133, with expression levels very low (2.6% and 3% respectively) 
(FIG. 4.7A).
The tumorigenic potential of ascites #3 was assessed by intraperitoneal 
injection in SCID mice at different cell doses (lOOxlO6, 50xl06 and 30xl06). 
In the first and second transplantations, mice developed both ascites and 
solid tumours, while in the subsequent in vivo passages we detected only 
ascites formation. Xenografted solid tumours recapitulated the original 
tumour heterogeneity, with wide areas of necrosis and endometrioid 
features. At the dose of 30xl06 cells, ascites developed in all mice treated 
(100% tumour take) and in all in vivo passages analyzed (FIG. 4.7A). As for 
the previous case, the percentage of body weight increment was 
exponential whereas the tumour onset decreased during in vivo 
transplantation. At the 5th in vivo passage, ascitic cells grew more rapidly
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than at the 1st in vivo passage, as the time necessary for ascites growth 
decreased from 200 days (1st passage) to 50 days (5th passage) (FIG. 4.7B). 
These results indicated that in vivo transplantation has again selected for 
those cancer cells with the highest tumorigenic and proliferative potential.
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Figure 4.7*. phenotypic characterization and in vivo tumorigenicity of ascites #3. 
A) FACS analysis of ascites #3. The percentage of positive tumour cells for indicated 
markers are shown. B) The cell dose 30x l06 of ascites #3 was intraperitoneally (i.p) 
injected in SCID mice and ascites growth was evaluated as % of body weight increment. 
Statistical analysis (linear regression) at different in vivo passages of ascites #2 after
injection of 3 0x l06 tumour cells.
186
4.3 Characterization of in vivo  stabilized cell lines.
4.3.1 Ascites #2: phenotypic characterization of xenograft-derived 
ascites
Ascites #2 was successfully transplanted in SCID mice for more than eight 
passages, as described in 4.2.3 paragraph. After xenograft-derived ascitic 
fluid withdrawal, ascitic cells were phenotypically characterized by FACS 
analyses in order to check if the expression of selected markers could be 
modulated after in vivo transplantation, furthermore to verify if in vivo 
growth could have selected for a subpopulation of cancer cells with a 
specific antigenic profile.
Epithelial phenotype, assessed by the expression of the EpCAM marker 
ranged from 46.9 % to 96.1% (FIG. 4.8A and FIG. 4.8B). The high 
percentage of EpCAM positivity confirms that the majority of the cancer 
cells analyzed were both epithelial and human in origin, excluding possible 
contamination of mouse cells.
CD44 expression levels increased rapidly after the 1st in vivo passage, 
suggesting that in vivo growth selectively stimulated the proliferation of 
CD44 positive cells. Indeed, starting from a positivity of 8.3% (1st passage), 
we observed that almost 50% of ascitic cells expressed this antigen in the 
subsequent in vivo passages (FIG. 4.8A and FIG. 4.8B).
CD133 and CXCR4 positivity were also evaluated, considering only the 
brightest cells to exclude possible false-positives due to fluorochrome 
internalization. As reported in Figures 4.8A and 4.8B, CD 133 was
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expressed by a small percentage of ascitic cells with a range of positivity 
from 0.2% to 10.8%. Compared to the patient’s ascitic phenotype (FIG. 
4.5B), CD133 expression decreased in vivo, achieving a stable expression 
level of about 1% (FIG. 4.8B). Considering the very low levels of CD 133 
positivity and to exclude probable CD 133 false-positives, epifluorescence 
analyses on FACS stained samples were performed and we demonstrated 
that only a small number of xenografted ascitic cells specifically expressed 
this molecule on the cell surface (representative image is shown in FIG. 
4.8C).
CXCR4 expression did not change significantly between the patient sample 
and the xenografted ascitic cells. This marker was expressed in all in vivo 
passages examined and almost 30% of ascitic cells expressed this receptor 
(FIG. 4.8A). Indeed, the CXCR4 expression level was very heterogeneous in 
xenograft derived ascites and we noted the co-existence of CXCR4 low and 
bright cells in the same cancer cell population. For this reason, we 
considered only the subpopulation of CXCR4 bright cells as being the 
tumour cells positive for this antigen. Except for a few cases, CXCR4 
positivity ranged from 4% to 20% (FIG. 4.8B). By epifluorescence analyses 
on FACS stained samples, we confirmed that only a minority of xenograft- 
derived ascitic cells specifically expressed this marker (representative 
image is shown in FIG. 4.8C).
Since the CD 133 marker was reported to be associated with the ovarian 
CSC phenotype, we evaluated the possible correlation between CD 133 and 
CXCR4. In double staining experiments and FACS analyses, we did not
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observe a clear overlap between the two tested markers in all the 
xenograft-derived ascites examined (FIG. 4.8A). The existence of a double 
CXCR4bnght/CD133bnght positive subpopulation was not easily detectable due 
to the variable degree of expression of both antigens. FACS analyses 
showed that double positive cells ranged from 0.1% to 4%, but 
epifluorescence analyses did not confirm these data (data not shown).
As shown in Figure 4.8D, we also tried to evaluate the differences in term 
of morphological parameters between CXCR4+, CD 133+ and 
CXCR4+/CD133+ tumour cells. Whereas CD133 expression was correlated 
with cancer cells with the highest SSC and FSC parameters (FIG. 4.8D red 
arrow), the CXCR4 positive subpopulation was composed of the smallest 
cancer cells (FIG. 4.8D yellow arrow). As expected, the double positive 
population was formed by those cells with intermediate FCS and SCS values 
(FIG. 4.8D orange arrow). Nevertheless the existence of a double positive 
ovarian cancer cell population may correspond to the most metastatic and 
chemoresistant subpopulation.
The Aldefluor assay was performed on the xenograft-derived ascites from 
patient #2 to evaluate the possible in vivo selection and amplification of 
ALDH-positive cells. A notable increase in ALDH positivity was observed 
after in vivo transplantation as compared to the patient sample (FIG. 4.5C). 
In fact almost 60% of xenograft-derived ascitic cells at the 3rd in vivo 
passage were found positive for this marker (FIG. 4.8D).
These results may indicate a possible role for CD 133 and CXCR4 in the 
ovarian CSC phenotype. These markers could be co-expressed together
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with ALDH by a subpopulation of ovarian cancer cells and these cells may 
be responsible for the tumour relapse, chemoresistance and metastasis.
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Figure 4.8: Ascites #2: characterization of xenograft-derived ascites
A) Expression levels of indicated markers were monitored at the 4th, 5th, 6th and 7th in vivo 
passages of ascites #2. B) FACS analysis of xenograft-derived ascitic cells. The 
percentage of positive tumour cells for indicated markers is shown. C) Representative 
epifluorescence images for CD133+ and CXCR4+ cells were reported. D) Example of 
FACS analysis of xenograft-derived ascitic cells for CD133+, CXCR4+ and 
CD133+/CXCR4+ cells. For each of these subpopulations are reported the morphological 
parameters; the analysis underlined the differences in terms of cell granularity and size 
among the three subpopulations. E) Aldefluor analysis of xenograft derived ascitic cells at
the 3rd in vivo passage.
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4.3.2 Ascites #2: correlation between selected markers and 
tumorigenic potential
Xenograft-derived ascitic cells were sorted for CD 133 or CXCR4 and 
positive and negative fractions were again i.p injected in SCID mice.
Three sorting experiments for CXCR4 at 5th, 7th and 8th in vivo passages 
were performed and sorted cells were i.p injected in SCID mice at a dose of 
0.5 x 106 for each subpopulation. Two sortings for CD133 were carried out 
at 5th and 7th in vivo passages and sorted cells were i.p injected in SCID 
mice at a dose of 0.5 x 106. The obtained results are summarized in Figure 
4.9. CXCR4 positive and negative cells demonstrated a similar in vivo take 
(100% of injected mice) and similar time of ascites onset and ascites 
growth, expressed as the percentage of body weight increment (FIG. 4.9A). 
On the contrary, the unsorted population grew more rapidly than either one 
of sorted subpopulations and gave rise to a more abundant ascites. In 
addition, the CD 133 positive and negative cells had a similar growth rate 
and did not differ significantly in terms of tumour take (100%) and time of 
tumour onset (FIG. 4.9B). Unsorted cancer cells had a similar growth 
potential to sorted CD 133 subpopulations.
Taken together these results suggest that both CD 133 and CXCR4 do not 
identify ovarian cancer cells with a higher tumorigenic potential. It could be 
possible that, within the heterogeneous cancer cell population, these two 
markers are linked to other CSC properties but not to tumour initiating 
capacity.
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Figure 4.9* Ascites #2- correlation between selected marker expression and
tumorigenic potential.
After sorting ascites #2 xenograft-derived ascitic cells for CXCR4 (mean of three 
experiments, four mice each group) A) and CD133 (mean of two experiments, three mice 
each group) B), positive, negative and unsorted populations were evaluated for their 
tumorigenic potential. 0 .5x l06 cells were i.p injected. Tumour growth was evaluated as % 
of increased body weight and non-treated mice were reported as control for normal body 
weight increment. The data are reported as linear regression analysis.
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4.3.3 Ascites #2 and #3: correlation between selected markers and 
expression of sternness markers
Cancer stem cells share some characteristics with normal stem cells (see 
Chapter ‘Introduction’). One of them is the expression of similar surface 
receptors (e.g. CXCR4, CD133, CD117 and CD44) that are either identified 
as stem cell markers or associated with homing and metastasis. Moreover, 
CSCs have in common with their normal counterparts the expression of 
transcription factors such as Oct4 and Nanog, which maintain a functional 
plasticity by promoting pluripotency and immortality.
Based on this assumption, we evaluated the possible correlation between 
CXCR4 or CD 133 expression and those of different genes linked to a 
sternness profile.
Xenograft-derived ascites from case #2 were sorted for CXCR4 at the 4th, 
5th and 6th passages and for CD133 at the 3rd, 5th and 7th in vivo passages. 
Sorted CXCR4 or CD133 positive tumour cells were evaluated by Real Time 
PCR for stem cell-associated genes (OCT4, NANOG, CD 133 and NESTIN). 
For both ascites #2 and #3 the analyses were performed using the negative 
fraction as an internal calibrator and considering significant only those
expression differences whose fold change was £ 2 (FIG. 4.10A). In two out
of three sorting experiments, ascitic cells, that were CXCR4 bright at the 
cell surface, exhibited significantly higher CXCR4 and CD133 mRNA levels 
than the CXCR4 negative cells. In all three sorting experiments, the 
expression level of OCT4 was up-modulated in CXCR4 positive cells and in
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two out of three sorting experiments NANOG and NESTIN  expression 
levels were higher in the CXCR4 bright cells than in the negative fraction. 
These results were confirmed by real time analysis of ascites #3. Also in 
this case, CXCR4 positive cells (sorted at the 3rd in vivo passage) 
expressed higher mRNA levels of stem cell-associated genes than the 
negative fraction (FIG. 4.10B). Association of increased expression of 
mRNA levels of 0CT4, NANOG and NESTIN  to CXCR4 seemed to be much 
more evident in ascites #2 than that in ascites #3.
CD 133 positive cells showed in all three sorting experiments significantly 
higher levels of CD133 mRNA, while the CXCR4 mRNA level was increased 
in two out of three experiments. mRNA levels of 0CT4 and NANOG were 
up-modulated in one out of three sorting experiments and the mRNA level 
of NESTIN  did not significantly change between CD 133 positive and 
negative cells (FIG. 4.IOC).
In conclusion, we found an enrichment in mRNA levels of stem cell- 
associated genes, with a good reproducibility, only in the sorted CXCR4 
positive cells, whereas in the CD 133 positive cells these genes seemed to 
be enriched to a very variable degree.
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Figure 4.10  ^ Ascites #2 and #3- correlation between selected subpopulations and
expression of sternness markers.
Real time analysis of sorted CXCR4 A) and CD133 C) positive and negative cells of ascites 
#2 at different in vivo passages. B) Real Time analysis of sorted CXCR4 positive and 
negative cells of ascites #3. Fold change for each sample and gene were relative to the 
internal calibrator (negative cells) and were indicated as Log RQ (relative quantification). 
Fold change of two, corresponding to Log RQ= ±0 . 3 ,  was considered significant in terms
of differential gene expression profile.
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4.3.4 Ascites #2 and #3- correlation between selected markers and 
expression of ABC transporters
Multi-drug resistance of tumour cells is an important element which leads 
to the ineffectiveness of chemotherapeutics. The identification of 
subpopulations of cancerous ovarian cells expressing multi-drug resistance 
factors and exhibiting cancer stem cell properties has recently become a 
major research interest (See Chapter ‘Introduction’). Drugs are effluxed 
from the cell by numerous cell surface transporters, the majority of which 
belong to the ABC (ATP binding cassette) transporter super-family. ABC 
transporters comprise seven families (ABCA-B-C-D-E-F and G) which 
include members involved in the efflux of structurally-unrelated drugs. 
ABCG1, ABCG2 and MDR1 (ABCB1) have been reported to be up-regulated 
in CSC/TIC of numerous tumour types (127) (360) (128).
To verify if CXCR4 and CD 133 expression could identify tumour 
subpopulations, expressing markers linked to chemoresistance, CXCR4 and 
CD 133 sorted fractions were analyzed by real time PCR for the expression 
of all known drug transporters of the ABC superfamily. For both ascites #2 
and #3 the analyses were performed using the negative fraction as an 
internal calibrator and considering significant only those genes with a fold-
change £ 2.
CXCR4 positive cells of ascites #2 xenograft-derived ascitic cells showed a 
variable pattern of modulation of selected ABC transporter mRNA levels, 
depending on the in vivo passage considered. In two out of three or in all in
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vivo tested passages, and for only a small number of ABC transporters, was 
there a concordant increase (ABCA10, ABCA12, ABCB10 and ABCF2) or 
decrease (ABCC2 and ABCA1) in the positive fraction as compared to the 
negative one (FIG. 4.11A).
Ascites #3 was sorted for CXCR4 at the 3rd in vivo passage and sorted 
subpopulations were analysed. In this case, mRNA expression levels of all 
ABC transporters were lower in the CXCR4 positive cells as compared to 
the negative subpopulation (FIG. 4.1 IB).
Ascites #2 sorted for CD 133 at two in vivo passages (3rd and 5th) was also 
analysed by Real time PCR for ABC transporter mRNA levels. The mRNA 
levels of the majority of the examined genes were more strongly expressed 
in the positive cells, especially those of the ABCA and ABCB sub-families. 
A moderate increase of transcripts of the ABCC and ABCG sub-families 
members was also observed (FIG. 4.11C).
Overall, in sorted subpopulations from both ascites #2 and #3: ABCG1 
appeared to be expressed at lower levels in CXCR4 positive cells and at 
higher levels in CD 133 positive cells; expression of ABCG2 mRNA was at a 
lower level in CXCR4 positive cells from ascites #3, while the gene 
expression level was similar between positive and negative fractions from 
ascites #2. Similarly, the fold-change of ABCG2 between CD 133 positive 
and negative cells was not significantly different (FIG. 4.11A-C).
Modulation of the expression profile of ABCB1, also known as MDR1, was 
not observed in ascitic cells expressing CXCR4, because no significant 
difference was found in CXCR4 positive cells as compared to the negative
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fraction (FIG. 4.11A and FIG. 4.1 IB). Conversely, in one out of two in vivo 
passages, sorted for CD 133, a strong up-modulation of MDR1 was 
observed in CD 133 positive cells (FIG. 4.11C).
These results suggest that CXCR4 expression in ovarian carcinoma or 
ascites may not be correlated to the chemoresistant phenotype of ovarian 
TICs. On the contrary, the strong up-modulation of ABC transporter 
observed in CD 133 positive cells suggests that this marker is probably 
expressed by those cells with a major ability to exclude chemotherapeutic 
agents.
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Figure 4.11: Ascites #2 and #3: correlation between selected subpopulations and
expression of ABC transporter.
A) Real Time analysis of sorted CXCR4 positive and negative cells of ascites #2 and B) 
ascites #3 at different in vivo passages. C) Real Time analysis of sorted CD133 positive 
and negative cells of ascites #2 at different in vivo passages.
Negative cells were used as an internal calibrator. Fold change of positive subpopulation is 
indicated as Log RQ (relative quantification). Only genes with a fold change ^ 2 were 
plotted in the graph and considered as statistically significant in terms of gene expression
profile.
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4.4 Ascites #2 and #3- in vivo modulation of CXCR4 and CD133 
expression
Another hallmark of the CSC subpopulation is the ability to generate 
phenotypically heterogeneous cancer cell lineages both in vitro and in vivo. 
To verify if CXCR4 or CD 133 positive cells had this potential, giving rise to 
tumour cells that either expressed or did not express these markers, 
xenografted ascites derived from injection of either positive or negative 
fractions were characterized by FACS analyses (FIG. 4.12).
Injection of CXCR4 sorted cells gave rise to ascites that contained cancer 
cells expressing moderate levels of this receptor, which were observed 
with a higher frequency than in the original sorted ascites. Irrespective of 
the nature of the injected cells, positive or negative for CXCR4 surface 
expression, xenograft-derived ascites showed a similar level of CXCR4 
expression (range of positive cells- 4.8 -32% and 3.6-49.2% for positive 
and negative fractions respectively; results are for 2 experiments, 3 mice 
in each group). Furthermore, samples derived from injection of both CXCR4 
positive and negative fractions were enriched in CD133-expressing cells, 
even if the percentage of positive cells was lower than that of the initial 
sample (range of positive cells- 0.1-5.9% and 0.7-13.1% for positive and 
negative fractions respectively; results are for 2 experiments, 3 mice in 
each group) (FIG. 4.12).
Injection of CD 133 positive cells generated ascites that showed moderate 
expression levels of both CD133 and CXCR4 (range of positive cells: 25.2-
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26.9% and 3.3-1.6% for CXCR4 and CD133 expression respectively; 
results are for 2 experiments, 3 mice in each group) (FIG. 4.12).
On the contrary, CD 133 negative cell injection gave rise to ascitic cells 
showing moderate levels of CXCR4 positivity and a total absence of CD 133 
expression (range of positive cells: 0.7-12% and 0-0% for CXCR4 and 
CD 133 expression respectively; results are for 2 experiments, 3 mice in 
each group) (FIG. 4.12). Evaluation of the double positive CXCR4/CD133 
subpopulation revealed that this cell subset was also in vivo modulated, as 
the percentage of double positive cells was variable among the samples 
analyzed, ranging from 2.4% to 8.1%.
These results suggest that cancer cells derived from injections of either 
CXCR4 positive or negative fractions give rise to phenotypically 
heterogeneous ascitic cells with a highly plastic phenotype. Moreover 
these data highlight the possibilities that, while CD 133 expression is not 
regulated by extrinsic factors but seems to be dependent on intrinsic 
cellular mechanisms, CXCR4 expression could be affected and modulated 
by both cellular and microenvironmental stimuli.
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% positivity in 
grow ing tu m o u rs 
(RANGE)
SORTING MARKER
CXCR4 ( 2  exp) CD133 (2 exp)
positive negative positive negative
CXCR4 4 .8 -3 2 3 .6 -4 9 .2 2 5 .2 -2 6 .9 0 .7 -1 2
CD133 0 .1 -5 .9 0 .7 -1 3 .1 CO CO 1 —1
.
b> 0 - 0
CXCR4/CD133 7.04 8.01 0 .1 -2 .4 0 -0
Figure 4.12: modulation of selected marker expression.
After sorting for CXCR4 or CD 133 the sorted subpopulations were in vivo re-injected and 
xenograft-derived ascites were phenotypically characterized by FACS analysis. The Table 
summarizes the result of FACS analyses after in vivo injection of sorted subpopulations. 
The percentage of CXCR4, CD133 and double positive cells are reported.
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4.5 Discussion
4.5.1 Establishing ovarian cancer sphere cell lines
Is a great challenge to identify the most appropriate source of tumour cells 
for the isolation of ovarian CSCs. While it would be desirable to use freshly 
collected samples from primary tumours or ascites, both direct sorting of 
these samples and/or establishing primary in vitro cultures have proven to 
be difficult tasks (see Chapter 2 ‘Material and Method’). Our results 
showing that ovarian cancer cell lines were difficult to derive from primary 
ovarian surgical specimens are consistent with previously published results. 
In the first published report supporting the existence of ovarian TICs, 
ascitic fluid cells from patients with advanced stage ovarian carcinomas 
were used and the growth potential of these cells was tested using in vitro 
colony formation assays (308).
Starting from a large cohort of ovarian cancer samples (primary tumours 
and ascites), we tried to select and to expand in vitro ovarian cancer cells 
able to grow in suspension as spheroids and to obtain a tumour sphere cell 
line for further characterization. After mechanical or enzymatic 
disaggregation, the growth as spheroids was possible from only a few 
cases and then for only a few in vitro passages. These results suggest that 
the in vitro conditions are critical for the expansion of spheres from ovarian 
cancer, but as yet they have not been precisely defined. We hypothesize 
that the sphere medium we used, designed for mammospheres, could 
induce the differentiation of ovarian tumour cells, as we observed for the
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A431 cancer cell line (see ‘Chapter 3’). Moreover, the attempt to create a 
more specific microenvironment for ovarian cancer cells by the addition of 
particular stimulating molecules, such as LPA (361) (359) and bFGF (362) 
(363) did not enhance sphere formation and proliferation. It cannot be 
excluded that a more appropriate mixture of growth factors and other 
molecules essential for ovarian cancer cell proliferation could be the key to 
a more conducive environment for primary sphere cultures from ovarian 
surgical samples.
However, the recent findings that spheres are not composed entirely of 
stem cells, as supported by recent papers investigating heterogeneity in 
mammospheres and melanospheres (372) possibly lessens the belief that 
the sphere formation assay is the definitive methodology for identifying 
cancer stem cells.
4.5.2 Identification o f ovarian CSCs by m arker expression
Besides anchorage independent in vitro growth, the expression of particular 
cell surface markers is another feature that has been used to identify and 
isolate CSCs from a variety of malignancies (364) (290) (365) (366).
Markers useful for the identification and characterization of normal stem 
cells in one organ are frequently exclusive of that tissue and may be not 
shared with stem cells of another organ (367) (368). This is likely to be 
applicable to cancer stem cells and the knowledge of markers of normal 
epithelial cells of the ovary could be of great help. Unfortunately, the 
difficulty in raising cultures of OSE cells and their pluripotency (299) (369),
210
have limited the acquisition of information in this field. Thus, we still have 
to rely on markers already identified as associated with CSCs in tumours 
other than ovarian cancer.
The search for TICs in ovarian cancer has resulted in observations that 
epithelial ovarian CSCs may be isolated on the basis of the expression of 
CD44/CD117 or CD133 markers, all associated with CSCs in other 
malignancies (310) (311) (312). Another potential CSC marker in EOC is the 
chemokine receptor CXCR4, expressed by CSCs in various solid tumours, 
described as associated with a subset of ovarian tumour cells, (228) (229) 
(230) (207).
Immunohistochemical analyses of cryostat-cut sections from primary 
ovarian cancer specimens from patients at an advanced stage revealed that 
CD44 and CD133 positivity on tumour cells was heterogeneous, frequently 
limited to small groups of cells, often present at the edge of the tumour 
invasive front. Analysis of CXCR4 expression has not been informative in 
cryostat-cut sections, probably due to the epitope characteristics of the 
antibody selected for this analysis. Few formalin-fixed paraffin embedded 
histological sections were characterized for CXCR4 expression and again 
the reactivity was highly heterogeneous and frequently confined to small 
groups of tumour cells.
We also evaluated the expression of CD44, CD133 and CXCR4 molecules in 
cell preparations from ovarian solid tumours and ascites. To identify the 
origin of the isolated cells, we used the EpCAM marker that characterizes 
all tumours of epithelial type until they progress and metastasize acquiring
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a mesenchymal phenotype, and whose reactivity was homogeneous on the 
examined cryostat-cut sections or histological sections from ovarian 
cancer. EpCAM was present at a high level with a high percentage of cells 
obtained from solid samples expressing the marker indicating that they are 
carcinoma cells. In the case of cell preparations from ascites, while the 
expression level of EpCAM on positive cells was high, the percentage of 
positive cells was variable, indicating that cells recovered from ascites are 
more heterogeneous and tumour cell preparations could be contaminated by 
other cell types. This was confirmed by the presence of monocytes and 
macrophages in the ascites, identified by CD45 expression analysis; 
however, subpopulations negative for both EpCAM and CD45 are present in 
some ascitic samples. We suggest that they are normal cells of mesothelial 
origin, often demonstrated to be present in ascites (370). However, we 
cannot exclude that some of the EpCAM negative/CD45 negative cells are 
tumour cells.
CD44, CD 133 and CXCR4 markers had a variable degree of expression on 
cells from both solid tumours and ascites, and all were present on a subset 
of ovarian cancer cells ranging from 3 to 27%. These results demonstrated 
that in a wide range of EOC primary tumours and ascites, cells do express 
CD 133, CD44 and CXCR4 but they are generally restricted to a 
subpopulation of ovarian cancer cells, potentially suggesting their 
association to ovarian CSCs. However, the limited number of cells 
recovered in the majority of cases precluded the sorting of cells expressing 
these markers and their further characterization for sternness markers.
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4.5.3 Isolation o f tumorigenic subpopulations by xenotransplantation
Operationally, CSCs isolated from various type of cancer, would be more 
tumorigenic than the bulk population when xenografted into 
immunocompromised mice such as athymic nude mice, lacking B 
lymphocytes, or in severe combined immunodeficient mice (SCID), lacking 
both T and B lymphocytes. In our in vivo assays, we used both mouse 
models and we found that ovarian cancer initiation was weakly supported 
after intraperitoneally injection in Nu/Nu mice (CD1 outbred and BalbC 
inbred). Tumour and ascitic growth was much more reproducible in the 
SCID mice. Injection of ovarian cancer cells isolated from ascites was able 
to propagate ascites much more efficiently if injected intraperitoneally 
instead of subcutaneously. The difficulties observed in solid tumour growth 
after subcutaneous implantation may be due to the differences between the 
native environment of ovarian cancer cells in patients and the environment 
into which these cells are transplanted in mice, which can reduce the 
engraftment of cells with tumorigenic potential. On the other hand, 
intraperitoneal injection, mimicking the native environment of ovarian 
cancer development, has to be considered the best in vivo assay for the 
evaluation of ovarian CSC tumorigenicity.
In spite of this, we were only able to establish transplantable tumour cell 
lines by intraperitoneal injection of ascitic cells from three cases of ovarian 
carcinoma ascites. Despite diversity in terms of histopathology, response to
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treatment and clinical features, the examined samples shared same common 
properties related to a sternness profile.
4.5.4 ALDH activity as a sternness m arker in EOC
In conjunction with other markers, ALDH activity has emerged as a 
potential screen to characterize highly clonogenic and undifferentiated 
multipotential stem/progenitor cells both in normal and neoplastic tissue 
(138) (325).
In the field of ovarian CSCs, three different examples have been reported.
Irrespective of any association to CSCs, ALDH positivity correlated
negatively with progression-free survival of EOC patients (326) (325)
(142). We have evaluated the ALDH activity in one of the selected samples
(ascites #2) and in its xenograft-derived ascites. A low percentage of
ALDH positive cells (1.9%) characterized the original ascites, but ALDH
activity significantly increased after three and nine in vivo passages (73.3%
and 78.4% respectively). It could be speculated that, in the case reported
here, in vivo transplantation might have selected those cancer cells
endowed with high detoxifying ability due to the expression of the ALDH
enzyme. Due to its high expression 070%  of tumour cells) here, as also
observed for the A431 cancer cell line, it is unlikely that ALDH activity
could be considered as a good indicator of a putative ovarian CSC.
However, it is possible that ALDH positivity could be an independent
prognostic factor not linked to a sternness phenotype in this type of cancer.
To support this hypothesis, we evaluated the possible presence of double
positive CXCR4bnght /Aldefluor+ cells (data not shown). Preliminary
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observations indicate that CXCR4 and ALDH mark two different 
subpopulations of ovarian cancer cells, further supporting the hypothesis 
that ALDH function is not an intrinsic property of an ovarian CSC.
4.5.5 Phenotypic characterization o f  xenotransplants from selec ted  
ascites fo r CD44, CD 133 and CXCR4
The analyses of serial in vivo transplants, particularly detailed in the case 
of ascites #2, revealed heterogeneity in term of marker expression. Indeed, 
we detected a stable in vivo selection of cancer cells that expressed high 
levels of CD44, while heterogeneous levels of CD 133 and CXCR4 were 
observed within ascites grown in animals injected with the same tumour 
population and within different in vivo passages.
Since the literature has identified CD44/CD117-expressing cells as a CSC 
subpopulation in EOC (311), we evaluated CD117 expression, observing 
that at least 1% of ovarian cancer cells were positive for this marker. 
However, we have not yet characterized the subpopulation of CD 177 
positive cells; future plans will be to evaluate the potential role of this 
molecule as an ovarian CSC marker in our in vivo model.
The in vivo increased expression of CD44, independently of tumour growth 
as a solid mass or as ascites, suggests that this molecule, whose 
expression is under epigenetic control (371) (372) (373), is exceedingly 
sensitive to some, as yet unidentified, factor(s) present in the mouse 
microenvironment, thus precluding its further analysis as a CSC/TIC marker 
in in vivo models.
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Since CD 133 expression was found to be associated with the ovarian CSC 
phenotype (374) (311) (312), we evaluated the possibility that CD133 and 
CXCR4 could recognize the same subpopulation of ovarian cancer cells with 
CSC properties. The existence of a double CXCR4bnght/CD133bnght positive 
subpopulation was not easily detectable due to the variable degree of 
expression of both antigens. In double staining experiments and FACS 
analyses, a small percentage of ovarian cancer cells seemed to co-express 
CD 133 and CXCR4, but we did not identify a clear overlap between the two 
tested markers. Moreover, morphological parameter analysis revealed that 
these two molecules are expressed by diverse subpopulations of ascitic 
cells with distinct side- and forward-scatter properties (SSC and FSC 
respectively), which did not overlap with each other. CXCR4 positive cells 
corresponded to the subpopulation with lower SSC and FSC parameters, 
which is a typical characteristic of normal and cancer stem cells. Finally, 
epifluorescence analyses confirmed that only a small number of ovarian 
cancer cells expressed either CXCR4 or CD 133.
These data argue for the possibility that CD 133 and CXCR4 recognize 
distinct subsets of ovarian CSCs with different morphological and functional 
properties. Although CSCs seem to be a special compartment of cancer 
cells, a recent theory suggests that CSC themselves are still a 
heterogeneous population with different biological properties and that 
multiple populations with CSC characteristics can co-exist in the same 
tumour (47) (375). From this point of view, CD133 and CXCR4 could specify
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two different and co-existing subsets of ovarian cancer cells with 
particular features, possibly related to diverse CSC characteristics (49).
4.5.6 Characterization o f CD133 or CXCR4 sorted  ascitic cells
Ascitic cells recovered from EOC xenografts were sorted for CD133 or 
CXCR4, and positive and negative cell fractions were characterized. 
Enrichment in mRNA levels of sternness genes, such as NANOG, NESTIN 
and OCT4, was observed with a good reproducibility in CXCR4 positive 
cells, whereas it was more variable in CD 133 positive cells. Furthermore, 
the expression levels of ABC transporters which can efflux drugs as well 
as physiological substrates (e.g. lipids), suggested that these genes can be 
reversibly turned on and off in CXCR4 positive cells, while in CD 133 
positive cells their up-modulation was a much more stable and evident 
feature, suggesting a difference in terms of chemoresistance potential 
between CXCR4 and CD 133 subpopulations.
ABCF2 has been found a useful prognostic marker in cervical and ovarian 
clear cell carcinoma, but its expression was unrelated to prognosis and 
clinical factors in endometrial cancer (376) (377). Our data revealed that 
ABCF2 expression levels were up-regulated in both CXCR4 and CD133 
positive cells, being particularly marked in the CXCR4 positive subset. We 
may speculate that ABCF2 could represent a prognostic factor not only in 
ovarian clear cell carcinoma but also in ovarian serous adenocarcinoma, but 
more detailed analyses in a large and well annotated series of cases are 
needed before drawing any conclusion on this subject.
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ABCG1, ABCG2 and ABCB1 (MDR1) have been reported to be up-regulated 
in TICs of numerous tumour types (127) (360) (128). ABCB1 was also 
demonstrated to be a good prognostic parameter in women with ovarian 
cancer (378). Our analyses showed that ABCB1 and ABCG1 were strongly 
up-modulated in CD133 positive cells, supporting our previous suggestion 
regarding CD 133 chemoresistance potential.
In summary, we did not found any correlation between CD 133 positivity and 
the ovarian cancer sternness phenotype. However, there was an association 
between the expression of resistance-related genes such as the ABC 
family transporters and CD133. Because CD133 expression is linked to a 
resistant phenotype, detection of CD 133 positive cells may be useful to 
predict the efficacy of specific cytotoxic therapy.
On the other hand, CXCR4 positive cells were associated with a more 
undifferentiated expression profile, but did not appear to be correlated with 
resistance-related factors (i.e. ABC transporters). Thus, CXCR4 positive 
cells may identify those tumour cells which maintain a partially un­
differentiated state (high levels of stem cell marker expression) and 
possibly responsible for tumour invasion and metastasis.
4.5.7 Tumorigenic potential o f  CD 133- or CXCR4- sorted  ascitic cells
The importance of tumorigenicity in defining CSCs has been debated 
because the CSCs represent “per se” a heterogeneous subpopulation of 
cancer cells. In all published studies in the field of ovarian CSCs, the 
tumours resulting from the putative CSC population contained both tumour
2 1 8
and non-tumour initiating cell populations, demonstrating the multipotential 
ability of the selected subpopulation.
We found that cells isolated from xenograft-derived ascites and sorted for 
CXCR4 and CD 133 positive cells were not enriched in cells with higher 
tumorigenic capacity. These results fitted well with previous studies, where 
CD 133 positive and negative fractions did not differ in their ability to form 
tumours in mice (260) (268). As noted for CD 133, both CXCR4 positive and 
negative cells were able to generate ascites in immunocompromised mice. 
The tumorigenic ability of both CXCR4 and CD 133 positive and negative 
cells seems to indicate that both markers, rather than distinguishing cells at 
different levels of a hierarchy, are reversibly expressed by tumorigenic 
ovarian cancer cells.
Cancer cells derived from injections of either CXCR4 positive or negative 
fractions gave rise to heterogeneous ascitic cells with a plastic phenotype; 
CXCR4 negative cells were able to generate ascites positive for this 
marker. The observed modulation of CXCR4 expression suggests that this 
marker could effectively identify the plastic and heterogeneous 
subpopulation of CSCs, but at the same time highlights the difficulty to use 
this molecule as a potential ovarian CSC therapeutic target. On the 
contrary, CD 133 negative cells generated ascitic cells that maintained the 
CD 133 negative phenotype.
Overall, these data highlight the potential involvement of different 
mechanisms regulating the expression of these two markers, being that of 
CD 133 inherently dependent on cellular mechanisms, and that of CXCR4
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under the control of both cellular and microenvironmental stimuli, such as 
CXCL12/SDF1, the natural ligand of CXCR4 (241). Further molecular 
analyses are needed to verify the existence of the hypothesized different 
expression regulators of CD 133 and CXCR4 in EOC CSCs.
4.5.8 EOC CSCs ex is ten ce : tentative conclusions and working 
hypothesis fo r future analyses
From our in vivo data, we would estimate that at least 5x l05 ovarian cancer
cells are needed to reliably propagate ascites and tumours when injected in
a specific mouse model and in a specific mouse-body location. Although we
were not able to identify markers that distinguish tumorigenic from non-
tumorigenic ovarian cancer cells, our data do not exclude the possibility
that ovarian cancer follows the cancer stem cell model. Altogether, our
results are in keeping with the recent notion that the heterogeneous
phenotypic and molecular traits of human cancer could be a function of
their CSC content (379) and of the CSC plasticity; in fact, marker
modulation could be explained in terms of the ability of CSCs to change
their features depending on the surrounding environment (6)
In conclusion, if we consider our results and recent developments of the
CSC model (368) (50), we believe that epithelial ovarian cancer may arise
from mutated stem or progenitor cells and that the observed heterogeneity
of the CSC population is caused by clonal evolution or partial differentiation
of the ovarian TICs. During cancer progression, it is possible that a range
of variable factors, such as oxygen concentration, immune status and
therapeutic treatments, causes the emergence of new CSC clones through
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genetic and epigenetic alterations. These  CSC clones may have acquired 
survival advantages during tumour progression and may co-ex ist, compete 
or cooperate with each other. (368) (51). Translating this assumption to our 
data, CD 133 and CXCR4 could identify two different clones of the ovarian 
CSC subpopulation with distinct properties, related to TIC features (FIG. 
4.13).
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Figure 4.13- Proposed model for ovarian CSC clonal evolution and heterogeneity
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